

IMPROVED PROCOAGULANT ANTIBODIES

INCORPORATION BY REFERENCE OF THE SEQUENCE LISTING

The present application is filed with a Sequence Listing in electronic form. The entire
5 contents of the sequence listing are hereby incorporated by reference.

BACKGROUND

In patients with a coagulopathy, such as in human beings with haemophilia A and B, various
steps of the coagulation cascade are rendered dysfunctional due to, for example, the
10 absence or insufficient presence of a functional coagulation factor. Such dysfunction of one
part of the coagulation cascade results in insufficient blood coagulation and potentially life-
threatening bleeding, or damage to internal organs, such as the joints.

Coagulation Factor VIII (FVIII) deficiency, commonly referred to as haemophilia A, is a
congenital bleeding disorder affecting approximately 420,000 people worldwide, of which
15 around 105,000 are currently diagnosed.

Patients with haemophilia A may receive coagulation factor replacement therapy such as
exogenous FVIII. Conventional treatment consists of replacement therapy, provided as
prophylaxis or on demand treatment of bleeding episodes. Until recently prophylactic
treatment for a patient with severe haemophilia A was up to three intravenous
20 injections/week with either plasma derived FVIII or recombinant FVIII or long-acting variants
thereof.

However, such patients are at risk of developing neutralizing antibodies, so-called inhibitors,
to such exogenous factors, rendering formerly efficient therapy ineffective. Haemophilia A
patients with inhibitors is a non-limiting example of a coagulopathy that is partly congenital
25 and partly acquired. Patients that have developed inhibitors to FVIII cannot be treated with
conventional replacement therapy. Exogenous coagulation factors may only be administered
intravenously, which is of considerable inconvenience and discomfort to patients. For
example, infants and toddlers may have to have intravenous catheters surgically inserted
into a chest vein, in order for venous access to be guaranteed. This leaves them at great risk
30 of developing bacterial infections.

In a bleeding individual, coagulation is initiated by formation of the Tissue Factor/Factor VIIa
(TF/FVIIa) complex when extravascular TF is exposed to activated FVII (FVIIa) in the blood.
TF/FVIIa complex formation leads to the activation of coagulation Factor X (FX) to activated
coagulation Factor Xa (FXa) which, together with activated coagulation Factor V (FVa),
35 generates a limited amount of thrombin, which in turn activates blood platelets. Activated

platelets support the assembly of the tenase complex composed of activated Factor VIII (FVIIIa) and activated coagulation Factor IX (FIXa). The tenase complex is a very efficient catalyst of FX activation and FIXa generated in this second step serves as the active protease in the FVa/FIXa pro-thrombinase complex which is responsible for the final thrombin burst. Thrombin cleaves fibrinogen to generate fibrin monomers, which polymerise to form a fibrin network which seals the leaking vessel and stops the bleeding. The rapid and extensive thrombin burst is a prerequisite for the formation of a solid and stable fibrin clot.

An inadequate FIXa formation and decreased thrombin generation caused by reduced or absent FVIII activity is the reason underlying the bleeding diathesis in haemophilia A patients.

As mentioned, proteolytic conversion of FX into its enzymatically active form FIXa can be achieved by the intrinsic FX-activating complex comprising FIXa and its cofactor FVIIIa. Cofactor binding increases the enzymatic activity of FIXa by about five orders of magnitude and is believed to result through multiple mechanisms as outlined by Scheiflinger *et al.* (2008) *J Thromb Haemost*, 6:315-322. Notably, FVIIIa has been found to stabilize a conformation of FIXa that has increased proteolytic activity towards FX (Kolkman JA, Mertens K (2000) *Biochemistry*, 39:7398-7405, Zögg T, Brandstetter H (2009) *Biol Chem*, 390:391-400). Based on this observation and realizing that antibodies are versatile binding proteins capable of mimicking a variety of protein-protein interactions, Scheiflinger *et al.* performed a screen for agonistic anti-FIXa antibodies characterized by an ability to enhance FX activation by FIXa in the presence of a phospholipid surface and calcium, but in the absence of the natural cofactor FVIIIa. From a screen of 5280 hybridoma supernatants, 88 were found to produce antibodies exhibiting various degrees of FIXa agonistic activity, cf. EP1220923 B1 and EP1660536 B1. With respect to the kinetics of FX activation and ability to stimulate thrombin generation in FVIII-deficient human plasma, EP1660536 B1 consistently points to the anti-FIXa antibody 224F3 as the most efficient antibody.

Recently, a new drug, emicizumab (HEMLIBRA®) also known as ACE910, has been approved for subcutaneous prophylactic treatment of Haemophilia A with or without inhibitors against conventional replacement therapy factors. Emicizumab is a humanized, bispecific anti-FIX(a)/anti-FX(a) monoclonal antibody developed by Chugai Pharmaceuticals/Roche Pharmaceuticals for the treatment of haemophilia A. Emicizumab is designed to mimic FVIII cofactor function (see Sampei *et al.*: (2013) *PLoS One*, 8, e57479 and WO2012067176), however, some patients have developed inhibitors against emicizumab rendering treatment with this compound ineffective.

There are still many unmet medical needs in the haemophilia community, in particular, and in subjects with coagulopathies, in general and the present invention relates to improved compounds capable of substituting for FVIII and thus being useful for the treatment of a coagulopathy such as haemophilia A.

5

SUMMARY

The present invention relates to compounds, which serve as a substitute for coagulation Factor VIII (FVIII) in patients suffering from a coagulopathy and in particular patients lacking functional FVIII, such as haemophilia A patients including haemophilia A patients with

10

inhibitors.
Hence, one aspect of the present invention relates to compounds capable of enhancing the generation of FXa and thus partially or completely restoring coagulation in patients lacking functional FVIII.

15

In one aspect, the compound is an antibody or antigen-binding fragment thereof. In one such aspect, the compound is a multispecific antibody or antigen-binding fragment thereof such as a bispecific antibody or antigen-binding fragment thereof.

In one particular aspect, the invention relates to procoagulant antibodies or antigen-binding fragment thereof which serve as a substitute for FVIII in patients lacking functional FVIII, such as haemophilia A patients.

20

In one such aspect, the antibody or antigen-binding fragment thereof is capable of binding FIX(a) and increases the enzymatic activity of FIXa towards FX, optionally also being capable of binding FX.

25

In one aspect, the invention relates to a procoagulant antibody or antigen-binding fragment thereof that is capable of binding FIX(a) and FX(a), including bispecific procoagulant antibodies or antigen-binding fragment thereof which increase the enzymatic activity of FIXa towards FX.

In one aspect, the invention relates to a procoagulant bispecific antibody or antigen-binding fragment thereof that is capable of binding to FIX(a) and FX(a).

30

A further aspect of the invention relates to the individual component (intermediate) antibodies or antigen-binding fragment thereof that are part of a procoagulant antibody, such as a particular anti-FIX(a) antibody or antigen-binding fragment thereof or a particular anti-FX(a) antibody or antigen-binding fragment thereof.

A further aspect of the invention relates to the manufacture of the antibodies or antigen-binding fragment thereof - and components (intermediates) thereof - as disclosed herein.

A further aspect of the invention relates to an antibody that competes with a procoagulant antibody or antigen-binding fragment thereof, as disclosed herein, for binding to FIX(a) and/or FX(a).

5 A further aspect of the invention relates to an antibody or antigen-binding fragment thereof which shares epitope residues or epitope hot-spot residues on FIX(a) and/or FX(a) with a procoagulant antibody or antigen-binding fragment hereof, as disclosed herein.

A further aspect of the invention is directed to the procoagulant antibodies or antigen-binding fragment thereof disclosed herein for prevention and/or treatment of a coagulopathy, a disease accompanying coagulopathy, or a disease caused by coagulopathy. In one aspect
10 the coagulopathy is haemophilia A with or without inhibitors.

A still further aspect of the invention relates to a pharmaceutical composition comprising a procoagulant antibody or antigen-binding fragment thereof as disclosed herein formulated for the delivery of said antibody for the prevention and/or treatment of a coagulopathy, such as haemophilia A with or without inhibitors, as well as an injection device with content thereof.

15 A further aspect of the invention is directed to a kit comprising (i) an antibody or antigen-binding fragment thereof as disclosed herein such as a bispecific antibody and (ii) instructions for use.

The invention may also solve further problems that will be apparent from the disclosure of the exemplary embodiments.

20

BRIEF DESCRIPTION OF THE FIGURES

Figure 1A-D shows alignments of sequences representing heavy- and light chain variable domains of the anti-FIX(a) (Fig. 1A and 1B) and anti-FX(a) (Fig. 1C and 1D) IgG antibodies as disclosed herein. CDR1, 2 and 3 sequences are highlighted in bold and underlined in
25 uppermost sequence and is representative for the remaining sequences.

Figure 2 shows thrombin generation test (TGT) results from the bispecific antibodies bimAb05-0745, bimAb05-3761, bimAb05-3769, bimAb05-0746, bimAb05-2112, bimAb05-2113, bimAb05-2114 and ACE910 in human tissue factor activated haemophilia A platelet-poor plasma (PPP). The experiment was performed as described in Example 16. Dotted and
30 stippled lines indicate the peak thrombin level (nM) observed in the absence of antibody in HA-PPP and normal PPP, respectively, and with their standard deviation indicated by dotted lines. The profiles of bimAb05-0745, bimAb05-3761, bimAb05-3769, bimAb05-0746, bimAb05-2112, bimAb05-2113 and bimAb05-2114 are indicated by down-pointing triangles,

whereas that of ACE910 is indicated by up-pointing triangles. Results are shown as mean $\pm$ standard deviation from at least three independent experiments.

Figure 3 shows thrombin generation test (TGT) results from the bispecific antibodies bimAb05-0745, bimAb05-3761, bimAb05-3769, bimAb05-0746, bimAb05-2112, bimAb05-2113, bimAb05-2114 and ACE910 in human tissue factor activated haemophilia A platelet-rich plasma (PRP). The experiment was performed as described in Example 16. Dotted and stippled lines indicate the peak thrombin level (nM) observed in the absence of antibody in HA-PRP and normal PRP, respectively, and with their standard deviation indicated by the dotted lines. The profiles of bimAb05-0745, bimAb05-3761, bimAb05-3769, bimAb05-0746, bimAb05-2112, bimAb05-2113 and bimAb05-2114 are indicated by down-pointing triangles, whereas that of ACE910 is indicated by up-pointing triangles. Results are shown as mean $\pm$ standard deviation from at least three independent experiments.

Figure 4A and 4B shows results from antibody binning experiments on an Octet Fortebio system using a modified in-tandem setup. Briefly, biotinylated human FIXa was captured on streptavidin tips. Captured FIXa was then saturated by initial exposure to a first (1st) bivalent anti-FIXa antibody, which was followed by a second exposure to an equimolar mixture of the first (1st) antibody and a second (2nd) bivalent anti-FIXa antibody. Binding responses for each of the three phases as well as the identity of the antibodies used are shown.

Figure 5 shows results from antibody binning experiments on an Octet Fortebio system using a modified in-tandem setup. Briefly, biotinylated human FXa was captured on streptavidin tips. Captured FXa was then saturated by initial exposure to a first (1st) bivalent anti-FXa antibody, which was followed by a second exposure to an equimolar mixture of the first (1st) antibody and a second (2nd) bivalent anti-FXa antibody. Binding responses for each of the three phases as well as the identity of the antibodies used are shown.

30 BRIEF DESCRIPTION OF THE SEQUENCES

SEQ ID NO:1 represents the amino acid sequence of human coagulation Factor IX.

SEQ ID NO:2 represents the amino acid sequence of human coagulation Factor X.

SEQ ID NOs:3-1194 and 1202-1249 represent the sequences of the heavy chain variable domains (VH) and light chain variable domains (VL) and Complementarity Determining

Regions (CDRs) of anti-FIX(a) and anti-FX(a) monoclonal antibodies (mAbs) described herein.

SEQ ID NO:1195 represents the human IgG4 heavy chain constant region with S228P and C-terminal lysine truncation.

- 5 SEQ ID NO:1196 represents the human IgG4 heavy chain constant region with S228P, F405L, R409K and C-terminal lysine truncation.

SEQ ID NO:1197 represents the human kappa light chain constant region.

SEQ ID NO:1198 represents the human IgG1 heavy chain constant region with F405L and C-terminal lysine truncation.

- 10 SEQ ID NO:1199 represents the human IgG1 heavy chain constant region with K405R and C-terminal lysine truncation.

SEQ ID NO:1200 represents a N-terminal His-tag.

SEQ ID NO:1201 represents a GS-linker.

- 15 The tables in Example 6 link the SEQ ID NOs to individual (component) anti-FIX(a) and anti-FX(a) antibodies and bispecific antibodies of the invention.

DESCRIPTION

In subjects with a coagulopathy, such as in human beings with haemophilia A, the coagulation cascade is rendered dysfunctional due to the absence or insufficient presence of functional FVIII. Such dysfunction of one part of the coagulation cascade results in

5 insufficient blood coagulation and potentially life-threatening bleeding, or damage to internal organs, such as the joints. The present invention relates to compounds, which serve as a substitute for coagulation Factor VIII (FVIII) in patients suffering from a coagulopathy and in particular patients lacking functional FVIII, such as haemophilia A patients including haemophilia A patients with inhibitors. In one aspect, such compound is an antibody.

10 In particular the inventors of the present invention have surprisingly identified antibodies which mimic FVIII cofactor activity with high potency and efficacy. In one particular aspect, the invention relates to procoagulant antibodies which serve as a substitute for FVIII in patients lacking functional FVIII, such as haemophilia A patients. In one such aspect, the procoagulant antibodies bind to and increase the enzymatic activity of coagulation Factor IXa

15 (FIXa) towards coagulation Factor X (FX), optionally also binding FX. In one such aspect the antibodies of the invention are bispecific antibodies capable of binding to FIX/FIXa and FX. A further aspect of the invention relates to the individual component (intermediate) antibodies or antigen-binding fragment thereof that are part of a multispecific procoagulant antibody, such as a particular anti-FIX(a) antibody or antigen-binding fragment thereof or a particular

20 anti-FX(a) antibody or antigen-binding fragment thereof. A further aspect of the invention relates to the manufacture of the antibodies or antigen-binding fragment thereof - and components (intermediates) thereof - as disclosed herein. A further aspect of the invention relates to an antibody that competes with a procoagulant antibody or antigen-binding fragment thereof, as disclosed herein, for binding to FIX(a)

25 and/or FX(a). A further aspect of the invention relates to an antibody or antigen-binding fragment thereof which shares epitope residues or epitope hot-spot residues on FIX(a) and/or FX(a) with a procoagulant antibody or antigen-binding fragment hereof, as disclosed herein. In one aspect, the antibody is a human or humanised antibody, such as a human or

30 humanised bispecific antibody. A further aspect of the invention is directed to the procoagulant antibodies or antigen-binding fragment thereof disclosed herein for prevention and/or treatment of a coagulopathy, a disease accompanying coagulopathy, or a disease caused by coagulopathy. In one aspect the coagulopathy is haemophilia A with or without inhibitors.

A still further aspect of the invention relates to a pharmaceutical composition comprising a procoagulant antibody or antigen-binding fragment thereof as disclosed herein formulated for the delivery of said antibody for the prevention and/or treatment of a coagulopathy, such as haemophilia A with or without inhibitors, as well as an injection device with content thereof.

- 5 A further aspect of the invention is directed to a kit comprising (i) an antibody or antigen-binding fragment thereof as disclosed herein such as a bispecific antibody and (ii) instructions for use.

Coagulation Factor IX

- Coagulation Factor IX (FIX) is a vitamin K-dependent coagulation factor with structural
10 similarities to Factor VII, prothrombin, Factor X, and Protein C. FIX circulates in plasma as a single-chain zymogen (SEQ ID NO:1). The circulating zymogen form consists of 415 amino acids divided into four distinct domains comprising an N-terminal γ -carboxyglutamic acid-rich (Gla) domain, two EGF domains and a C-terminal trypsin-like serine protease domain. Activation of FIX occurs by limited proteolysis at Arg145 and Arg180 to release the activation
15 peptide (residues 146 to 180 of SEQ ID NO:1). Thus, activated FIX (FIXa) is composed of residues 1-145 of SEQ ID NO:1 (light chain) and residues 181-415 of SEQ ID NO:1 (heavy chain).

Circulating FIX molecules thus comprise the FIX zymogen and the activated form of FIX which are herein generally referred to as FIX and FIXa with reference to SEQ ID NO:1.

- 20 Activated Factor IX is referred to as Factor IXa or FIXa. The term "FIX (SEQ ID NO:1) and/or the activated form thereof (FIXa)" may also be referred to as "FIX/FIXa" or simply "FIX(a)". FIXa is a trypsin-like serine protease that serves a key role in haemostasis by generating, as part of the tenase complex, most of the Factor Xa required to support proper thrombin formation during coagulation.
- 25 FIX is herein represented by SEQ ID NO:1 corresponding to the Ala148 allelic form of human FIX (Anson *et al.* EMBO J. 1984 3:1053-1060; McGraw *et al.*, Proc Natl Acad Sci USA. 1985 82:2847-2851; Graham *et al.* Am. J. Hum. Genet. 1988 42:573-580). In the present invention FIX is intended to cover all natural variants of FIX, such as the T148 variant (Uniprot ID P00740).

Coagulation Factor X

FX is a vitamin K-dependent coagulation factor with structural similarities to Factor VII, prothrombin, FIX, and protein C. FX circulates in plasma as a two-chain zymogen including residues 1-139 of SEQ ID NO:2 (light chain) and residues 143-448 of SEQ ID NO:2 (heavy chain). Human FX zymogen comprises four distinct domains comprising an N-terminal

gamma-carboxyglutamic acid rich (Gla) domain (residues 1-45), two EGF domains, EGF1 (residues 46-82) and EGF2 (residues 85-125), respectively, and a C-terminal trypsin-like serine protease domain (residues 195-448). Activation of FX occurs by limited proteolysis at Arg194, which results in the release of the activation peptide (residues 143-194). Thus, activated FX (FXa) is composed of residues 1-139 of SEQ ID NO:2 (light chain) and residues 195-448 of SEQ ID NO:2 (activated heavy chain). Circulating Factor X molecules thus comprises the FX zymogen and the activated form of FX which are herein referred to as FX and FXa, respectively, with reference to SEQ ID NO:2. In the present invention FX is intended to cover all natural variants of FX. The term "FX (SEQ ID NO:2) and/or the activated form thereof (FXa)" may also be referred to as "FX/FXa" or "FX(a)".

Antibodies

The term "antibody" herein refers to a protein, derived from an immunoglobulin sequence, which is capable of binding to an antigen or a portion thereof. The term antibody includes, but is not limited to, full length antibodies of any class (or isotype), that is, IgA, IgD, IgE, IgG, IgM and/or IgY. The term antibody includes - but is not limited to - antibodies that are bivalent, such as bispecific antibodies.

Natural full-length antibodies comprise at least four polypeptide chains: two heavy chains (HC) and two light chains (LC) that are connected by disulfide bonds. In some cases, natural antibodies comprise less than four chains, as in the case of the IgNARs found in Chondrichthyes. One class of immunoglobulins of particular pharmaceutical interest is the IgGs. In humans, the IgG class may be divided into four sub-classes IgG1, IgG2, IgG3 and IgG4, based on the sequence of their heavy chain constant regions. The light chains can be divided into two types, kappa and lambda chains, based on differences in their sequence composition. IgG molecules are composed of two heavy chains, interlinked by two or more disulfide bonds, and two light chains, each attached to a heavy chain by a disulfide bond. An IgG heavy chain may comprise a heavy chain variable domain (V_H) and up to three heavy chain constant (C_H) domains: C_{H1} , C_{H2} and C_{H3} . A light chain may comprise a light chain variable domain (V_L) and a light chain constant domain (C_L). V_H and V_L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs) or hypervariable regions (HvRs), interspersed with regions that are more conserved, termed framework regions (FR). V_H and V_L domains are typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The heavy and light chain variable domains containing the hypervariable regions (CDRs) form a structure that is capable of interacting with an antigen, whilst the constant region of an antibody may mediate binding of the

immunoglobulin to host tissues or factors, including, but not limited to various cells of the immune system (effector cells), Fc receptors and the first component, C1q, of the C1 complex of the classical complement system.

Antibodies of the invention may be monoclonal antibodies (mAbs), in the sense that they
5 represent a set of unique heavy and light chain variable domain sequences as expressed from a single B-cell or by a clonal population of B cells. Antibodies of the invention may be produced and purified using various methods that are known to a person skilled in the art. For example, antibodies may be produced from hybridoma cells. Antibodies may be produced by B-cell expansion. Antibodies or fragment thereof may be recombinantly
10 expressed in mammalian or microbial expression systems, or by *in vitro* translation. Antibodies or fragment thereof may also be recombinantly expressed as cell surface bound molecules, by means of e.g. phage display, bacterial display, yeast display, mammalian cell display or ribosome or mRNA display.

Antibodies of the current invention may be isolated. The term "isolated antibody" refers to an
15 antibody that has been separated and/or recovered from (an)other component(s) in the environment in which it was produced and/or that has been purified from a mixture of components present in the environment in which it was produced.

Certain antigen-binding fragments of antibodies may be suitable in the context of the current invention, as it has been shown that the antigen-binding function of an antibody can be
20 performed by fragments of a full-length antibody. The term "antigen-binding fragment" of an antibody refers to one or more fragment(s) of an antibody that retain(s) the ability to specifically bind to or recognise an antigen, such as FIX/FIXa, FX/FXa or another target molecule, as described herein. Examples of antigen-binding fragments include (but is not limited to) Fab, Fab', Fab₂, Fab'₂, Fv (typically the combination of V_L and V_H domains of a
25 single arm of an antibody), single-chain Fv (scFv); see e.g. Bird *et al.* Science 1988; 242:423-426; and Huston *et al.* PNAS 1988; 85:5879-5883), dsFv, Fd (typically the V_H and C_H1 domain), monovalent molecules comprising both a single V_H and a single V_L domain; minibodies, diabodies, triabodies, tetrabodies, and kappa bodies (see, e.g. Ill *et al.* (1997) Protein Eng 10: 949-57); as well as one or more isolated CDRs or a functional paratope,
30 where the isolated CDRs or antigen-binding residues or polypeptides can be associated or linked together so as to form a functional antibody fragment. These antibody fragments may be obtained using conventional techniques known to those skilled in the art, and the fragments may be screened for utility in the same manner as intact antibodies.

"Fab fragments" of an antibody, including "Fab" and "Fab'₂" fragments, can be derived from
35 an antibody by cleavage of the heavy chain in the hinge region on the N-terminal or C-

terminal side, respectively, of the hinge cysteine residues connecting the heavy chains of the antibody. A "Fab" fragment includes the variable and constant domains of the light chain and the variable domain and C_H1 domain of the heavy chain. "Fab'₂" fragments comprise a pair of "Fab" fragments that are generally covalently linked by their hinge cysteines. A Fab' is

5 formally derived from a Fab'₂ fragment by cleavage of the hinge disulfide bonds connecting the heavy chains in the Fab'₂. Other chemical couplings than disulfide linkages of antibody fragments are also known in the art. A Fab fragment retains the ability of the parent antibody to bind to its antigen, potentially with a lower affinity. Fab'₂ fragments are capable of bivalent binding, whereas Fab and Fab' fragments can only bind monovalently. Generally, Fab

10 fragments lack the constant C_H2 and C_H3 domains, i.e. the Fc part, where interaction with the Fc receptors and C1q would occur. Thus, Fab fragments are in general devoid of effector functions. Fab fragments may be produced by methods known in the art, either by enzymatic cleavage of an antibody, e.g. using papain to obtain the Fab or pepsin to obtain the Fab'₂, Fab fragments including Fab, Fab', Fab'₂ may be produced recombinantly using techniques

15 that are well known to the person skilled in the art.

An "Fv" (fragment variable) fragment is an antibody fragment that contains a complete antigen recognition and binding site, and generally comprises one heavy and one light chain variable domain in association that can be covalent in nature, for example in a single chain variable domain fragment (scFv). It is in this configuration that the three hypervariable

20 regions of each variable domain interact to define an antigen-binding site on the surface of the V_H-V_L dimer. Collectively, the six hypervariable regions or a subset thereof confer antigen binding specificity to the antibody.

"Single-chain Fv" or "scFv" antibody comprise the V_H and V_L domains of antibody, where these domains are present in a single polypeptide chain. Generally, the Fv polypeptide

25 further comprises a polypeptide linker between the V_H and V_L domains that enables the scFv to form the desired structure for antigen binding. For a review of scFv, see Pluckthun, 1994, In: *The Pharmacology of Monoclonal Antibodies*, Vol. 113, Rosenberg and Moore eds. Springer-Verlag, New York, pp. 269-315.

"Single-chain Fab" or "scFab" antibody comprise the V_H, C_H1, V_L and C_L domains of an

30 antibody, where these domains are present in a single polypeptide chain. Generally, the Fab polypeptide further comprises a polypeptide linker between either V_H and C_L or V_L and C_H1 domains that enables the scFab to form the desired structure for antigen binding (Koerber *et al.* (2015) *J Mol Biol.* 427:576-86).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, in

35 which fragments comprise a heavy chain variable domain (V_H) connected to a light chain

variable domain (V_L) in the same polypeptide chain (V_H and V_L). By using a linker that is too short to allow pairing between the two variable domains on the same chain, the variable domains are forced to pair with complementary domains of another chain, creating two antigen-binding sites.

- 5 The expression "linear antibodies" refers to antibodies as described in Zapata *et al.* (1995) Protein Eng. 8: 1057-1062. Briefly, these antibodies contain a pair of tandem Fd segments (V_H - C_H1 - V_H - C_H1) that, together with complementary light chain polypeptides, form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
- 10 Antibody fragments may be obtained using conventional recombinant or protein engineering techniques and the fragments can be screened for binding to FIX and the activated form thereof, FX or another function, in the same manner as intact antibodies.
- Antibody fragments of the invention may be made by truncation, e.g. by removal of one or more amino acids from the N and/or C-terminal ends of a polypeptide. Fragments may also be generated by one or more internal deletions.
- 15 An antibody of the invention may be, or may comprise, a fragment of the antibody, or a variant of any one of the antibodies disclosed herein. An antibody of the invention may be, or may comprise, an antigen binding portion of one of these antibodies, or variants thereof. For example, an antibody of the invention may be a Fab fragment of one of these antibodies or variants thereof, or it may be a single chain antibody derived from one of these antibodies, or
- 20 a variant thereof. Also, an antibody of the invention may be a combination of a full length antibody and fragment thereof.
- The term "one-armed" as used herein, refers to a particular type of monovalent antibody constituted by an antibody heavy chain, a truncated heavy chain lacking the Fab region, and a single light chain.
- 25 The term "monospecific" antibody as used herein, refers to an antibody which is capable of binding to one particular epitope (including but not limited to bivalent antibodies).
- The term "bispecific" antibody as used herein, refers to an antibody which is capable of binding to two different antigens or two different epitopes on the same antigen.
- The term "trispecific" antibody as used herein, refers to an antibody which is capable of
- 30 binding to three different antigens or three different epitopes on the same antigen or three different epitopes present on two different antigens.
- The term "multispecific" antibody as used herein, refers to an antibody which is capable of binding to two or more different antigens or two or more different epitopes on the same antigen. Multispecific antibodies thus comprise bi- and trispecific antibodies.

Bispecific antibodies in full length IgG format can be generated by fusion of two individual hybridomas to form a hybrid quadroma which produces a mixture of antibodies including a fraction of bispecific heterodimerising antibodies (Chelius D. *et al.*; *MAbs*. 2010 May-Jun; 2(3): 309–319). Bispecific heterodimerising antibodies may alternatively be produced by

5 using recombinant technologies. Heterodimerisation can also be achieved by engineering the dimerisation interface of the Fc region to promote heterodimerisation. One example hereof is the so-called knob-in-hole mutations where sterically bulky side chains (knobs) are introduced in one Fc matched by sterically small side chains (holes) on the opposite Fc thereby creating steric complementarity promoting heterodimerisation. Other methods for

10 engineered heterodimerisation Fc interfaces are electrostatic complementarity, fusion to non-IgG heterodimerisation domains or utilising the natural Fab-arm exchange phenomenon of human IgG4 to control heterodimerisation. Examples of heterodimerised bispecific antibodies are well described in the literature, e.g. (Klein C, *et al.*; *MAbs*. 2012 Nov-Dec; 4(6): 653–663). Special attention has to be paid to the light chains in heterodimeric antibodies. Correct

15 pairing of LCs and HCs can be accomplished by the use of a common light chain. Again engineering of the LC/HC interface can be used to promote heterodimerisation or light chain cross-over engineering as in CrossMabs. *In vitro* re-assembly under mildly reducing conditions of antibodies from two individual IgGs containing appropriate mutations can also be used to generate bispecific antibodies (e.g. Labrijn *et al.*, *PNAS*, 110, 5145-5150 (2013)).

20 Also the natural Fab-arm exchange method is reported to ensure correct light chains pairing. Multispecific antibody-based molecules may also be expressed recombinantly as fusion proteins combining the natural modules of IgGs to form multispecific and multivalent antibody derivatives as described in the literature. Examples of fusion antibodies are DVD-Igs, IgG-scFV, Diabodies, DARTs etc. Specific detection or purification tags, half-life extension

25 moieties or other components can be incorporated in the fusion proteins. Additional non-IgG modalities may also be incorporated in the fusion proteins. Bispecific full length antibodies based on Fc heterodimerisation are commonly referred to as asymmetric IgGs, irrespective of the LC pairing methodology.

Generally, bispecific antibodies may be produced in a variety of molecular formats as

30 reviewed by Brinkmann *et al.* (Brinkmann *et al.* The making of bispecific antibodies. *Mabs* 9, 182-212 (2017)).

Multispecific antibody-based molecules may also be produced by chemical conjugation or coupling of individual full length IgGs or coupling of fragments of IgGs to form multispecific and multivalent antibody derivatives as described in the literature. Examples are chemically

35 coupled Fab fragments, IgG-dimer etc. Specific detection or purification tags, half-life

extension molecules or other components can be incorporated in the conjugate proteins. Additional non-IgG polypeptide may also be incorporated in the fusion proteins. Multispecific molecules may also be produced by combining recombinant and chemical methods including those described above.

- 5 In one aspect, an antibody of the invention is a chimeric antibody, a human antibody or a humanised antibody. Such antibody can be generated by using, for example, suitable antibody display or immunization platforms or other suitable platforms or methods known in the field. The term "human antibody", as used herein, is intended to include antibodies having variable domains in which at least a portion of a framework region and/or at least a portion of a CDR region are derived from human germline immunoglobulin sequences. For example, a human antibody may have variable domains in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region or a portion thereof is also derived from human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*).

- Such a human antibody may be a human monoclonal antibody. Such a human monoclonal antibody may be produced by a hybridoma which includes a B cell obtained from a transgenic nonhuman animal, e.g., a transgenic mouse, having a genome comprising human immunoglobulin heavy and light chain gene segments repertoires, fused to an immortalised cell.

- Human antibodies may be isolated from sequence libraries built on selections of human germline sequences, further diversified with natural and synthetic sequence diversity.
- 25 Human antibodies may be prepared by *in vitro* immunisation of human lymphocytes followed by transformation of the lymphocytes with Epstein-Barr virus.

Human antibodies may be produced by recombinant methods known in the art.

The term "human antibody derivative" refers to any modified form of the human antibody, such as a conjugate of the antibody and another agent or antibody.

- 30 The term "humanised antibody", as used herein, refers to a human/non-human antibody that contains a sequence (CDR regions or parts thereof) derived from a non-human immunoglobulin. A humanised antibody is, thus, a human immunoglobulin (recipient antibody) in which residues from at least a hypervariable region of the recipient are replaced by residues from a hypervariable region of an antibody from a non-human species (donor antibody) such as from a mouse, rat, rabbit or non-human primate, which have the desired

specificity, affinity, sequence composition and functionality. In some instances, framework (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. An example of such a modification is the introduction of one or more so-called back-mutations, which are typically amino acid residues derived from the donor antibody.

- 5 Humanisation of an antibody may be carried out using recombinant techniques known to the person skilled in the art (see, e.g., Antibody Engineering, Methods in Molecular Biology, vol. 248, edited by Benny K. Lo). A suitable human recipient framework for both the light and heavy chain variable domain may be identified by, for example, sequence or structural homology. Alternatively, fixed recipient frameworks may be used, e.g., based on knowledge
10 of structure, biophysical and biochemical properties. The recipient frameworks can be germline derived or derived from a mature antibody sequence. CDR regions from the donor antibody can be transferred by CDR grafting. The CDR grafted humanised antibody can be further optimised for e.g. affinity, functionality and biophysical properties by identification of critical framework positions where re-introduction (back-mutation) of the amino acid residue
15 from the donor antibody has beneficial impact on the properties of the humanised antibody. In addition to donor antibody derived back-mutations, the humanised antibody can be engineered by introduction of germline residues in the CDR or framework regions, elimination of immunogenic epitopes, site-directed mutagenesis, affinity maturation, etc. Furthermore, humanised antibodies may comprise residues that are not found in the
20 recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, a humanised antibody will comprise at least one – typically two – variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and in which all or substantially all of the FR residues are those of a human immunoglobulin sequence. The humanised antibody can, optionally,
25 also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

The term “humanised antibody derivative” refers to any modified form of the humanised antibody, such as a conjugate of the antibody and a chemical agent or a conjugate of the antibody with another antibody.

- 30 The term “chimeric antibody”, as used herein, refers to an antibody comprising portions of antibodies derived from two or more species. For example, the genes encoding such antibody comprise genes encoding variable domains and genes encoding constant domains originated from two different species. For example, the genes encoding variable domains of a mouse monoclonal antibody may be joined to the genes encoding the constant domains of
35 an antibody of human origin.

The fragment crystallisable region ("Fc region"/"Fc domain") of an antibody is the C-terminal region of an antibody, which comprises the hinge and the constant C_H2 and C_H3 domains. The Fc domain may interact with cell surface receptors called Fc receptors, as well as some proteins of the complement system. The Fc region enables antibodies to interact with the immune system. In one aspect of the invention, antibodies may be engineered to include modifications within the Fc region, typically to alter one or more of its functional properties, such as serum half-life, complement fixation, Fc-receptor binding, protein stability and/or antigen-dependent cellular cytotoxicity, or lack thereof, among others. Furthermore, an antibody of the invention may be chemically modified (e.g., one or more chemical moieties can be attached to the antibody) or be modified to alter its glycosylation, again to alter one or more functional properties of the antibody. An IgG1 antibody may carry a modified Fc domain comprising one or more, and perhaps all of the following mutations that will result in decreased affinity to certain Fc-gamma receptors (L234A, L235E, and G237A) and in reduced C1q-mediated complement fixation (A330S and P331S), respectively (residue numbering according to the EU index). Alternatively, other amino acid substitutions, and combinations thereof and combinations with the above mentioned, known in the art to lead to altered (reduced or increased) Fc-gamma receptor binding may be used.

The isotype of an antibody of the invention may be IgG, such as IgG1, such as IgG2, such as IgG4. If desired, the class of an antibody may be "switched" by known techniques. For example, an antibody that was originally produced as an IgM molecule may be class switched to an IgG antibody. Class switching techniques also may be used to convert one IgG subclass to another, for example: from IgG1 to IgG2 or IgG4; from IgG2 to IgG1 or IgG4; or from IgG4 to IgG1 or IgG2. Engineering of antibodies to generate constant region chimeric molecules, by combination of regions from different IgG subclasses, can also be performed.

In one embodiment the hinge region of the antibody is modified such that the number of cysteine residues in the hinge region is altered, e.g., increased or decreased. This approach is described further for instance in U.S. Patent No. 5,677,425 by Bodmer *et al.*

The constant region may be modified to stabilise the antibody, e.g., to reduce the risk of a bivalent antibody separating into half antibodies. For example, in an IgG4 constant region, residue S228 (according to the EU numbering index and S241 according to Kabat) may be mutated to a proline (P) residue to stabilise inter heavy chain disulphide bridge formation at the hinge (see, e.g., Angal *et al.* Mol Immunol. 1993; 30:105-8).

Antibodies or fragment thereof may be defined in terms of their complementarity-determining regions (CDRs). The term "complementarity-determining region" or "hypervariable region", when used herein, refers to the regions of an antibody in which amino acid residues involved

in antigen-binding are situated. The region of hypervariability or CDRs can be identified as the regions with the highest variability in amino acid alignments of antibody variable domains. Databases can be used for CDR identification such as the Kabat database, the CDRs e.g. being defined as comprising amino acid residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) of the light-chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy-chain variable domain; (Kabat *et al.* 1991; Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Alternatively CDRs can be defined as those residues from a "hypervariable loop" (residues 26-33 (L1), 50-52 (L2) and 91-96 (L3) in the light-chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy-chain variable domain; Chothia and Lesk, J. Mol. Biol. 1987; 196:901-917). Typically, the numbering of amino acid residues in this region is performed by the method described in Kabat *et al. supra*. Phrases such as "Kabat position", "Kabat residue", and "according to Kabat" herein refer to this numbering system for heavy chain variable domains or light chain variable domains. Using the Kabat numbering system, the actual linear amino acid sequence of a peptide may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a framework (FR) or CDR of the variable domain. For example, a heavy chain variable domain may include amino acid insertions (residue 52a, 52b and 52c according to Kabat) after residue 52 of CDR H2 and inserted residues (e.g. residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FR residue 82. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a "standard" Kabat numbered sequence.

The term "framework region" or "FR" residues refer to those V_H or V_L amino acid residues that are not within the CDRs, as defined herein.

An antibody of the invention may comprise a CDR region from one or more of the specific antibodies disclosed herein.

The term "procoagulant antibody" refers to an antibody which potentiates blood coagulation for example by accelerating the process of blood coagulation and/or increasing the enzymatic activity of one or more coagulation factors.

The term "procoagulant activity" refers to the ability of a compound, such as an antibody, to potentiate blood coagulation for example by accelerating the process of blood coagulation and/or increasing the enzymatic activity of one or more coagulation factors.

The term "antigen" (Ag) refers to the molecular entity used for immunisation of an immunocompetent vertebrate to produce the antibody (Ab) that recognizes the Ag. Herein,

Ag is termed more broadly and is generally intended to include target molecules that are

specifically recognized by the Ab, thus including fragments or mimics of the molecule used in the immunisation process, or other process, e.g. phage display, used for generating the Ab.

The present invention encompasses variants of the antibodies, or antigen-binding fragments thereof of the invention, which may comprise 1, 2, 3, 4 or 5 amino acid substitutions and/or

5 deletions and/or insertions in the individual sequences disclosed herein.

"Substitution" variants preferably involve the replacement of one or more amino acid(s) with the same number of amino acid(s). Substitutions may be, but are not limited to, conservative substitutions. For example, an amino acid may be substituted to an amino acid with similar biochemical properties, for example, a basic amino acid may be substituted to another basic

10 amino acid (e.g. lysine to arginine), an acidic amino acid may be substituted to another acidic amino acid (e.g. glutamate to aspartate), a neutral amino acid may be substituted to another

neutral amino acid (e.g. threonine to serine), a charged amino acid may be substituted to another charged amino acid (e.g. glutamate to aspartate), a hydrophilic amino acid may be substituted to another hydrophilic amino acid (e.g. asparagine to glutamine), a hydrophobic

15 amino acid may be substituted to another hydrophobic amino acid (e.g. alanine to valine), a polar amino acid may be substituted to another polar amino acid (e.g. serine to threonine), an aromatic amino acid may be substituted to another aromatic amino acid (e.g.

phenylalanine to tryptophan) and an aliphatic amino acid may be substituted to another aliphatic amino acid (e.g. leucine to isoleucine).

20 Preferred variants include those in which instead of the amino acid which appears in the sequence comprises a structural analog of the amino acid.

Epitope and paratope

The term "epitope", as used herein, is defined in the context of a molecular interaction between an "antigen binding polypeptide", such as an antibody (Ab), and its corresponding

25 antigen (Ag). Generally, "epitope" refers to the area or region on an Ag to which an Ab binds, i.e. the area or region in physical contact with the Ab. Physical contact may be defined using various criteria (e.g. a distance cut-off of 2-6 Å, such as 3 Å, such as 3.5 Å such as 4 Å, such as 4.5 Å, such as 5Å; or solvent accessibility) for atoms in the Ab and Ag molecules.

FIX/FIXa and FX/FXa may comprise a number of different epitopes, which may include,

30 without limitation, (1) linear peptide epitopes (2) conformational epitopes which consist of one or more non-contiguous amino acids located near each other in the mature FIX/FIXa or FX/FXa conformation; and (3) epitopes which consist, either in whole or part, of molecular structures covalently attached to FIX/FIXa or FX/FXa, such as carbohydrate groups.

The epitope for a given antibody (Ab)/antigen (Ag) pair can be described and characterized

35 at different levels of detail using a variety of experimental and computational epitope

mapping methods. The experimental methods include mutagenesis, X-ray crystallography, Nuclear Magnetic Resonance (NMR) spectroscopy, Hydrogen Deuterium eXchange Mass Spectrometry (HDX-MS) and various competition binding methods; methods that are known in the art. As each method relies on a unique principle, the description of an epitope is
5 intimately linked to the method by which it has been determined. Thus, depending on the epitope mapping method employed, the epitope for a given Ab/Ag pair may be described differently.

In the context of an X-ray derived crystal structure defined by spatial coordinates of a complex between an Ab, e.g. a Fab fragment, and its Ag, the term epitope is herein, unless
10 otherwise specified or contradicted by context, specifically defined as FIX/FIXa or FX/FXa residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å, from a heavy atom in the Ab.

Epitopes described at the amino acid level, e.g. determined from an X-ray structure, are said to be identical if they contain the same set of amino acid residues. Epitopes are said to
15 overlap if at least one amino acid residue is shared by the epitopes. Epitopes are said to be separate (unique) if no amino acid residue is shared by the epitopes.

The definition of the term "paratope" is derived from the above definition of "epitope" by reversing the perspective. Thus, the term "paratope" refers to the area or region on the antibody, or fragment thereof to which an antigen binds, i.e. to which it makes physical
20 contact to the antigen.

In the context of an X-ray derived crystal structure, defined by spatial coordinates of a complex between an Ab, such as a Fab fragment, and its Ag, the term paratope is herein, unless otherwise specified or contradicted by context, specifically defined as Ab residues
25 characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å from a heavy atom in FIX/FIXa or FX/FXa.

The epitope and paratope for a given antibody (Ab)/antigen (Ag) pair may be identified by routine methods. For example, the general location of an epitope may be determined by assessing the ability of an antibody to bind to different fragments or variants of FIX/FIXa or FX/FXa. The specific amino acids within FIX/FIXa or FX/FXa that make contact with an
30 antibody (epitope) and the specific amino acids in an antibody that make contact with FIX/FIXa or FX/FXa (paratope) may also be determined using routine methods. For example, the antibody and target molecule may be combined and the Ab:Ag complex may be crystallised. The crystal structure of the complex may be determined and used to identify specific sites of interaction between the antibody and its target.

Epitopes on an antigen may comprise one or more hot-spot residues, i.e. residues which are particularly important for the interaction with the cognate antibody, and where interactions mediated by the side chain of said hot-spot residue contribute significantly to the binding energy for the antibody/antigen interaction (Peng et al. (2014) *PNAS* 111, E2656-E2665).

5 Hot-spot residues can be identified by testing variants of the antigen (here FIX/FIXa and FX), where single epitope residues have been substituted by e.g. alanine, for binding to the cognate antibody. If substitution of an epitope residue with alanine has a strong impact on binding to the antibody, said epitope residue is considered a hot-spot residue, and therefore of particular importance for binding of the antibody to the antigen.

10 Antibodies that bind to the same antigen can be characterised with respect to their ability to bind to their common antigen simultaneously and may be subjected to "competition binding"/"binning". In the present context, the term "binning" refers to a method of grouping antibodies that bind to the same antigen. "Binning" of antibodies may be based on competition binding of two antibodies to their common antigen in assays based on standard
15 techniques.

An antibody's "bin" is defined using a reference antibody. If a second antibody is unable to bind to an antigen at the same time as the reference antibody, the second antibody is said to belong to the same "bin" as the reference antibody. In this case, the reference and the second antibody competitively bind the same part of an antigen and are coined "competing
20 antibodies". If a second antibody is capable of binding to an antigen at the same time as the reference antibody, the second antibody is said to belong to a separate "bin". In this case, the reference and the second antibody do not competitively bind the same part of an antigen and are coined "non-competing antibodies".

Antibody "binning" does not provide direct information about the epitope.

25 Competing antibodies, i.e. antibodies belonging to the same "bin" may have identical epitopes, overlapping epitopes or even separate epitopes. The latter is the case if the reference antibody bound to its epitope on the antigen takes up the space required for the second antibody to contact its epitope on the antigen ("steric hindrance"). Non-competing antibodies generally have separate epitopes. Thus, in some embodiments antibodies of the
30 invention will bind to the same epitope as at least one of the antibodies specifically disclosed herein.

Competition assays for determining whether an antibody competes for binding with, an anti-FIX/FIXa or anti-FX/FXa antibody disclosed herein are known in the art. Exemplary competition assays include immunoassays (e.g., ELISA assays, RIA assays), surface

plasmon resonance analysis (e.g. using a BIAcore™ instrument), biolayer interferometry (ForteBio®) and flow cytometry.

Typically, a competition assay involves the use of an antigen bound to a solid surface or expressed on a cell surface, a test FIX- or FIXa binding antibody and a reference antibody.

- 5 The reference antibody is labelled and the test antibody is unlabelled. Competitive inhibition is measured by determining the amount of labelled reference antibody bound to the solid surface or cells in the presence of the test antibody. Usually the test antibody is present in excess (e.g., 1, 5, 10, 20, 100, 1000, 10000 or 100000 fold). Antibodies identified as being competitive in the competition assay (i.e., competing antibodies) include antibodies binding
10 to the same epitope, or overlapping epitopes, as the reference antibody, and antibodies binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur.

- In an exemplary competition assay, a reference anti-FIX or anti-FIXa antibody is biotinylated using commercially available reagents. The biotinylated reference antibody is mixed with
15 serial dilutions of the test antibody or unlabelled reference antibody (self-competition control) resulting in a mixture of various molar ratios (e.g., 1, 5, 10, 20, 100, 1000, 10000 or 100000 fold) of test antibody (or unlabelled reference antibody) to labelled reference antibody. The antibody mixture is added to a FIX or FIXa polypeptide coated-ELISA plate. The plate is then washed, and horseradish peroxidase (HRP)-streptavidin is added to the plate as the detection
20 reagent. The amount of labelled reference antibody bound to the target antigen is detected following addition of a chromogenic substrate (e.g., TMB (3,3',5,5'-tetramethylbenzidine) or ABTS (2,2'-azino-di-(3-ethylbenzthiazoline-6- sulfonate)), which are known in the art. Optical density readings (OD units) are made using a spectrometer (e.g. SpectraMax® M2 spectrometer (Molecular Devices)). The response (OD units) corresponding to zero percent
25 inhibition is determined from wells without any competing antibody. The response (OD units) corresponding to 100% inhibition, i.e. the assay background, is determined from wells without any labelled reference antibody or test antibody. Percent inhibition of labelled reference antibody to FIX or FIXa by the test antibody (or the unlabelled reference antibody) at each concentration is calculated as follows: % inhibition = (1- (OD units - 100%
30 inhibition)/(0% inhibition - 100% inhibition))* 100.

The person skilled in the art will understand that similar assays may be performed to determine if two or more anti-FX/FXa antibodies shares a binding region, a bin and/or competitively binds the antigen. Persons skilled in the art will also appreciate that the competition assay can be performed using various detection systems known in the art.

A test antibody competes with the reference antibody for binding to the antigen if an excess of one antibody (e.g., 1, 5, 10, 20, 100, 1000, 10000 or 100000 fold) inhibits binding of the other antibody, e.g., by at least 50%, 75%, 90%, 95% or 99%, as measured in a competitive binding assay.

- 5 Unless otherwise indicated competition is determined using a competitive ELISA assay as described above.

The term "binding affinity" is herein used as a measure of the strength of a non-covalent interaction between two molecules, e.g. an antibody, or fragment thereof, and an antigen.

The term "binding affinity" is used to describe monovalent interactions.

- 10 Binding affinity between two molecules, e.g. an antibody, or fragment thereof, and an antigen, through a monovalent interaction may be quantified by determining the equilibrium dissociation constant (K_D). K_D can be determined by measurement of the kinetics of complex formation and dissociation, e.g. by the Surface Plasmon Resonance (SPR) method or the Isothermal Titration Calorimetry (ITC) method. The rate constants corresponding to the
- 15 association and the dissociation of a monovalent complex are referred to as the association rate constant k_a (or k_{on}) and dissociation rate constant k_d (or k_{off}), respectively. K_D is related to k_a and k_d through the equation $K_D = k_d / k_a$.

- Following the above definition, binding affinities associated with different molecular interactions, such as comparison of the binding affinity of different antibodies for a given
- 20 antigen, may be compared by comparison of the K_D values for the individual antibody/antigen complexes.

- The value of the dissociation constant can be determined directly by well-known methods. Standard assays to evaluate the binding ability of ligands such as antibodies towards targets are known in the art and include, for example, ELISAs, Western blots, RIAs, and flow
- 25 cytometry analysis. The binding kinetics and binding affinity of the antibody also can be assessed by standard assays known in the art, such as SPR. Preferably, however, isothermal titration calorimetry (ITC) may be used to measure affinities for an antibody/target interaction as well as to derive thermodynamic parameters for the interaction.

- A competitive binding assay can be conducted in which the binding of the antibody to the
- 30 target is compared to the binding of the target by another ligand of that target, such as another antibody.

- The K_D of an antibody of the invention for its target may be less than 100 μM such as less than 10 μM , such as less than 9 μM , such as less than 8 μM , such as less than 7 μM , such as less than 6 μM , such as less than 5 μM , such as less than 4 μM , such as less than 3 μM ,
- 35 such as less than 2 μM , such as less than 1 μM , such as less than 0.9 μM , such as less

than 0.8 μM , such as less than 0.7 μM , such as less than 0.6 μM , such as less than 0.5 μM , such as less than 0.4 μM , such as less than 0.3 μM , such as less than 0.2 μM , such as less than 0.1 μM .

In one such embodiment the antibody is a bispecific antibody comprising an anti-FX arm with a K_D towards FX of less than 100 μM such as less than 10 μM , such as less than 9 μM , such as less than 8 μM , such as less than 7 μM , such as less than 6 μM , such as less than 5 μM , such as less than 4 μM , such as less than 3 μM , such as less than 2 μM , such as less than 1 μM , such as less than 0.9 μM , such as less than 0.8 μM , such as less than 0.7 μM , such as less than 0.6 μM , such as less than 0.5 μM , such as less than 0.4 μM , such as less than 0.3 μM , such as less than 0.2 μM , such as less than 0.1 μM , such as less than 0.09 μM , such as less than 0.08 μM , such as less than 0.07 μM , such as less than 0.06 μM , such as less than 0.05 μM , such as less than 0.04 μM , such as less than 0.03 μM , such as less than 0.02 μM , such as less than 0.01 μM , such as less than 9 nM, such as less than 8 nM, such as less than 7 nM, such as less than 6 nM, such as less than 5 nM, such as less than 4 nM, such as less than 3 nM, such as less than 2 nM, such as less than 1 nM such as less than 0.5 nM.

The antibodies and antibody fragment thereof as described herein may be combined with other antibodies and antibody fragments known in the art creating bispecific, trispecific or multispecific antibody molecules. Compounds mimicking FVIII cofactor function have previously been created using other FIX(a) and FX(a) binding domains, which may potentially each substitute for the FIX(a) and/or FX(a) binding domains described herein. It is thus clear that the FIX(a) and FX(a) binding domains of the invention are of separate interest as individual component (intermediate) molecules, as part of a bi-, tri- or multispecific antibody comprising at least one FIX(a) and/or FX(a) binding domain.

The activity of procoagulant antibodies including bi-, tri and multispecific antibodies may be determined by methods known in the art. Standard assays include whole blood-Thrombin-Generation Test (TGT), measuring of clotting time by thrombelastography (TEG) and FXa generation assays.

Identity

The term "identity" as known in the art, refers to a relationship between the sequences of two or more polypeptides, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptides, as determined by the number of matches between strings of two or more amino acid residues. "Identity" measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (i.e., "algorithms"). Identity of related polypeptides can be readily calculated by known methods.

In the present invention similarity and identity were determined using Needleman (Needleman *et al.* J. Mol. Biol. 1970; 48:443-453) from EMBOSS-6.6.0 using the parameters 10 and 0.5 for gaps opening and extensions, respectively (gapopen=10, gapextend=0.5).

Pharmaceutical formulations

- 5 In another aspect, the present invention provides compositions and formulations comprising compounds of the invention, such as the antibodies described herein. For example, the invention provides a pharmaceutical composition that comprises one or more antibodies of the invention, formulated together with a pharmaceutically acceptable carrier.
- Accordingly, one object of the invention is to provide a pharmaceutical formulation
- 10 comprising such an antibody which is present in a concentration from 0.25 mg/ml to 250 mg/ml, and wherein said formulation has a pH from 2.0 to 10.0. The formulation may further comprise one or more of a buffer system, a preservative, a tonicity agent, a chelating agent, a stabilizer, or a surfactant, as well as various combinations thereof. The use of
- preservatives, isotonic agents, chelating agents, stabilizers and surfactants in
- 15 pharmaceutical compositions is well-known to the skilled person. Reference may be made to Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
- In one embodiment the pharmaceutical formulation is an aqueous formulation. Such a formulation is typically a solution or a suspension, but may also include colloids, dispersions, emulsions, and multi-phase materials. The term "aqueous formulation" is defined as a
- 20 formulation comprising at least 50% w/w water. Likewise, the term "aqueous solution" is defined as a solution comprising at least 50% w/w water, and the term "aqueous suspension" is defined as a suspension comprising at least 50% w/w water.
- In another embodiment the pharmaceutical formulation is a freeze-dried formulation, to which a solvent and/or a diluent is added prior to use.
- 25 In a further aspect, the pharmaceutical formulation comprises an aqueous solution of such an antibody, and a buffer, wherein the antibody is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from about 2.0 to about 10.0.
- In one embodiment the present invention relates to an injection device with content of said composition. In some embodiments the pharmaceutical composition of the invention is
- 30 intended for use and/or contained in an injection device. In some embodiments, the injection device is a disposable, pre-filled, multi-dose pen of the FlexTouch® type (supplier Novo Nordisk A/S, Denmark). In some embodiments the injection device is a single shot device.
- In some embodiments the injection device is a fixed dose device, such as one configured to deliver multiple predetermined doses of drug, sometimes referred to as a multiple fixed dose
- 35 device or a fixed dose, multi-shot device.

In one embodiment the pharmaceutical composition of the invention is administered using an injection device comprising a tube having a needle gauge of 20 or greater.

In one embodiment a bispecific antibody according to table 1 herein is administered using an injection device comprising a tube having a needle gauge of 20 or greater.

- 5 In one embodiment a bispecific antibody according to table 1 herein is administered using an injection device comprising a tube having a needle gauge of 20 to 36. In one such embodiment the bispecific antibody is selected from a list consisting of bimAb05-0745, bimAb05-3761, bimAb05-3761, bimAb05-2112, bimAb05-2113, bimAb05-2114, bimAb05-3769, bimAb05-4271, bimAb05-4756, bimAb05-0396, bimAb05-0417 and bimAb05-0438,

10 **Administration and dosages**

A compound of the invention, such as an antibody, may be administered parenterally, such as intravenously, such as intramuscularly, such as subcutaneously. Alternatively, an antibody of the invention may be administered via a non-parenteral route, such as periorally or topically. An antibody of the invention may be administered prophylactically. An antibody of the invention may be administered therapeutically (on demand).

- 15 The dose of the compounds to be delivered may be from about 0.01 mg to 500 mg of the compound per day, preferably from about 0.1 mg to 250 mg per day, and more preferably from about 0.5 mg to about 250 mg per day, per week, per second week or per month as loading and maintenance doses, depending on the severity of the condition. A suitable dose may also be adjusted for a particular compound based on the properties of that compound, including its *in vivo* half-life or mean residence time and its biological activity. For example, compounds to be delivered could in one embodiment be administered once weekly, or in another embodiment once every second week or in another embodiment once monthly and in either of said embodiments in a dose of for example 0.025, 0.05, 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 mg per kg body weight.

- 25 The compositions containing the compounds as disclosed herein can be administered for prophylactic and/or in some embodiments therapeutic treatments. In therapeutic applications, compositions are administered to a subject already suffering from a disease, such as any bleeding disorder as described above, in an amount sufficient to cure, alleviate or partially arrest the disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective amount". As will be understood by the person skilled in the art amounts effective for this purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject.

Embodiments

The invention is further described by the following embodiments:

1. An antibody or antigen-binding fragment thereof capable of binding to Factor IX (FIX) according to SEQ ID NO:1 and/or the activated form thereof (FIXa).
- 5 2. The antibody or antigen-binding fragment thereof according to embodiment 1, wherein the antibody or antigen-binding fragment thereof is part of "BinB" as described herein.
3. The antibody or antigen-binding fragment thereof according to embodiment 1, wherein the antibody or antigen-binding fragment thereof competes with a reference antibody wherein the reference antibody comprises
 - 10 a. a heavy chain variable domain identified by SEQ ID NO:35 and a light chain variable domain identified by SEQ ID NO:39,
 - b. a heavy chain variable domain identified by SEQ ID NO:43 and a light chain variable domain identified by SEQ ID NO:47, or
 - c. a heavy chain variable domain identified by SEQ ID NO:51 and a light chain variable domain identified by SEQ ID NO:55, or
 - 15 d. a heavy chain variable domain identified by SEQ ID NO:67 and a light chain variable domain identified by SEQ ID NO:71, or
 - e. a heavy chain variable domain identified by SEQ ID NO:1202 and a light chain variable domain identified by SEQ ID NO:1206, or
 - 20 f. a heavy chain variable domain identified by SEQ ID NO:1210 and a light chain variable domain identified by SEQ ID NO:1214, or
 - g. a heavy chain variable domain identified by SEQ ID NO:1218 and a light chain variable domain identified by SEQ ID NO:1222, or
 - h. a heavy chain variable domain identified by SEQ ID NO:1226 and a light chain variable domain identified by SEQ ID NO:1230, or
 - 25 i. a heavy chain variable domain identified by SEQ ID NO:1234 and a light chain variable domain identified by SEQ ID NO:1238, or
 - j. a heavy chain variable domain identified by SEQ ID NO:1242 and a light chain variable domain identified by SEQ ID NO:1246.
- 30 4. The antibody or antigen-binding fragment thereof according to the previous embodiment, wherein the reference antibody is a Fab.
5. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof comprises

- 5 a. a heavy chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:35 and a light chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:39; or
- b. a heavy chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:43 and a light chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:47; or
- c. a heavy chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:51 and a light chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:55; or
- 10 d. a heavy chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:67 and a light chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:71, or
- e. a heavy chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1202 and a light chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1206, or
- 15 f. a heavy chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1210 and a light chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1214, or
- g. a heavy chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1218 and a light chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1222, or
- 20 h. a heavy chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1226 and a light chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1230, or
- i. a heavy chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1234 and a light chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1238, or
- 25 j. a heavy chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1242 and a light chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:1246.
- 30 6. The antibody or antigen-binding fragment thereof according to embodiment 5, wherein the heavy chain variable domain is at least 92, 94, 96, 97, 98, 99, 99.1 or 99.2 % identical to the sequence identified by SEQ ID NO:35, 43, 51, 67, 1202, 1210, 1218, 1226, 1234 or 1242 respectively.

7. The antibody or antigen-binding fragment thereof according to embodiment 5, wherein the light chain variable domain is at least 92, 94, 96, 97, 98, 99, 99.1 or 99.2 % identical to the sequence identified by SEQ ID NO: 39, 47, 55, 71, 1206, 1214, 1222, 1230, 1238 or 1246 respectively.
- 5 8. The antibody or antigen-binding fragment thereof according to embodiment 6 and 7, wherein both the heavy chain variable domain and the light chain variable domain are at least 92, 94, 96, 97, 98, 99, 99.1 or 99.2 % identical to the identified SEQ IDs.
9. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of
- 10 binding an epitope comprising one or more of the amino acid residues L337, R338, S339, T340, K341 and T343 of SEQ ID NO:1.
10. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding an epitope comprising amino acid residue R338 of SEQ ID NO:1.
- 15 11. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding an epitope comprising amino acid residues R338 and K341 of SEQ ID NO:1.
12. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of
- 20 binding an epitope comprising two or three of the amino acid residues L337, R338, S339, T340, K341 and T343 of SEQ ID NO:1.
13. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding an epitope comprising four or five of the amino acid residues L337, R338,
- 25 S339, T340, K341 and T343 of SEQ ID NO:1.
14. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding an epitope comprising
- 30 a. R338, S339, T340, K341 and T343,
b. L337, S339, T340, K341 and T343,
c. L337, R338, T340, K341 and T343,
d. L337, R338, S339, K341 and T343,
e. L337, R338, S339, T340 and T343
f. L337, R338, S339, T340 and K341,
35 g. L337, R338, S339 and T340, or

- h. R338, T340 and K341
of SEQ ID NO:1.
15. The antibody or antigen-binding fragment thereof according to any of embodiments 1-11, wherein the antibody or antigen-binding fragment thereof is capable of binding an epitope comprising amino acid residues
- 5 a. R338, T340 and K341 of SEQ ID NO:1, or
b. L337, R338, S339, T340 and K341 of SEQ ID NO:1.
16. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, comprising a paratope having the following amino acid residues
- 10 a. H30, D31, W53, D56, S102, S104, Y106 and N107 in the heavy chain variable domain (SEQ ID NO:67) and Y91 and S92 in the light chain variable domain (SEQ ID NO:71), optionally comprising one, two or three amino acid substitutions in the ten recited paratope amino acid residues, or
b. H30, D31, W53, S102, S104, Y106 and N107 in the heavy chain variable
15 domain (SEQ ID NO:51) and residues Y91 and S92 in the light chain variable domain (SEQ ID NO:55), optionally comprising one, two or three amino acid substitutions in the nine recited paratope amino acid residues.
17. The antibody or antigen-binding fragment thereof according to any of embodiments 1-16, comprising a paratope having the following amino acid residues D30, D31, W53,
20 S102, S104 and N107 in the heavy chain variable domain (SEQ ID NO:35) and Y91 and S92 in the light chain variable domain (SEQ ID NO:39), optionally comprising one, two or three amino acid substitutions in the eight recited paratope amino acid residues.
18. The antibody or antigen-binding fragment thereof according to embodiment 16 or 17
25 wherein said substitution(s) is/are a conservative substitution(s).
19. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof comprises
- a.
- 30 i. three heavy chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:35 and
ii. three light chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the light chain variable domain identified by SEQ ID NO:39, or
35 b.

- 5
- i. three heavy chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:43 and
 - ii. three light chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the light chain variable domain identified by SEQ ID NO:47, or
- c.
- 10
- i. three heavy chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:51 and
 - ii. three light chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the light chain variable domain identified by SEQ ID NO:55, or
- d.
- 15
- i. three heavy chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:67 and
 - ii. three light chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the light chain variable domain identified by SEQ ID NO:71, or
- 20
- e.
- 25
- i. three heavy chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:1202 and
 - ii. three light chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the light chain variable domain identified by SEQ ID NO:1206, or
- f.
- 30
- i. three heavy chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:1210 and
 - ii. three light chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the light chain variable domain identified by SEQ ID NO:1214, or
- 35
- g.

- 5
- 10
- 15
- 20
- 25
- 30
- i. three heavy chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:1218 and
 - ii. three light chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the light chain variable domain identified by SEQ ID NO:1222, or
 - h.
 - i. three heavy chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:1226 and
 - ii. three light chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the light chain variable domain identified by SEQ ID NO:1230, or
 - i.
 - i. three heavy chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:1234 and
 - ii. three light chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the light chain variable domain identified by SEQ ID NO:1238, or
 - j.
 - i. three heavy chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:1242 and
 - ii. three light chain CDR sequences with at most 10 amino acid changes compared to the CDR sequences of the light chain variable domain identified by SEQ ID NO:1246.
 - 20. The antibody or antigen-binding fragment thereof according to embodiment 19, wherein the three heavy chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the identified SEQ ID NOs.
 - 21. The antibody or antigen-binding fragment thereof according to embodiment 19, wherein the three heavy chain CDR sequences have at most 5, such as 4, such as 3,

such as 2 or at most 1 amino acid changes compared to the CDRs of the identified SEQ ID NOs.

22. The antibody or antigen-binding fragment thereof according to embodiment 19,
wherein the three light chain CDR sequences have at most 9, such as 8, such as 7 or
5 such as 6 amino acid changes compared to the CDRs of the identified SEQ ID NOs.
23. The antibody or antigen-binding fragment thereof according to embodiment 19,
wherein the three light chain CDR sequences have at most 5, such as 4, such as 3,
such as 2 or at most 1 amino acid changes compared to the CDRs of the identified
SEQ IDs.
- 10 24. The antibody or antigen-binding fragment thereof according to any of the previous
embodiments, wherein the antibody or antigen-binding fragment thereof comprises
- a. the CDR sequences of the heavy chain variable domain identified by SEQ ID
NO:35 and the CDR sequences of the light chain variable domain identified by
SEQ ID NO:39, or
 - 15 b. the CDR sequences of the heavy chain variable domain identified by SEQ ID
NO:43 and the CDR sequences of the light chain variable domain identified by
SEQ ID NO:47, or
 - c. the CDR sequences of the heavy chain variable domain identified by SEQ ID
NO:51 and the CDR sequences of the light chain variable domain identified by
20 SEQ ID NO:55, or
 - d. the CDR sequences of the heavy chain variable domain identified by SEQ ID
NO:67 and the CDR sequences of the light chain variable domain identified by
SEQ ID NO:71, or
 - e. the CDR sequences of the heavy chain variable domain identified by SEQ ID
25 NO:1202 and the CDR sequences of the light chain variable domain identified
by SEQ ID NO:1206, or
 - f. the CDR sequences of the heavy chain variable domain identified by SEQ ID
NO:1210 and the CDR sequences of the light chain variable domain identified
by SEQ ID NO:1214, or
 - 30 g. the CDR sequences of the heavy chain variable domain identified by SEQ ID
NO:1218 and the CDR sequences of the light chain variable domain identified
by SEQ ID NO:1222, or
 - h. the CDR sequences of the heavy chain variable domain identified by SEQ ID
35 NO:1226 and the CDR sequences of the light chain variable domain identified
by SEQ ID NO:1230, or

- i. the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:1234 and the CDR sequences of the light chain variable domain identified by SEQ ID NO:1238, or
 - j. the CDR sequences of the heavy chain variable domain identified by SEQ ID NO:1242 and the CDR sequences of the light chain variable domain identified by SEQ ID NO:1246.
25. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof comprises
- a. a heavy chain variable domain identified by SEQ ID NO:35 and a light chain variable domain identified by SEQ ID NO:39, or
 - b. a heavy chain variable domain identified by SEQ ID NO:43 and a light chain variable domain identified by SEQ ID NO:47, or
 - c. a heavy chain variable domain identified by SEQ ID NO:51 and a light chain variable domain identified by SEQ ID NO:55, or
 - d. a heavy chain variable domain identified by SEQ ID NO:67 and a light chain variable domain identified by SEQ ID NO:71, or
 - e. a heavy chain variable domain identified by SEQ ID NO:1202 and a light chain variable domain identified by SEQ ID NO:1206, or
 - f. a heavy chain variable domain identified by SEQ ID NO:1210 and a light chain variable domain identified by SEQ ID NO:1214, or
 - g. a heavy chain variable domain identified by SEQ ID NO:1218 and a light chain variable domain identified by SEQ ID NO:1222, or
 - h. a heavy chain variable domain identified by SEQ ID NO:1226 and a light chain variable domain identified by SEQ ID NO:1230, or
 - i. a heavy chain variable domain identified by SEQ ID NO:1234 and a light chain variable domain identified by SEQ ID NO:1238, or
 - j. a heavy chain variable domain identified by SEQ ID NO:1242 and a light chain variable domain identified by SEQ ID NO:1246.
26. An antibody or antigen-binding fragment thereof capable of binding to FX (SEQ ID NO:2) and/or the activated form thereof (FXa).
27. The antibody or antigen-binding fragment thereof according to embodiment 26, wherein the antibody or antigen-binding fragment thereof is part of "Bin2".
28. The antibody or antigen-binding fragment thereof according to embodiment 26, wherein the antibody or antigen-binding fragment thereof competes with a reference antibody wherein the reference antibody comprises

- a. a heavy chain variable domain identified by SEQ ID NO:467 and a light chain variable domain identified by SEQ ID NO:471, or
- b. a heavy chain variable domain identified by SEQ ID NO:483 and a light chain variable domain identified by SEQ ID NO:487, or
- 5 c. a heavy chain variable domain identified by SEQ ID NO:707 and a light chain variable domain identified by SEQ ID NO:711, or
- d. a heavy chain variable domain identified by SEQ ID NO:731 and a light chain variable domain identified by SEQ ID NO:735, or
- e. a heavy chain variable domain identified by SEQ ID NO:907 and a light chain variable domain identified by SEQ ID NO:911, or
- 10 f. a heavy chain variable domain identified by SEQ ID NO:1075 and a light chain variable domain identified by SEQ ID NO:1079.
29. The antibody according to any of the previous embodiments, wherein the reference antibody is a Fab.
- 15 30. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:467, 483, 707, 731, 907 or 1075 and a light chain variable domain at least 90% identical to the sequence identified by SEQ ID NO:471, 487, 711, 735, 911 or 1079.
- 20 31. The antibody or antigen-binding fragment thereof according to embodiment 30, wherein the heavy chain variable domain is at least 92, 94, 96, 97, 98, 99, 99.1 or 99.2 % identical to the sequence identified by SEQ ID NO: 467, 483, 707, 731, 907 or 1075.
32. The antibody or antigen-binding fragment thereof according to embodiment 30,
- 25 wherein the light chain variable domain is at least 92, 94, 96, 97, 98, 99, 99.1 or 99.2 % identical to the sequence identified by SEQ ID NO:471, 487, 711, 735, 911 or 1079.
33. The antibody or antigen-binding fragment thereof according to embodiment 31 and 32, wherein both the heavy chain variable domain and the light chain variable domain are at least 92, 94, 96, 97, 98, 99 or 99.1 % identical to the identified SEQ IDs.
- 30 34. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding an epitope comprising one or more of the amino acid residues E103, Q104, V108, R113, T116, L117, D119, I125, T127, E228, F229, Y230, E266, R287, P291, I292, P304, L419, K420, D423, R424, M426, K427 and T428 of FX(a).

35. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding an epitope comprising 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 of the amino acid residues E103, Q104, V108, R113, T116, L117, D119, I125, T127, E228, F229, Y230, E266, R287, P291, I292, P304, L419, K420, D423, R424, M426, K427 and T428 of FX(a)
36. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding an epitope comprising the amino acid residues Y230, D423, R424 and K427 of FX(a).
37. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding an epitope comprising the amino acid residues E103, Q104, V108, R113, T116, L117, D119, I125, T127, E228, F229, Y230, E266, R287, P291, I292, P304, L419, K420, D423, R424, M426, K427 and T428 of FX(a).
38. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, comprising a paratope comprising the following amino acid residues K23, S25, G26, Y27, F29, W33, D52, S54, D55, F57, S77, H100, Y101, Y102, N103, S104 in the heavy chain variable domain (SEQ ID NO:467) and residues V29, S30, S31, Y33, Y50, Q52, S54, R55, R57 and D94 in the light chain variable domain (SEQ ID NO:471), optionally comprising one, two, three, four or five amino acid substitutions, deletions or insertions in the 26 recited paratope amino acid residues.
39. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding an epitope comprising one or more of the amino acid residues E103, Q104, V108, R113, T116, L117, A118, D119, I125, T127, S227, E228, Y230, R287, I292, L303, P304, L419, K420, D423, R424, M426, K427 and T428 of FX(a).
40. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding an epitope comprising 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 of the amino acid residues E103, Q104, V108, R113, T116, L117, A118, D119, I125, T127, S227, E228, Y230, R287, I292, L303, P304, L419, K420, D423, R424, M426, K427 and T428 of FX(a).
41. The antibody or antigen-binding fragment thereof according to any of the previous embodiments, wherein the antibody or antigen-binding fragment thereof is capable of

binding an epitope comprising the amino acid residues E103, Q104, V108, R113, T116, L117, D119, I125, T127, E228, F229, Y230, E266, R287, P291, I292, P304, L419, K420, D423, R424, M426, K427 and T428 of FX(a).

42. The antibody or antigen-binding fragment thereof according to any of the previous
5 embodiments, comprising a paratope comprising the following amino acid residues
K23, G24, S25, G26, Y27, W33, D52, S54, D55, Y57, S77, L99, H100, Y101, Y102,
N103 and S104 in the variable heavy chain domain (SEQ ID NO:483) and residues
S30, S31, Y33, Y50, Q52, S54, R55, R57, Y92 and D94 in the light chain variable
10 domain (SEQ ID NO:487), optionally comprising one, two, three, four or five amino
acid substitutions, deletions or insertions in the 27 recited paratope amino acid
residues.
43. The antibody or antigen-binding fragment thereof according to embodiment 38 or 42
wherein said substitution(s) is/are a conservative substitution(s).
44. The antibody or antigen-binding fragment thereof according to any of embodiments
15 26-43, wherein the antibody or antigen-binding fragment thereof comprises
- a. three heavy chain CDR sequences with at most 10 amino acid changes
compared to the CDR sequences of the heavy chain variable domain identified
by SEQ ID NO:467 and
three light chain CDR sequences with at most 10 amino acid changes
20 compared to the CDR sequences of the light chain variable domain identified
by SEQ ID NO:471; or
- b. three heavy chain CDR sequences with at most 10 amino acid changes
compared to the CDR sequences of the heavy chain variable domain identified
by SEQ ID NO:483, and
25 three light chain CDR sequences with at most 10 amino acid changes
compared to the CDR sequences of the light chain variable domain identified
by SEQ ID NO:487.
45. The antibody or antigen-binding fragment thereof according to embodiment 44,
wherein the three heavy chain CDR sequences have at most 9, such as 8, such as 7
30 or such as 6 amino acid changes compared to the CDRs of the identified SEQ IDs.
46. The antibody or antigen-binding fragment thereof according to embodiment 44,
wherein the three heavy chain CDR sequences have at most 5, such as 4, such as 3,
such as 2 or at most 1 amino acid changes compared to the CDRs of the identified
SEQ IDs.

47. The antibody or antigen-binding fragment thereof according to embodiment 44,
wherein the three light chain CDR sequences have at most 9, such as 8, such as 7 or
such as 6 amino acid changes compared to the CDRs of the identified SEQ IDs.
48. The antibody or antigen-binding fragment thereof according to embodiment 44,
5 wherein the three light chain CDR sequences have at most 5, such as 4, such as 3,
such as 2 or at most 1 amino acid changes compared to the CDRs of the identified
SEQ IDs.
49. The antibody or antigen-binding fragment thereof according to any of the previous
embodiments, wherein the antibody or antigen-binding fragment thereof comprises the
10 CDR sequences of
- a. the heavy chain variable domain identified by SEQ ID NO:467 and the CDR
sequences of the light chain variable domain identified by SEQ ID NO:471; or
 - b. the heavy chain variable domain identified by SEQ ID NO:483 and the CDR
sequences of the light chain variable domain identified by SEQ ID NO:487; or
 - 15 c. the heavy chain variable domain identified by SEQ ID NO:555 and the CDR
sequences of the light chain variable domain identified by SEQ ID NO:559; or
 - d. the heavy chain variable domain identified by SEQ ID NO:587 and the CDR
sequences of the light chain variable domain identified by SEQ ID NO:591; or
 - e. the heavy chain variable domain identified by SEQ ID NO:707 and the CDR
20 sequences of the light chain variable domain identified by SEQ ID NO:711; or
 - f. the heavy chain variable domain identified by SEQ ID NO:731 and the CDR
sequences of the light chain variable domain identified by SEQ ID NO:735; or
 - g. the heavy chain variable domain identified by SEQ ID NO:907 and the CDR
sequences of the light chain variable domain identified by SEQ ID NO:911; or
 - 25 h. the heavy chain variable domain identified by SEQ ID NO:1075 and the CDR
sequences of the light chain variable domain identified by SEQ ID NO:1079.
50. The antibody or antigen-binding fragment thereof according to any of the previous
embodiments, wherein the antibody or antigen-binding fragment thereof comprises
- a. a heavy chain variable domain identified by SEQ ID NO:467 and a light chain
30 variable domain identified by SEQ ID NO:471; or
 - b. a heavy chain variable domain identified by SEQ ID NO:483 and a light chain
variable domain identified by SEQ ID NO:487; or
 - c. a heavy chain variable domain identified by SEQ ID NO:555 and a light chain
variable domain identified by SEQ ID NO:559; or

- d. a heavy chain variable domain identified by SEQ ID NO:587 and a light chain variable domain identified by SEQ ID NO:591; or
- e. a heavy chain variable domain identified by SEQ ID NO:707 and a light chain variable domain identified by SEQ ID NO:711; or
- 5 f. a heavy chain variable domain identified by SEQ ID NO:731 and a light chain variable domain identified by SEQ ID NO:735; or
- g. a heavy chain variable domain identified by SEQ ID NO:907 and a light chain variable domain identified by SEQ ID NO:911; or
- 10 h. a heavy chain variable domain identified by SEQ ID NO:1075 and a light chain variable domain identified by SEQ ID NO:1079.
51. A multispecific antibody or antigen-binding fragment thereof capable of binding to FIX according to SEQ ID NO:1 or the activated form thereof (FIXa), and FX (SEQ ID NO:2) or the activated form thereof (FXa).
52. The multispecific antibody or antigen-binding fragment thereof according to
15 embodiment 51, wherein the antibody comprises an antibody or antigen-binding fragment thereof according to any of the previous embodiments 1-50.
53. The multispecific antibody or antigen-binding fragment thereof according to embodiment 51, wherein the antibody comprises an antibody or antigen-binding fragment thereof according to any of the previous embodiments 2-25.
- 20 54. The multispecific antibody or antigen-binding fragment thereof according to embodiment 51, wherein the antibody comprises an antibody or antigen-binding fragment thereof according to any of the previous embodiments 26-50.
55. The multispecific antibody or antigen-binding fragment thereof according to embodiment 51, wherein the antibody comprises an antibody or antigen-binding
25 fragment thereof according to any of the previous embodiments 27-50.
56. The multispecific antibody or antigen-binding fragment thereof according to embodiment 51, wherein the antibody comprises an antibody or antigen-binding fragment thereof according to any of the previous embodiments 1-25 and an antigen-binding fragment according to any of the previous embodiments 26-50.
- 30 57. The multispecific antibody or antigen-binding fragment thereof according to embodiment 51, wherein the antibody comprises an antibody or antigen-binding fragment thereof according to any of the previous embodiments 2-25 and an antibody or antigen-binding fragment thereof according to any of the previous embodiments 27-50.

58. The multispecific antibody or antigen-binding fragment thereof according to any of embodiments 51-57 comprising
- 5 a. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:38, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:42, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 10 the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:470, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:474, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 15 b. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:38, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:42, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 20 the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO: 486, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO: 490, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 25 c. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:46, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 30 the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:50, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:470, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 35

- the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:474, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 5 d. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:54, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:58, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 10 the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:470, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:474, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 15 e. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:54, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:58, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 20 the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:486, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 25 the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:490, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- f. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:54, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 30 the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:58, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:558, optionally comprising 1, 2 or 3 amino acid substitutions and/or
- 35

- deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID
NO:562, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; or
- 5 g. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID
NO:54, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID
NO:58, optionally comprising 1, 2 or 3 amino acid substitutions and/or
10 deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID
NO:590, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID
15 NO:594, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; or
- h. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID
NO:54, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
20 the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID
NO:58, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID
NO:710, optionally comprising 1, 2 or 3 amino acid substitutions and/or
25 deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID
NO:714, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; or
- i. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID
30 NO:54, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID
NO:58, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
35 the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID

- NO:734, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:738, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 5 j. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:54, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:58, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 10 the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:910, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:914, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 15 k. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:54, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:58, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 20 the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:1078, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:1082, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 25 l. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:70, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:74, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 30
35

- the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:470, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:474, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 5 m. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:70, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 10 the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:74, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:486, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 15 the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:490, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- n. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:1205, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 20 the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:1209, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 25 the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:1213, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:1217, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 30 o. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:1221, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:1225, optionally comprising 1, 2 or 3 amino acid substitutions and/or
- 35

- deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID
NO:470, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
- 5 the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID
NO:474, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; or
- p. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID
NO:1229, optionally comprising 1, 2 or 3 amino acid substitutions and/or
10 deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID
NO:1233, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID
15 NO:470, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID
NO:474, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; or
- 20 q. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID
NO:1237, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID
NO:1241, optionally comprising 1, 2 or 3 amino acid substitutions and/or
25 deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID
NO:470, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID
30 NO:474, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; or
- r. the anti-FIX(a) antibody heavy chain CDR3 sequence identified by SEQ ID
NO:1245, optionally comprising 1, 2 or 3 amino acid substitutions and/or
deletions and/or insertions; and
35 the anti-FIX(a) antibody light chain CDR3 sequence identified by SEQ ID

- NO:1249, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR3 sequence identified by SEQ ID NO:470, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR3 sequence identified by SEQ ID NO:474, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
59. The multispecific antibody or antigen-binding fragment thereof according to any of embodiments 51-57 comprising
- a. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:36, 37 and 38, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:40, 41 and 42, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- b. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:36, 37 and 38, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:40, 41 and 42, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:484, 485 and 486, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:488, 489 and 490, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or

- 5 c. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:44, 45 and 46, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:48, 49 and 50, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 10 the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 15 d. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:52, 53 and 54, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:56, 57 and 58, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 20 e. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:52, 53 and 54, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:56, 57 and 58, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:708, 709 and 710, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID
- 25
- 30

- NOs:712, 713 and 714, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 5 f. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:52, 53 and 54, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:56, 57 and 58, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 10 the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:732, 733 and 734, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:736, 737 and 738, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 15 g. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:52, 53 and 54, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:56, 57 and 58, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 20 the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:908, 909 and 910, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:912, 913 and 914, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 25 h. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:52, 53 and 54, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 30 the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:56, 57 and 58, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:1076, 1077 and 1078, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 35

- the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:1080, 1081 and 1082, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 5 i. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:52, 53 and 54, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:56, 57 and 58, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 10 the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs: 484, 485 and 486, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:488, 489 and 490, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 15 j. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:68, 69 and 70, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs: 72, 73 and 74, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 20 the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 25 the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- k. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:68, 69 and 70, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 30 the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:72, 73 and 74, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:484, 485 and 486, respectively, optionally comprising 1, 2 or 3 amino
- 35

- acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID
NOs:488, 489 and 490, respectively, optionally comprising 1, 2 or 3 amino
acid substitutions and/or deletions and/or insertions; or
- 5 I. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ
ID NOs:1203, 1204 and 1205, respectively, optionally comprising 1, 2 or 3
amino acid substitutions and/or deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID
NOs:1207, 1208 and 1209, respectively, optionally comprising 1, 2 or 3
10 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID
NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino
acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID
15 NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino
acid substitutions and/or deletions and/or insertions; or
- m. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ
ID NOs:1211, 1212 and 1213, respectively, optionally comprising 1, 2 or 3
amino acid substitutions and/or deletions and/or insertions; and
20 the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID
NOs:1215, 1216 and 1217, respectively, optionally comprising 1, 2 or 3
amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID
NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino
25 acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID
NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino
acid substitutions and/or deletions and/or insertions; or
- n. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ
30 ID NOs:1219, 1220 and 1221, respectively, optionally comprising 1, 2 or 3
amino acid substitutions and/or deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID
NOs:1223, 1224 and 1225, respectively, optionally comprising 1, 2 or 3
amino acid substitutions and/or deletions and/or insertions; and
35 the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID

- 5 NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 10 o. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:1227, 1228 and 1229, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:1231, 1232 and 1233, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 15 the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 20 p. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:1235, 1236 and 1237, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:1239, 1240 and 1241, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 25 the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; or
- 30 q. the anti-FIX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:1243, 1244 and 1245, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FIX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:1247, 1248 and 1249, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
- 35

- the anti-FX(a) antibody heavy chain CDR1-3 sequences identified by SEQ ID NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions; and
the anti-FX(a) antibody light chain CDR1-3 sequences identified by SEQ ID NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid substitutions and/or deletions and/or insertions.
- 5
60. The multispecific antibody or antigen-binding fragment thereof according to embodiment 51 wherein the antibody is a bispecific antibody capable of specifically binding FIX(a) and FX(a) wherein the binding domains are those of the mAb pairs consisting of: mAb01-9933/mAb01-8174, mAb01-9933/mAb01-9772, mAb01-9978/mAb01-8174, mAb01-9978/mAb01-9772, mAb01-9985/mAb01-8174, mAb01-9985/mAb01-9772, mAb01-9994/mAb01-8174, mAb01-9994/mAb01-9772, mAb01-9985/mAb11-1431, mAb01-9985/mAb11-1434, mAb01-9985/mAb11-1457, mAb01-9985/mAb11-1480, mAb01-9985/mAb11-1121, mAb01-9985/mAb11-1125, mAb11-0173 / mAb01-8174, mAb11-1204 / mAb01-8174, mAb11-1495 / mAb01-8174, mAb11-1501 / mAb01-8174 or mAb11-1502 / mAb01-8174.
- 10
- 15
61. The multispecific antibody or antigen-binding fragment thereof according to any of embodiments 51-60 wherein the antibody or antigen-binding fragment thereof is a procoagulant antibody.
- 20
62. The multispecific antibody or antigen-binding fragment thereof according to any of embodiments 51-60 wherein the antibody or antigen-binding fragment thereof is capable of increasing the procoagulant activity of FIXa.
63. The multispecific antibody or antigen-binding fragment thereof according to any of embodiments 51-60 wherein the antibody or antigen-binding fragment thereof is capable of increasing the enzymatic activity of FIXa towards FX.
- 25
64. The multispecific antibody or antigen-binding fragment thereof according to any of embodiments 51-60 wherein the antibody or antigen-binding fragment thereof is capable of functionally substituting for FVIII and/or FVIIIa.
65. The multispecific antibody or antigen-binding fragment thereof according to any of embodiments 51-64 wherein the antibody or antigen-binding fragment thereof is a bispecific antibody.
- 30
66. The multispecific antibody or antigen-binding fragment thereof according to any of embodiments 63-65 wherein the increase of the enzymatic activity of FIXa towards FX is determined in a FIXa generation assay as described herein using a monovalent one-armed anti-FIX/FIXa antibody where in the stimulation index is at least 1300, 1400,
- 35

- 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 3000, 3500,
4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000,
10500, 11000, 11500, 12000, 12500, 13000, 13500, 13730, 14000, 14500, 15000,
15500, 16000, 16500, 17000, 17500, 18000, 18500, 19000 or 19500 fold when
5 measured using an one-armed antibody concentration resulting in at least 80%
saturation of FIXa.
67. The multispecific antibody or antigen-binding fragment thereof according to any of
embodiments 51-65 wherein said antibody or antigen-binding fragment thereof is
capable of providing a mean peak thrombin (in nM) of at least 47, 48, 49, 50, 55, 60,
10 65, 70, 75, 80, 85, 90, 95, 100, 105 or 107 at a compound concentration of 900 nM in
a TGT assay (in HA-PRP) according to example 16 herein.
68. The antibody according to any of the previous embodiments wherein the antibody
isotype is IgG1, IgG2, IgG3 or IgG4 or a combination thereof.
69. A pharmaceutical composition comprising an antibody or antigen-binding fragment
15 thereof according to any of the previous embodiments and optionally one or more
pharmaceutically acceptable carrier(s).
70. The pharmaceutical composition comprising an antibody or antigen-binding fragment
thereof according to embodiment 69 for the treatment of a coagulopathy or blood
coagulation disorder, such as haemophilia A with or without inhibitors.
- 20 71. The antibody or antigen-binding fragment thereof or composition according to any of
the previous embodiments for use in a method of treatment of a coagulopathy or blood
coagulation disorder.
72. The antibody or antigen-binding fragment thereof or composition according to any of
the previous embodiments for use in the treatment of haemophilia A with or without
25 inhibitors.
73. A method of treating a subject suffering from a coagulopathy or blood coagulation
disorder, comprising administering to said subject an antibody or antigen-binding
fragment thereof or composition according to any of the previous embodiments.
74. A method according to embodiment 73 wherein the coagulopathy or blood coagulation
30 disorder is haemophilia A or haemophilia A with inhibitors.
75. Use of an antibody or antigen-binding fragment thereof or composition according to
any of embodiments 1-69 for the manufacture of a medicament for the treatment of a
subject in need thereof.

76. Use of an antibody or antigen-binding fragment thereof or composition according to any of embodiments 1-69 for the manufacture of a medicament for the treatment of haemophilia A with or without inhibitors.
77. A eukaryotic cell which expresses the antibody or antigen-binding fragment thereof,
5 according to any one of embodiments 1-68.
78. A kit comprising the antibody or antigen-binding fragment thereof or composition according to any of embodiments 1-69 and instructions for use.
79. The antibody or antigen-binding fragment thereof according to any of embodiments 1-25 wherein the antibody or antigen-binding fragment thereof is a component
10 (intermediate) for use in a procoagulant multispecific antibody.
80. The antibody or antigen-binding fragment thereof according to any of embodiments 26-50 wherein the antibody or antigen-binding fragment thereof is a component (intermediate) for use in a procoagulant multispecific antibody.
81. The antibody or antigen-binding fragment thereof according to any of embodiments 1-25 wherein the antibody or antigen-binding fragment thereof is a component
15 (intermediate) for use in the manufacture of a procoagulant multispecific antibody.
82. The antibody or antigen-binding fragment thereof according to any of embodiments 26-50 wherein the antibody or antigen-binding fragment thereof is an a component (intermediate) for use in the manufacture of a procoagulant multispecific antibody.
83. The multispecific antibody or antigen-binding fragment thereof according to any of
20 embodiments 61-68 wherein the procoagulant activity of said antibody is improved over the multispecific antibodies disclosed in WO2018/141863.
84. The multispecific antibody or antigen-binding fragment thereof according to embodiment 83 wherein said improvement is determined using an assay as disclosed
25 herein, such as in a FXa generation assay using monovalent one-armed (OA) anti-FIXa antibodies (as described in example 12 herein), a haemophilia A (HA) plasma TGT assay (as described in example 15 herein), in a HA-PPP TGT assay or in a HA-PRP TGT assay (as described in example 16 herein) or in a murine Tail Vein Transsection (TVT) model (as described in example 17 herein).
85. The multispecific antibody or antigen-binding fragment thereof according to
30 embodiment 51, wherein the antibody or antigen binding fragment thereof is a bispecific antibody comprising an antibody or antigen-binding fragment thereof according to embodiment 14 and an antibody or antigen-binding fragment thereof according to embodiment 36 or 37.

86. The multispecific antibody or antigen-binding fragment thereof according to embodiment 85 wherein the stimulation of the enzymatic activity of FIXa towards FX is determined in a FXa generation assay as described in example 12 herein using a monovalent one-armed anti-FIX/FIXa antibody where in the stimulation index is at least 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10000, 10500, 11000, 11500, 12000, 12500, 13000, 13500, 13730, 14000, 14500, 15000, 15500, 16000, 16500, 17000, 17500, 18000, 18500, 19000 or 19500 fold when measured using an one-armed antibody concentration resulting in at least 80% saturation of FIXa.
87. The multispecific antibody or antigen-binding fragment thereof according to any of embodiment 85 wherein said antibody or antigen-binding fragment thereof is capable of providing a mean peak thrombin (in nM) of at least 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105 or 107 at a compound concentration of 900 nM in a TGT assay (in HA-PRP) according to example 16 herein.
88. The antibody according to any of embodiments 85-87 wherein the antibody isotype is IgG1 or IgG4.
89. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to any of embodiments 85-88 and optionally one or more pharmaceutically acceptable carrier(s).
90. The pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to embodiment 89 for the treatment of a coagulopathy or blood coagulation disorder, such as haemophilia A with or without inhibitors.
91. The antibody or antigen-binding fragment thereof or composition according to any of embodiments 83-90 for use in a method of treatment of a coagulopathy or blood coagulation disorder.
92. The antibody or antigen-binding fragment thereof or composition according to any of embodiments 91 for use in the treatment of haemophilia A with or without inhibitors.
93. A method of treating a subject suffering from a coagulopathy or blood coagulation disorder, comprising administering to said subject an antibody or antigen-binding fragment thereof or composition according to any of embodiments 83-90.
94. A method according to embodiment 93 wherein the coagulopathy or blood coagulation disorder is haemophilia A or haemophilia A with inhibitors.

95. Use of an antibody or antigen-binding fragment thereof or composition according to any of embodiments 83-89 for the manufacture of a medicament for the treatment of a subject in need thereof.
- 5 96. Use of an antibody or antigen-binding fragment thereof or composition according to any of embodiments 83-89 for the manufacture of a medicament for the treatment of haemophilia A with or without inhibitors.
97. A eukaryotic cell which expresses the antibody or antigen-binding fragment thereof, according to any one of embodiments 83-88.
- 10 98. A kit comprising the antibody or antigen-binding fragment thereof or composition according to any of embodiments 83-89 and instructions for use.
99. The antibody or antigen-binding fragment thereof according to any of embodiments 83-88 wherein the antibody or antigen-binding fragment capable of binding to FIX(a) is a component (intermediate) for use in a procoagulant multispecific antibody.
- 15 100. The antibody or antigen-binding fragment thereof according to any of embodiments 83-88 wherein the antibody or antigen-binding fragment thereof capable of binding to FIX(a) is a component (intermediate) for use in the manufacture of a procoagulant multispecific antibody.
101. The antibody or antigen-binding fragment thereof according to any of embodiments 83-88 wherein the antibody or antigen-binding fragment thereof is a component (intermediate) for use in the manufacture of a procoagulant multispecific antibody.
- 20 102. An injection device comprising an antibody or antigen-binding fragment thereof or composition according to any of embodiments 51-69.
103. An injection device comprising an antibody or antigen-binding fragment thereof or composition according to any of embodiments 83-90.
- 25 104. The injection device according to embodiment 102 wherein said device is a disposable and/or pre-filled and/or multi-dose device, such as a pen.
105. The injection device according to embodiment 104 wherein said device is a pre-filled pen.
- 30 106. The injection device according to embodiment 104 wherein said device is a multi-dose pen.
107. The injection device according to any of embodiments 102, 104, 105 or 106 wherein said injection device comprises a tube having a needle gauge of 20 to 36.
108. The injection device according to embodiment 103 wherein said device is a disposable and/or pre-filled and/or multi-dose device, such as a pen.

109. The injection device according to embodiment 103 wherein said device is a pre-filled pen.
110. The injection device according to embodiment 108 wherein said device is a multi-dose pen.
- 5 111. The injection device according to any of embodiments 103, 108, 109 or 110 wherein said injection device comprises a tube having a needle gauge of 20 to 36.

In some embodiments the antibodies or antigen-binding fragments thereof of the invention are procoagulant bispecific antibodies capable of binding to FIX (SEQ ID NO:1) and/or the activated form thereof (FIXa) and to FX (SEQ ID NO:2) and/or the activated form thereof (FXa).

In one embodiment the bispecific antibody (bimAb) is bimAb05-0745 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

- 15 VH CDR1 (SEQ ID NO:68): DYAMH
 VH CDR2 (SEQ ID NO:69): GISWKGDIGGYVDSVKG
 VH CDR3 (SEQ ID NO:70): SYGSGSFYNAFDS
 VL CDR1 (SEQ ID NO:72): RASQSISSWLA
 VL CDR2 (SEQ ID NO:73): KASRLDR
 20 VL CDR3 (SEQ ID NO:74): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:468): TSWIV
 VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG
 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV
 25 VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA
 VL CDR2 (SEQ ID NO:473): GQSSRTR
 VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-0746 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

- 30 VH CDR1 (SEQ ID NO:44): DYAMH
 VH CDR2 (SEQ ID NO:45): GISWKGDIGGYVDSVKG
 VH CDR3 (SEQ ID NO:46): SYGSGSFYNAFDS
 VL CDR1 (SEQ ID NO:48): RASQSISSWLA
 VL CDR2 (SEQ ID NO:49): KASRLER
 35 VL CDR3 (SEQ ID NO:50): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

5 VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-1229 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

10 VH CDR1 (SEQ ID NO:4): DYAMH

VH CDR2 (SEQ ID NO:5): GISWRGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:6): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:8): RASQSISSWLA

VL CDR2 (SEQ ID NO:9): KASRLER

15 VL CDR3 (SEQ ID NO:10): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:460): TSWIV

VH CDR2 (SEQ ID NO:461): MIDPSDSFTSYSPSFQG

VH CDR3 (SEQ ID NO:462): LHYYHSEEFDV

20 VL CDR1 (SEQ ID NO:464): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:465): GASSRAR

VL CDR3 (SEQ ID NO:466): QQFGSSRLFT

In one embodiment the bispecific antibody is bimAb05-2112 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

25 VH CDR1 (SEQ ID NO:68): DYAMH

VH CDR2 (SEQ ID NO:69): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:70): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:72): RASQSISSWLA

VL CDR2 (SEQ ID NO:73): KASRLDR

30 VL CDR3 (SEQ ID NO:74): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:484): TSWIS

VH CDR2 (SEQ ID NO:485): MIDPSDSYTSYSPSFQG

VH CDR3 (SEQ ID NO:486): LHYYNSEEFDV

35 VL CDR1 (SEQ ID NO:488): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:489): GQSSRTR

VL CDR3 (SEQ ID NO:490): QQYGDSQLFT

In one embodiment the bispecific antibody is bimAb05-2113 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

5 VH CDR1 (SEQ ID NO:36): DYAMH

VH CDR2 (SEQ ID NO:37): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:38): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:40): RASQSISSWLA

VL CDR2 (SEQ ID NO:41): KASKLDR

10 VL CDR3 (SEQ ID NO:42): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:484): TSWIS

VH CDR2 (SEQ ID NO:485): MIDPSDSYTSYSPSFQG

VH CDR3 (SEQ ID NO:486): LHYYNSEEFDV

15 VL CDR1 (SEQ ID NO:488): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:489): GQSSRTR

VL CDR3 (SEQ ID NO:490): QQYGDSQLFT

In one embodiment the bispecific antibody is bimAb05-2114 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:484): TSWIS

VH CDR2 (SEQ ID NO:485): MIDPSDSYTSYSPSFQG

30 VH CDR3 (SEQ ID NO:486): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:488): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:489): GQSSRTR

VL CDR3 (SEQ ID NO:490): QQYGDSQLFT

In one embodiment the bispecific antibody is bimAb05-2115 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:44): DYAMH
VH CDR2 (SEQ ID NO:45): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:46): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:48): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:49): KASRLER
VL CDR3 (SEQ ID NO:50): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:484): TSWIS
VH CDR2 (SEQ ID NO:485): MIDPSDSYTSYSPSFQG
10 VH CDR3 (SEQ ID NO:486): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:488): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:489): GQSSRTR
VL CDR3 (SEQ ID NO:490): QQYGDSQLFT

In one embodiment the bispecific antibody is bimAb05-2375 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:4): DYAMH
VH CDR2 (SEQ ID NO:5): GISWRGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:6): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:8): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:9): KASRLER
VL CDR3 (SEQ ID NO:10): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:468): TSWIV
VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG
25 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:473): GQSSRTR
VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-2379 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:4): DYAMH
VH CDR2 (SEQ ID NO:5): GISWRGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:6): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:8): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:9): KASRLER

VL CDR3 (SEQ ID NO:10): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:476): TSWIV

VH CDR2 (SEQ ID NO:477): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:478): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:480): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:481): GASSRAR

VL CDR3 (SEQ ID NO:482): QQFGSSRLFT

In one embodiment the bispecific antibody is bimAb05-2532 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:12): DYAMH

VH CDR2 (SEQ ID NO:13): GISWRGDIIGYVDSVKG

VH CDR3 (SEQ ID NO:14): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:16): RASKSISSWLA

15 VL CDR2 (SEQ ID NO:17): KASRLDR

VL CDR3 (SEQ ID NO:18): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:460): TSWIV

VH CDR2 (SEQ ID NO:461): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:462): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:464): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:465): GASSRAR

VL CDR3 (SEQ ID NO:466): QQFGSSRLFT

In one embodiment the bispecific antibody is bimAb05-3279 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:36): DYAMH

VH CDR2 (SEQ ID NO:37): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:38): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:40): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:41): KASKLDR

VL CDR3 (SEQ ID NO:42): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:460): TSWIV

VH CDR2 (SEQ ID NO:461): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:462): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:464): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:465): GASSRAR

VL CDR3 (SEQ ID NO:466): QQFGSSRLFT

In one embodiment the bispecific antibody is bimAb05-3409 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:44): DYAMH

VH CDR2 (SEQ ID NO:45): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:46): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:48): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:49): KASRLER

VL CDR3 (SEQ ID NO:50): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:460): TSWIV

VH CDR2 (SEQ ID NO:461): MIDPSDSFTSYSPSFQG

15 VH CDR3 (SEQ ID NO:462): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:464): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:465): GASSRAR

VL CDR3 (SEQ ID NO:466): QQFGSSRLFT

In one embodiment the bispecific antibody is bimAb05-3416 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:460): TSWIV

VH CDR2 (SEQ ID NO:461): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:462): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:464): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:465): GASSRAR

VL CDR3 (SEQ ID NO:466): QQFGSSRLFT

In one embodiment the bispecific antibody is bimAb05-3755 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:68): DYAMH
VH CDR2 (SEQ ID NO:69): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:70): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:72): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:73): KASRLDR
VL CDR3 (SEQ ID NO:74): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:460): TSWIV
VH CDR2 (SEQ ID NO:461): MIDPSDSFTSYSPSFQG
10 VH CDR3 (SEQ ID NO:462): LHYYHSEEFDV
VL CDR1 (SEQ ID NO:464): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:465): GASSRAR
VL CDR3 (SEQ ID NO:466): QQFGSSRLFT

In one embodiment the bispecific antibody is bimAb05-3761 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:36): DYAMH
VH CDR2 (SEQ ID NO:37): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:38): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:40): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:41): KASKLDR
VL CDR3 (SEQ ID NO:42): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:468): TSWIV
VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG
25 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:473): GQSSRTR
VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-3769 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-3770 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:60): DYAMH

VH CDR2 (SEQ ID NO:61): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:62): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:64): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:65): KASRLER

VL CDR3 (SEQ ID NO:66): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-3862 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:20): DYAMH

VH CDR2 (SEQ ID NO:21): GISWRGDIGGYVDS VKG

VH CDR3 (SEQ ID NO:22): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:24): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:25): KASRLDR

VL CDR3 (SEQ ID NO:26): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-3863 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:28): DYAMH

VH CDR2 (SEQ ID NO:29): GISWRGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:30): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:32): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:33): KASRLER

VL CDR3 (SEQ ID NO:34): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

15 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-3880 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:76): DYAMH

VH CDR2 (SEQ ID NO:77): GISWRGDIKGYVDSVKG

VH CDR3 (SEQ ID NO:78): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:80): RASKSISSWLA

25 VL CDR2 (SEQ ID NO:81): KASRLDR

VL CDR3 (SEQ ID NO:82): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-3886 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:84): DYAMH
VH CDR2 (SEQ ID NO:85): GISWRGDIKGYVDSVKG
VH CDR3 (SEQ ID NO:86): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:88): RASQSISSWLA
5 VL CDR2 (SEQ ID NO:89): KASRLDR
VL CDR3 (SEQ ID NO:90): LEYNSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV
VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG
10 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:473): GQSSRTR
VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-3955 wherein the anti-FIX(a) arm

15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:92): DYAMH
VH CDR2 (SEQ ID NO:93): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:94): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:96): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:97): KAQRLDR
VL CDR3 (SEQ ID NO:98): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV
VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG
25 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:473): GQSSRTR
VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4100 wherein the anti-FIX(a) arm

30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:100): DYAMH
VH CDR2 (SEQ ID NO:101): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:102): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:104): RASQSIKSWLA
35 VL CDR2 (SEQ ID NO:105): KASRLDR

VL CDR3 (SEQ ID NO:106): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4114 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:108): DYAMH

VH CDR2 (SEQ ID NO:109): GISWKGDIGGYADSVKG

VH CDR3 (SEQ ID NO:110): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:112): RASKSISSWLA

15 VL CDR2 (SEQ ID NO:113): KASRLER

VL CDR3 (SEQ ID NO:114): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4121 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:116): DYAMH

VH CDR2 (SEQ ID NO:117): GISWKGDIGGYADSVKG

VH CDR3 (SEQ ID NO:118): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:120): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:121): KASRLER

VL CDR3 (SEQ ID NO:122): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4220 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:212): DYAMH

VH CDR2 (SEQ ID NO:213): GISWKGDIGGYADSVKG

VH CDR3 (SEQ ID NO:214): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:216): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:217): KASKLDR

VL CDR3 (SEQ ID NO:218): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

15 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4226 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:220): DYAMH

VH CDR2 (SEQ ID NO:221): GISWKGDIGGYADSVKG

VH CDR3 (SEQ ID NO:222): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:224): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:225): KASKLER

VL CDR3 (SEQ ID NO:226): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4283 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:228): DYAMH
VH CDR2 (SEQ ID NO:229): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:230): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:232): RASQSISSWLA

5 VL CDR2 (SEQ ID NO:233): KASKLDR

VL CDR3 (SEQ ID NO:234): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

10 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4289 wherein the anti-FIX(a) arm

15 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:236): DYAMH

VH CDR2 (SEQ ID NO:237): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:238): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:240): RASQSISSWLA

20 VL CDR2 (SEQ ID NO:241): KASKLER

VL CDR3 (SEQ ID NO:242): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

25 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4292 wherein the anti-FIX(a) arm

30 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:252): DYAMH

VH CDR2 (SEQ ID NO:253): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:254): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:256): RASQSISSWLA

35 VL CDR2 (SEQ ID NO:257): KASKLER

VL CDR3 (SEQ ID NO:258): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4293 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:244): DYAMH

VH CDR2 (SEQ ID NO:245): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:246): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:248): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:249): KASKLDR

VL CDR3 (SEQ ID NO:250): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4387 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:260): DYAMH

VH CDR2 (SEQ ID NO:261): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:262): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:264): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:265): KASKLDR

VL CDR3 (SEQ ID NO:266): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4392 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:268): DYAMH

VH CDR2 (SEQ ID NO:269): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:270): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:272): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:273): KASKLER

VL CDR3 (SEQ ID NO:274): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

15 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4419 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:124): DYAMH

VH CDR2 (SEQ ID NO:125): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:126): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:128): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:129): KASKLDR

VL CDR3 (SEQ ID NO:130): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4422 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:276): DYAMH
VH CDR2 (SEQ ID NO:277): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:278): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:280): RASQSISSWLA
5 VL CDR2 (SEQ ID NO:281): KASKLDR
VL CDR3 (SEQ ID NO:282): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV
VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG
10 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:473): GQSSRTR
VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4428 wherein the anti-FIX(a) arm

15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:284): DYAMH
VH CDR2 (SEQ ID NO:285): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:286): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:288): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:289): KASKLER
VL CDR3 (SEQ ID NO:290): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV
VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG
25 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:473): GQSSRTR
VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4443 wherein the anti-FIX(a) arm

30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:300): DYAMH
VH CDR2 (SEQ ID NO:301): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:302): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:304): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:305): KASKLER

VL CDR3 (SEQ ID NO:306): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4444 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:292): DYAMH

VH CDR2 (SEQ ID NO:293): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:294): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:296): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:297): KASKLDR

VL CDR3 (SEQ ID NO:298): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4601 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:188): DYAMH

VH CDR2 (SEQ ID NO:189): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:190): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:192): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:193): KASRLDR

VL CDR3 (SEQ ID NO:194): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4604 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:140): DYAMH

VH CDR2 (SEQ ID NO:141): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:142): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:144): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:145): KASRLDR

VL CDR3 (SEQ ID NO:146): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

15 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4608 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:204): DYAMH

VH CDR2 (SEQ ID NO:205): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:206): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:208): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:209): KASRLDR

VL CDR3 (SEQ ID NO:210): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4611 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:180): DYAMH
VH CDR2 (SEQ ID NO:181): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:182): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:184): RASQSISSWLA
5 VL CDR2 (SEQ ID NO:185): KASRLDR
VL CDR3 (SEQ ID NO:186): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV
VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG
10 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:473): GQSSRTR
VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4612 wherein the anti-FIX(a) arm

15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:196): DYAMH
VH CDR2 (SEQ ID NO:197): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:198): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:200): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:201): KASRLDR
VL CDR3 (SEQ ID NO:202): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV
VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG
25 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:473): GQSSRTR
VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4613 wherein the anti-FIX(a) arm

30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:172): DYAMH
VH CDR2 (SEQ ID NO:173): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:174): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:176): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:177): KASRLDR

VL CDR3 (SEQ ID NO:178): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4615 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:164): DYAMH

VH CDR2 (SEQ ID NO:165): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:166): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:168): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:169): KASRLDR

VL CDR3 (SEQ ID NO:170): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

20 VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

25 In one embodiment the bispecific antibody is bimAb05-4617 wherein the anti-FIX(a) arm
comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:148): DYAMH

VH CDR2 (SEQ ID NO:149): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:150): SYGSGSFYNAFDS

30 VL CDR1 (SEQ ID NO:152): RASQSISSWLA

VL CDR2 (SEQ ID NO:153): KASRLDR

VL CDR3 (SEQ ID NO:154): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

35 VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

- VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:473): GQSSRTR
VL CDR3 (SEQ ID NO:474): QQFGDSQLFT
- 5 In one embodiment the bispecific antibody is bimAb05-4618 wherein the anti-FIX(a) arm comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:156): DYAMH
VH CDR2 (SEQ ID NO:157): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:158): SYGSGSFYNAFDS
- 10 VL CDR1 (SEQ ID NO:160): RASQSISSWLA
VL CDR2 (SEQ ID NO:161): KASRLDR
VL CDR3 (SEQ ID NO:162): LEYSSYIRT
and wherein the anti-FX(a) arm comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:468): TSWIV
- 15 VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG
VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:473): GQSSRTR
VL CDR3 (SEQ ID NO:474): QQFGDSQLFT
- 20 In one embodiment the bispecific antibody is bimAb05-4684 wherein the anti-FIX(a) arm comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
- 25 VL CDR1 (SEQ ID NO:56): RASQSISSWLA
VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT
and wherein the anti-FX(a) arm comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:500): TSWIS
- 30 VH CDR2 (SEQ ID NO:501): MIDPSDSYTSYSPSFQG
VH CDR3 (SEQ ID NO:502): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:504): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:505): GQSSRTR
VL CDR3 (SEQ ID NO:506): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4685 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

5 VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

10 VH CDR1 (SEQ ID NO:508): TSWIS

VH CDR2 (SEQ ID NO:509): MIDPSDSFTSYSPSFQG

VH CDR3 (SEQ ID NO:510): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:512): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:513): GQSSRTR

15 VL CDR3 (SEQ ID NO:514): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4686 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

20 VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

25 VH CDR1 (SEQ ID NO:516): TSWIS

VH CDR2 (SEQ ID NO:517): MIDPSDSYTSYSPSFQG

VH CDR3 (SEQ ID NO:518): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:520): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:521): GQSSRTR

30 VL CDR3 (SEQ ID NO:522): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4687 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

35 VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

5 VH CDR1 (SEQ ID NO:524): TSWIS

VH CDR2 (SEQ ID NO:525): MIDPSDSYTSYSPSFQG

VH CDR3 (SEQ ID NO:526): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:528): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:529): GQSSRTR

10 VL CDR3 (SEQ ID NO:530): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4688 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

15 VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

20 and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:532): TSWIS

VH CDR2 (SEQ ID NO:533): MIDPSDSFTSYSPSFQG

VH CDR3 (SEQ ID NO:534): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:536): RASQSVSSSYLA

25 VL CDR2 (SEQ ID NO:537): GQSSRTR

VL CDR3 (SEQ ID NO:538): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4689 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

30 VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

35 and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:540): TSWIV
VH CDR2 (SEQ ID NO:541): MIDPSDSYTSYSPSFQG
VH CDR3 (SEQ ID NO:542): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:544): RASQSVSSSYLA
5 VL CDR2 (SEQ ID NO:545): GQSSRTR
VL CDR3 (SEQ ID NO:546): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4690 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
10 VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

15 and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:556): TSWIV
VH CDR2 (SEQ ID NO:557): MIDPSDSFTSYSPSFQG
VH CDR3 (SEQ ID NO:558): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:560): RASQSVSSSYLA
20 VL CDR2 (SEQ ID NO:561): GQSSRTR
VL CDR3 (SEQ ID NO:562): QQYGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4692 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
25 VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

30 and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:564): TSWIS
VH CDR2 (SEQ ID NO:565): MIDPSDSFTSYSPSFQG
VH CDR3 (SEQ ID NO:566): LHYYHSEEFDV
VL CDR1 (SEQ ID NO:568): RASQSVSSSYLA
35 VL CDR2 (SEQ ID NO:569): GQSSRTR

VL CDR3 (SEQ ID NO:570): QQYGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4693 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

5 VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

10 and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:572): TSWIS

VH CDR2 (SEQ ID NO:573): MIDPSDSYTSYSPSFQG

VH CDR3 (SEQ ID NO:574): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:576): RASQSVSSSYLA

15 VL CDR2 (SEQ ID NO:577): GQSSRTR

VL CDR3 (SEQ ID NO:578): QQYGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4694 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

20 VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

25 VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:580): TSWIS

VH CDR2 (SEQ ID NO:581): MIDPSDSYTSYSPSFQG

VH CDR3 (SEQ ID NO:582): LHYYHSEEFDV

30 VL CDR1 (SEQ ID NO:584): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:585): GQSSRTR

VL CDR3 (SEQ ID NO:586): QQYGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4695 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

35 VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

5 VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:492): TSWIS

VH CDR2 (SEQ ID NO:493): MIDPSDSFTSYSPSFQG

VH CDR3 (SEQ ID NO:494): LHYYNSEEFDV

10 VL CDR1 (SEQ ID NO:496): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:497): GQSSRTR

VL CDR3 (SEQ ID NO:498): QQYGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4696 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

15 VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

20 VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:588): TSWIV

VH CDR2 (SEQ ID NO:589): MIDPSDSYTSYSPSFQG

VH CDR3 (SEQ ID NO:590): LHYYNSEEFDV

25 VL CDR1 (SEQ ID NO:592): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:593): GQSSRTR

VL CDR3 (SEQ ID NO:594): QQYGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4697 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

30 VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

35 VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:596): TSWIV

VH CDR2 (SEQ ID NO:597): MIDPSDSFTSYSPSFQG

VH CDR3 (SEQ ID NO:598): LHYYNSEEFDV

5 VL CDR1 (SEQ ID NO:600): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:601): GASSRAR

VL CDR3 (SEQ ID NO:602): QQYGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4698 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

10 VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

15 VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:604): TSWIS

VH CDR2 (SEQ ID NO:605): MIDPSDSYTSYSPSFQG

VH CDR3 (SEQ ID NO:606): LHYYNSEEFDV

20 VL CDR1 (SEQ ID NO:608): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:609): GASSRAR

VL CDR3 (SEQ ID NO:610): QQYGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4699 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

25 VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

30 VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:612): TSWIS

VH CDR2 (SEQ ID NO:613): MIDPSDSFTSYSPSFQG

VH CDR3 (SEQ ID NO:614): LHYYHSEEFDV

35 VL CDR1 (SEQ ID NO:616): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:617): GASSRAR

VL CDR3 (SEQ ID NO:618): QQYGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4700 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

5 VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

VL CDR2 (SEQ ID NO:57): KASKLER

10 VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:620): TSWIS

VH CDR2 (SEQ ID NO:621): MIDPSDSYTSYSPSFQG

VH CDR3 (SEQ ID NO:622): LHYYHSEEFDV

15 VL CDR1 (SEQ ID NO:624): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:625): GASSRAR

VL CDR3 (SEQ ID NO:626): QQYGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4701 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:628): TSWIS

VH CDR2 (SEQ ID NO:629): MIDPSDSYTSYSPSFQG

30 VH CDR3 (SEQ ID NO:630): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:632): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:633): GASSRAR

VL CDR3 (SEQ ID NO:634): QQYGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4702 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:636): TSWIS
VH CDR2 (SEQ ID NO:637): MIDPSDSFTSYSPSFQG
10 VH CDR3 (SEQ ID NO:638): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:640): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:641): GASSRAR
VL CDR3 (SEQ ID NO:642): QQYGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4703 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:644): TSWIV
VH CDR2 (SEQ ID NO:645): MIDPSDSYTSYSPSFQG
25 VH CDR3 (SEQ ID NO:646): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:648): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:649): GASSRAR
VL CDR3 (SEQ ID NO:650): QQYGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4704 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:652): TSWIV

VH CDR2 (SEQ ID NO:653): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:654): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:656): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:657): GQSSRTR

VL CDR3 (SEQ ID NO:658): QQFGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4705 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:660): TSWIS

VH CDR2 (SEQ ID NO:661): MIDPSDSYTSYSPSFQG

20 VH CDR3 (SEQ ID NO:662): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:664): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:665): GQSSRTR

VL CDR3 (SEQ ID NO:666): QQFGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4706 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:668): TSWIS

VH CDR2 (SEQ ID NO:669): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:670): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:672): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:673): GQSSRTR

VL CDR3 (SEQ ID NO:674): QQFGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4707 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:676): TSWIS

VH CDR2 (SEQ ID NO:677): MIDPSDSYTSYSPSFQG

15 VH CDR3 (SEQ ID NO:678): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:680): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:681): GQSSRTR

VL CDR3 (SEQ ID NO:682): QQFGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4708 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:684): TSWIS

VH CDR2 (SEQ ID NO:685): MIDPSDSYTSYSPSFQG

30 VH CDR3 (SEQ ID NO:686): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:688): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:689): GQSSRTR

VL CDR3 (SEQ ID NO:690): QQFGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4709 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:692): TSWIS
VH CDR2 (SEQ ID NO:693): MIDPSDSFTSYSPSFQG
10 VH CDR3 (SEQ ID NO:694): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:696): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:697): GQSSRTR
VL CDR3 (SEQ ID NO:698): QQFGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4710 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 20 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:700): TSWIV
VH CDR2 (SEQ ID NO:701): MIDPSDSYTSYSPSFQG
25 VH CDR3 (SEQ ID NO:702): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:704): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:705): GQSSRTR
VL CDR3 (SEQ ID NO:706): QQFGDSRLFT

In one embodiment the bispecific antibody is bimAb05-4788 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:308): DYAMH
VH CDR2 (SEQ ID NO:309): GISWKGDIGGYVDS VKG
VH CDR3 (SEQ ID NO:310): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:312): RASQSISSWLA

- 35 VL CDR2 (SEQ ID NO:313): KASRLDR

VL CDR3 (SEQ ID NO:314): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4884 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:316): DYAMH

VH CDR2 (SEQ ID NO:317): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:318): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:320): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:321): KASRLDR

VL CDR3 (SEQ ID NO:322): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4895 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:340): DYAMH

VH CDR2 (SEQ ID NO:341): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:342): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:344): RASQSIQSWLA

30 VL CDR2 (SEQ ID NO:345): KASRLDR

VL CDR3 (SEQ ID NO:346): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4896 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:324): DYAMH

VH CDR2 (SEQ ID NO:325): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:326): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:328): RASQKISSWLA

10 VL CDR2 (SEQ ID NO:329): KASRLDR

VL CDR3 (SEQ ID NO:330): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

15 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4898 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:332): DYAMH

VH CDR2 (SEQ ID NO:333): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:334): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:336): RASQQISSWLA

25 VL CDR2 (SEQ ID NO:337): KASRLDR

VL CDR3 (SEQ ID NO:338): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4903 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:356): DYAMH
VH CDR2 (SEQ ID NO:357): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:358): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:360): RASQSISSWLA

5 VL CDR2 (SEQ ID NO:361): KASRLDR

VL CDR3 (SEQ ID NO:362): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

10 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4906 wherein the anti-FIX(a) arm

15 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:348): DYAMH

VH CDR2 (SEQ ID NO:349): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:350): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:352): RASQSISSWLA

20 VL CDR2 (SEQ ID NO:353): KASRLDK

VL CDR3 (SEQ ID NO:354): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

25 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4910 wherein the anti-FIX(a) arm

30 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:364): DYAMH

VH CDR2 (SEQ ID NO:365): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:366): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:368): RASQSISSWLA

35 VL CDR2 (SEQ ID NO:369): KASRLDR

VL CDR3 (SEQ ID NO:370): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4914 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:372): DYAMH

VH CDR2 (SEQ ID NO:373): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:374): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:376): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:377): KASRLDR

VL CDR3 (SEQ ID NO:378): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4915 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:380): DYAMH

VH CDR2 (SEQ ID NO:381): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:382): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:384): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:385): KASRLDR

VL CDR3 (SEQ ID NO:386): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4919 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:388): DYAMH

VH CDR2 (SEQ ID NO:389): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:390): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:392): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:393): KASRLDR

VL CDR3 (SEQ ID NO:394): LEYQSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

15 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4920 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:404): DYAMH

VH CDR2 (SEQ ID NO:405): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:406): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:408): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:409): KASRLDR

VL CDR3 (SEQ ID NO:410): LEYSSWIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4921 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:396): DYAMH
VH CDR2 (SEQ ID NO:397): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:398): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:400): RASQSISSWLA

5 VL CDR2 (SEQ ID NO:401): KASRLDR

VL CDR3 (SEQ ID NO:402): LEYKSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

10 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4924 wherein the anti-FIX(a) arm

15 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:420): DYAMH

VH CDR2 (SEQ ID NO:421): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:422): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:424): RASQSISSWLA

20 VL CDR2 (SEQ ID NO:425): KASRLDR

VL CDR3 (SEQ ID NO:426): LEYNSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

25 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4927 wherein the anti-FIX(a) arm

30 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:412): DYAMH

VH CDR2 (SEQ ID NO:413): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:414): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:416): RASQSISSWLA

35 VL CDR2 (SEQ ID NO:417): KASRLDR

VL CDR3 (SEQ ID NO:418): LEYRSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-5092 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:428): DYAMH

VH CDR2 (SEQ ID NO:429): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:430): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:432): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:433): KASKLDR

VL CDR3 (SEQ ID NO:434): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-5095 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:132): DYAMH

VH CDR2 (SEQ ID NO:133): GISWKGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:134): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:136): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:137): KASRLDR

VL CDR3 (SEQ ID NO:138): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-5204 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:436): DYAMH

VH CDR2 (SEQ ID NO:437): GISWRGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:438): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:440): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:441): KASKLDR

VL CDR3 (SEQ ID NO:442): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

15 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-5205 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:444): DYAMH

VH CDR2 (SEQ ID NO:445): GISWRGDIGGYVDSVKG

VH CDR3 (SEQ ID NO:446): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:448): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:449): KASRLER

VL CDR3 (SEQ ID NO:450): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-5240 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:452): DYAMH
VH CDR2 (SEQ ID NO:453): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:454): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:456): RASQSISSWLA

5 VL CDR2 (SEQ ID NO:457): KASRLDR

VL CDR3 (SEQ ID NO:458): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

10 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-5339 wherein the anti-FIX(a) arm

15 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

20 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:772): TSWIS

VH CDR2 (SEQ ID NO:773): MIDPSDSFTSYSPSFQG

25 VH CDR3 (SEQ ID NO:774): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:776): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:777): GQSSRTR

VL CDR3 (SEQ ID NO:778): QQFGSSQLFT

In one embodiment the bispecific antibody is bimAb05-5340 wherein the anti-FIX(a) arm

30 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

35 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:708): TSWIV

VH CDR2 (SEQ ID NO:709): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:710): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:712): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:713): GQSSRTR

VL CDR3 (SEQ ID NO:714): QQFGSSQLFT

In one embodiment the bispecific antibody is bimAb05-5341 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:780): TSWIS

VH CDR2 (SEQ ID NO:781): MIDPSDSYTSYSPSFQG

20 VH CDR3 (SEQ ID NO:782): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:784): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:785): GQSSRTR

VL CDR3 (SEQ ID NO:786): QQFGSSQLFT

In one embodiment the bispecific antibody is bimAb05-5342 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:764): TSWIS

VH CDR2 (SEQ ID NO:765): MIDPSDSYTSYSPSFQG

35 VH CDR3 (SEQ ID NO:766): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:768): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:769): GQSSRTR

VL CDR3 (SEQ ID NO:770): QQFGSSQLFT

In one embodiment the bispecific antibody is bimAb05-5343 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:788): TSWIS

VH CDR2 (SEQ ID NO:789): MIDPSDSYTSYSPSFQG

15 VH CDR3 (SEQ ID NO:790): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:792): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:793): GQSSRTR

VL CDR3 (SEQ ID NO:794): QQFGSSQLFT

In one embodiment the bispecific antibody is bimAb05-5344 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:796): TSWIS

VH CDR2 (SEQ ID NO:797): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:798): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:800): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:801): GQSSRTR

VL CDR3 (SEQ ID NO:802): QQFGSSQLFT

In one embodiment the bispecific antibody is bimAb05-5345 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:820): TSWIS
VH CDR2 (SEQ ID NO:821): MIDPSDSYTSYSPSFQG
10 VH CDR3 (SEQ ID NO:822): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:824): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:825): GQSSRTR
VL CDR3 (SEQ ID NO:826): QQFGESQLFT

In one embodiment the bispecific antibody is bimAb05-5346 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:804): TSWIV
VH CDR2 (SEQ ID NO:805): MIDPSDSYTSYSPSFQG
25 VH CDR3 (SEQ ID NO:806): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:808): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:809): GQSSRTR
VL CDR3 (SEQ ID NO:810): QQFGSSQLFT

In one embodiment the bispecific antibody is bimAb05-5347 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:828): TSWIS

VH CDR2 (SEQ ID NO:829): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:830): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:832): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:833): GQSSRTR

VL CDR3 (SEQ ID NO:834): QQFGESQLFT

In one embodiment the bispecific antibody is bimAb05-5348 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:812): TSWIV

VH CDR2 (SEQ ID NO:813): MIDPSDSYTSYSPSFQG

20 VH CDR3 (SEQ ID NO:814): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:816): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:817): GQSSRTR

VL CDR3 (SEQ ID NO:818): QQFGSSQLFT

In one embodiment the bispecific antibody is bimAb05-5349 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:836): TSWIS

VH CDR2 (SEQ ID NO:837): MIDPSDSYTSYSPSFQG

35 VH CDR3 (SEQ ID NO:838): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:840): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:841): GQSSRTR

VL CDR3 (SEQ ID NO:842): QQFGESQLFT

In one embodiment the bispecific antibody is bimAb05-5350 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:716): TSWIV

VH CDR2 (SEQ ID NO:717): MIDPSDSFTSYSPSFQG

15 VH CDR3 (SEQ ID NO:718): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:720): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:721): GQSSRTR

VL CDR3 (SEQ ID NO:722): QQFGESQLFT

In one embodiment the bispecific antibody is bimAb05-5351 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:844): TSWIS

VH CDR2 (SEQ ID NO:845): MIDPSDSYTSYSPSFQG

30 VH CDR3 (SEQ ID NO:846): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:848): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:849): GQSSRTR

VL CDR3 (SEQ ID NO:850): QQFGESQLFT

In one embodiment the bispecific antibody is bimAb05-5352 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:852): TSWIS
VH CDR2 (SEQ ID NO:853): MIDPSDSFTSYSPSFQG
10 VH CDR3 (SEQ ID NO:854): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:856): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:857): GQSSRTR
VL CDR3 (SEQ ID NO:858): QQFGESQLFT

In one embodiment the bispecific antibody is bimAb05-5353 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:876): TSWIS
VH CDR2 (SEQ ID NO:877): MIDPSDSYTSYSPSFQG
25 VH CDR3 (SEQ ID NO:878): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:880): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:881): GQSSRTR
VL CDR3 (SEQ ID NO:882): QQFGNSQLFT

In one embodiment the bispecific antibody is bimAb05-5354 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:860): TSWIV

VH CDR2 (SEQ ID NO:861): MIDPSDSYTSYSPSFQG

5 VH CDR3 (SEQ ID NO:862): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:864): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:865): GQSSRTR

VL CDR3 (SEQ ID NO:866): QQFGESQLFT

In one embodiment the bispecific antibody is bimAb05-5355 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:884): TSWIS

VH CDR2 (SEQ ID NO:885): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:886): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:888): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:889): GQSSRTR

VL CDR3 (SEQ ID NO:890): QQFGNSQLFT

In one embodiment the bispecific antibody is bimAb05-5356 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:868): TSWIV

VH CDR2 (SEQ ID NO:869): MIDPSDSYTSYSPSFQG

35 VH CDR3 (SEQ ID NO:870): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:872): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:873): GQSSRTR

VL CDR3 (SEQ ID NO:874): QQFGESQLFT

In one embodiment the bispecific antibody is bimAb05-5357 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:892): TSWIS

VH CDR2 (SEQ ID NO:893): MIDPSDSYTSYSPSFQG

15 VH CDR3 (SEQ ID NO:894): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:896): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:897): GQSSRTR

VL CDR3 (SEQ ID NO:898): QQFGNSQLFT

In one embodiment the bispecific antibody is bimAb05-5358 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:724): TSWIV

VH CDR2 (SEQ ID NO:725): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:726): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:728): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:729): GQSSRTR

VL CDR3 (SEQ ID NO:730): QQFGNSQLFT

In one embodiment the bispecific antibody is bimAb05-5359 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:900): TSWIS
VH CDR2 (SEQ ID NO:901): MIDPSDSYTSYSPSFQG
10 VH CDR3 (SEQ ID NO:902): LHYYHSEEFDV
VL CDR1 (SEQ ID NO:904): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:905): GQSSRTR
VL CDR3 (SEQ ID NO:906): QQFGNSQLFT

In one embodiment the bispecific antibody is bimAb05-5361 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 20 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:924): TSWIV
VH CDR2 (SEQ ID NO:925): MIDPSDSYTSYSPSFQG
25 VH CDR3 (SEQ ID NO:926): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:928): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:929): GQSSRTR
VL CDR3 (SEQ ID NO:930): QQFGNSQLFT

In one embodiment the bispecific antibody is bimAb05-5362 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 35 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:908): TSWIS

VH CDR2 (SEQ ID NO:909): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:910): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:912): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:913): GQSSRTR

VL CDR3 (SEQ ID NO:914): QQFGNSQLFT

In one embodiment the bispecific antibody is bimAb05-5363 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:732): TSWIV

VH CDR2 (SEQ ID NO:733): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:734): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:736): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:737): GQSSRTR

VL CDR3 (SEQ ID NO:738): QQFGQSQLFT

In one embodiment the bispecific antibody is bimAb05-5364 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:916): TSWIV

VH CDR2 (SEQ ID NO:917): MIDPSDSYTSYSPSFQG

35 VH CDR3 (SEQ ID NO:918): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:920): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:921): GQSSRTR

VL CDR3 (SEQ ID NO:922): QQFGNSQLFT

In one embodiment the bispecific antibody is bimAb05-5365 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:932): TSWIS

VH CDR2 (SEQ ID NO:933): MIDPSDSYTSYSPSFQG

15 VH CDR3 (SEQ ID NO:934): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:936): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:937): GQSSRTR

VL CDR3 (SEQ ID NO:938): QQFGQSQLFT

In one embodiment the bispecific antibody is bimAb05-5366 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:940): TSWIS

VH CDR2 (SEQ ID NO:941): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:942): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:944): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:945): GQSSRTR

VL CDR3 (SEQ ID NO:946): QQFGQSQLFT

In one embodiment the bispecific antibody is bimAb05-5367 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:964): TSWIV
VH CDR2 (SEQ ID NO:965): MIDPSDSYTSYSPSFQG
10 VH CDR3 (SEQ ID NO:966): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:968): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:969): GQSSRTR
VL CDR3 (SEQ ID NO:970): QQFGQSQLFT

In one embodiment the bispecific antibody is bimAb05-5369 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:972): TSWIV
VH CDR2 (SEQ ID NO:973): MIDPSDSYTSYSPSFQG
25 VH CDR3 (SEQ ID NO:974): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:976): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:977): GQSSRTR
VL CDR3 (SEQ ID NO:978): QQFGQSQLFT

In one embodiment the bispecific antibody is bimAb05-5370 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:948): TSWIS

VH CDR2 (SEQ ID NO:949): MIDPSDSYTSYSPSFQG

5 VH CDR3 (SEQ ID NO:950): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:952): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:953): GQSSRTR

VL CDR3 (SEQ ID NO:954): QQFGQSQLFT

In one embodiment the bispecific antibody is bimAb05-5371 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:740): TSWIV

VH CDR2 (SEQ ID NO:741): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:742): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:744): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:745): GQSSRTR

VL CDR3 (SEQ ID NO:746): QQFGDAQLFT

In one embodiment the bispecific antibody is bimAb05-5372 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:956): TSWIS

VH CDR2 (SEQ ID NO:957): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:958): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:960): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:961): GQSSRTR

VL CDR3 (SEQ ID NO:962): QQFGQSQLFT

In one embodiment the bispecific antibody is bimAb05-5373 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:980): TSWIS

VH CDR2 (SEQ ID NO:981): MIDPSDSYTSYSPSFQG

15 VH CDR3 (SEQ ID NO:982): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:984): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:985): GQSSRTR

VL CDR3 (SEQ ID NO:986): QQFGDAQLFT

In one embodiment the bispecific antibody is bimAb05-5374 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:988): TSWIS

VH CDR2 (SEQ ID NO:989): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:990): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:992): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:993): GQSSRTR

VL CDR3 (SEQ ID NO:994): QQFGDAQLFT

In one embodiment the bispecific antibody is bimAb05-5375 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:1012): TSWIV
VH CDR2 (SEQ ID NO:1013): MIDPSDSYTSYSPSFQG
10 VH CDR3 (SEQ ID NO:1014): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:1016): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:1017): GQSSRTR
VL CDR3 (SEQ ID NO:1018): QQFGDAQLFT

In one embodiment the bispecific antibody is bimAb05-5377 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:1020): TSWIV
VH CDR2 (SEQ ID NO:1021): MIDPSDSYTSYSPSFQG
25 VH CDR3 (SEQ ID NO:1022): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:1024): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:1025): GQSSRTR
VL CDR3 (SEQ ID NO:1026): QQFGDAQLFT

In one embodiment the bispecific antibody is bimAb05-5378 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:996): TSWIS

VH CDR2 (SEQ ID NO:997): MIDPSDSYTSYSPSFQG

5 VH CDR3 (SEQ ID NO:998): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:1000): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1001): GQSSRTR

VL CDR3 (SEQ ID NO:1002): QQFGDAQLFT

In one embodiment the bispecific antibody is bimAb05-5379 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:748): TSWIV

VH CDR2 (SEQ ID NO:749): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:750): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:752): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:753): GQSSRTR

VL CDR3 (SEQ ID NO:754): QQFGDTQLFT

In one embodiment the bispecific antibody is bimAb05-5380 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1004): TSWIS

VH CDR2 (SEQ ID NO:1005): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:1006): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:1008): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1009): GQSSRTR

VL CDR3 (SEQ ID NO:1010): QQFGDAQLFT

In one embodiment the bispecific antibody is bimAb05-5381 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1028): TSWIS

VH CDR2 (SEQ ID NO:1029): MIDPSDSYTSYSPSFQG

15 VH CDR3 (SEQ ID NO:1030): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:1032): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1033): GQSSRTR

VL CDR3 (SEQ ID NO:1034): QQFGDTQLFT

In one embodiment the bispecific antibody is bimAb05-5383 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1052): TSWIS

VH CDR2 (SEQ ID NO:1053): MIDPSDSYTSYSPSFQG

30 VH CDR3 (SEQ ID NO:1054): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:1056): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1057): GQSSRTR

VL CDR3 (SEQ ID NO:1058): QQFGDTQLFT

In one embodiment the bispecific antibody is bimAb05-5384 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:1036): TSWIS
VH CDR2 (SEQ ID NO:1037): MIDPSDSFTSYSPSFQG
10 VH CDR3 (SEQ ID NO:1038): LHYYHSEEFDV
VL CDR1 (SEQ ID NO:1040): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:1041): GQSSRTR
VL CDR3 (SEQ ID NO:1042): QQFGDTQLFT

In one embodiment the bispecific antibody is bimAb05-5385 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:1060): TSWIS
VH CDR2 (SEQ ID NO:1061): MIDPSDSFTSYSPSFQG
25 VH CDR3 (SEQ ID NO:1062): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:1064): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:1065): GQSSRTR
VL CDR3 (SEQ ID NO:1066): QQFGDTQLFT

In one embodiment the bispecific antibody is bimAb05-5386 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1044): TSWIS

VH CDR2 (SEQ ID NO:1045): MIDPSDSYTSYSPSFQG

5 VH CDR3 (SEQ ID NO:1046): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:1048): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1049): GQSSRTR

VL CDR3 (SEQ ID NO:1050): QQFGDTQLFT

In one embodiment the bispecific antibody is bimAb05-5387 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1068): TSWIV

VH CDR2 (SEQ ID NO:1069): MIDPSDSYTSYSPSFQG

20 VH CDR3 (SEQ ID NO:1070): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:1072): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1073): GQSSRTR

VL CDR3 (SEQ ID NO:1074): QQFGDTQLFT

In one embodiment the bispecific antibody is bimAb05-5388 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1076): TSWIV

VH CDR2 (SEQ ID NO:1077): MIDPSDSYTSYSPSFQG

35 VH CDR3 (SEQ ID NO:1078): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:1080): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1081): GQSSRTR

VL CDR3 (SEQ ID NO:1082): QQFGDTQLFT

In one embodiment the bispecific antibody is bimAb05-5389 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1100): TSWIS

VH CDR2 (SEQ ID NO:1101): MIDPSDSYTSYSPSFQG

15 VH CDR3 (SEQ ID NO:1102): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:1104): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1105): GQSSRTR

VL CDR3 (SEQ ID NO:1106): QQFGDNQLFT

In one embodiment the bispecific antibody is bimAb05-5390 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:756): TSWIV

VH CDR2 (SEQ ID NO:757): MIDPSDSFTSYSPSFQG

30 VH CDR3 (SEQ ID NO:758): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:760): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:761): GQSSRTR

VL CDR3 (SEQ ID NO:762): QQFGDNQLFT

In one embodiment the bispecific antibody is bimAb05-5391 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:1108): TSWIS
VH CDR2 (SEQ ID NO:1109): MIDPSDSYTSYSPSFQG
10 VH CDR3 (SEQ ID NO:1110): LHYYHSEEFDV
VL CDR1 (SEQ ID NO:1112): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:1113): GQSSRTR
VL CDR3 (SEQ ID NO:1114): QQFGDNQLFT

In one embodiment the bispecific antibody is bimAb05-5392 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:1084): TSWIS
VH CDR2 (SEQ ID NO:1085): MIDPSDSYTSYSPSFQG
25 VH CDR3 (SEQ ID NO:1086): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:1088): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:1089): GQSSRTR
VL CDR3 (SEQ ID NO:1090): QQFGDNQLFT

In one embodiment the bispecific antibody is bimAb05-5393 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1116): TSWIS

VH CDR2 (SEQ ID NO:1117): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:1118): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:1120): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1121): GQSSRTR

VL CDR3 (SEQ ID NO:1122): QQFGDNQLFT

In one embodiment the bispecific antibody is bimAb05-5394 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1092): TSWIS

VH CDR2 (SEQ ID NO:1093): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:1094): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:1096): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1097): GQSSRTR

VL CDR3 (SEQ ID NO:1098): QQFGDNQLFT

In one embodiment the bispecific antibody is bimAb05-5395 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1124): TSWIV

VH CDR2 (SEQ ID NO:1125): MIDPSDSYTSYSPSFQG

35 VH CDR3 (SEQ ID NO:1126): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:1128): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1129): GQSSRTR

VL CDR3 (SEQ ID NO:1130): QQFGDNQLFT

In one embodiment the bispecific antibody is bimAb05-5396 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1132): TSWIV

VH CDR2 (SEQ ID NO:1133): MIDPSDSYTSYSPSFQG

15 VH CDR3 (SEQ ID NO:1134): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:1136): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1137): GQSSRTR

VL CDR3 (SEQ ID NO:1138): QQFGDNQLFT

In one embodiment the bispecific antibody is bimAb05-5397 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1156): TSWIS

VH CDR2 (SEQ ID NO:1157): MIDPSDSYTSYSPSFQG

30 VH CDR3 (SEQ ID NO:1158): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:1160): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1161): GQSSRTR

VL CDR3 (SEQ ID NO:1162): QQFGDDQLFT

In one embodiment the bispecific antibody is bimAb05-5399 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA

- 5 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:1164): TSWIS
VH CDR2 (SEQ ID NO:1165): MIDPSDSYTSYSPSFQG
10 VH CDR3 (SEQ ID NO:1166): LHYYHSEEFDV
VL CDR1 (SEQ ID NO:1168): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:1169): GQSSRTR
VL CDR3 (SEQ ID NO:1170): QQFGDDQLFT

In one embodiment the bispecific antibody is bimAb05-5400 wherein the anti-FIX(a) arm

- 15 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
20 VL CDR2 (SEQ ID NO:57): KASKLER
VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

- VH CDR1 (SEQ ID NO:1140): TSWIS
VH CDR2 (SEQ ID NO:1141): MIDPSDSYTSYSPSFQG
25 VH CDR3 (SEQ ID NO:1142): LHYYNSEEFDV
VL CDR1 (SEQ ID NO:1144): RASQSVSSSYLA
VL CDR2 (SEQ ID NO:1145): GQSSRTR
VL CDR3 (SEQ ID NO:1146): QQFGDDQLFT

In one embodiment the bispecific antibody is bimAb05-5401 wherein the anti-FIX(a) arm

- 30 comprises the following CDR-sequences:
VH CDR1 (SEQ ID NO:52): DYAMH
VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKS VKG
VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:56): RASQSISSWLA
35 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1172): TSWIS

VH CDR2 (SEQ ID NO:1173): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:1174): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:1176): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1177): GQSSRTR

VL CDR3 (SEQ ID NO:1178): QQFGDDQLFT

10 In one embodiment the bispecific antibody is bimAb05-5402 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1148): TSWIS

VH CDR2 (SEQ ID NO:1149): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:1150): LHYYHSEEFDV

VL CDR1 (SEQ ID NO:1152): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1153): GQSSRTR

VL CDR3 (SEQ ID NO:1154): QQFGDDQLFT

25 In one embodiment the bispecific antibody is bimAb05-5403 wherein the anti-FIX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1180): TSWIV

VH CDR2 (SEQ ID NO:1181): MIDPSDSYTSYSPSFQG

35 VH CDR3 (SEQ ID NO:1182): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:1184): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1185): GQSSRTR

VL CDR3 (SEQ ID NO:1186): QQFGDDQLFT

In one embodiment the bispecific antibody is bimAb05-5406 wherein the anti-FIX(a) arm

5 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

10 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1188): TSWIV

VH CDR2 (SEQ ID NO:1189): MIDPSDSYTSYSPSFQG

15 VH CDR3 (SEQ ID NO:1190): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:1192): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:1193): GQSSRTR

VL CDR3 (SEQ ID NO:1194): QQFGDDQLFT

In one embodiment the bispecific antibody is bimAb05-5413 wherein the anti-FIX(a) arm

20 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:52): DYAMH

VH CDR2 (SEQ ID NO:53): GISWRGDIGGYVKSVKG

VH CDR3 (SEQ ID NO:54): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:56): RASQSISSWLA

25 VL CDR2 (SEQ ID NO:57): KASKLER

VL CDR3 (SEQ ID NO:58): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:548): TSWIV

VH CDR2 (SEQ ID NO:549): MIDPSDSYTSYSPSFQG

30 VH CDR3 (SEQ ID NO:550): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:552): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:553): GQSSRTR

VL CDR3 (SEQ ID NO:554): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4271 wherein the anti-FIX(a) arm

35 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1203): DYAMH
VH CDR2 (SEQ ID NO:1204): GISWKGDIGGYVDSVKG
VH CDR3 (SEQ ID NO:1205): SYGSGSFYNAFDS
VL CDR1 (SEQ ID NO:1207): RASQSISSWLA

5 VL CDR2 (SEQ ID NO:1208): KASKLDR

VL CDR3 (SEQ ID NO:1209): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

10 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-4756 wherein the anti-FIX(a) arm

15 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1211): DYAMH

VH CDR2 (SEQ ID NO:1212): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:1213): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:1215): RASQSISSWLA

20 VL CDR2 (SEQ ID NO:1216): KASKLER

VL CDR3 (SEQ ID NO:1217): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

25 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-0396 wherein the anti-FIX(a) arm

30 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1219): DYAMH

VH CDR2 (SEQ ID NO:1220): GISWRGDIGGYAKSVKG

VH CDR3 (SEQ ID NO:1221): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:1223): RASQSISSWLA

35 VL CDR2 (SEQ ID NO:1224): KASKLDR

VL CDR3 (SEQ ID NO:1225): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

5 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-0417 wherein the anti-FIX(a) arm

10 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1227): DYAMH

VH CDR2 (SEQ ID NO:1228): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:1229): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:1231): RASQSISSWLA

15 VL CDR2 (SEQ ID NO:1232): KASKLDR

VL CDR3 (SEQ ID NO:1233): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

20 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody is bimAb05-0438 wherein the anti-FIX(a) arm

25 comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:1235): DYAMH

VH CDR2 (SEQ ID NO:1236): GISWRGDIGGYVKS VKG

VH CDR3 (SEQ ID NO:1237): SYGSGSFYNAFDS

VL CDR1 (SEQ ID NO:1239): RASQSISSWLA

30 VL CDR2 (SEQ ID NO:1240): KASKLDR

VL CDR3 (SEQ ID NO:1241): LEYSSYIRT

and wherein the anti-FX(a) arm comprises the following CDR-sequences:

VH CDR1 (SEQ ID NO:468): TSWIV

VH CDR2 (SEQ ID NO:469): MIDPSDSFTSYSPSFQG

35 VH CDR3 (SEQ ID NO:470): LHYYNSEEFDV

VL CDR1 (SEQ ID NO:472): RASQSVSSSYLA

VL CDR2 (SEQ ID NO:473): GQSSRTR

VL CDR3 (SEQ ID NO:474): QQFGDSQLFT

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains
5 corresponding to SEQ ID NO:67 and SEQ ID NO:71, respectively, and
anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471,
respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains
corresponding to SEQ ID NO:43 and SEQ ID NO:47, respectively, and
10 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471,
respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains
corresponding to SEQ ID NO:3 and SEQ ID NO:7, respectively, and
anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:459 and SEQ ID NO:463,
15 respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains
corresponding to SEQ ID NO:67 and SEQ ID NO:71, respectively, and
anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:483 and SEQ ID NO:487,
respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains
corresponding to SEQ ID NO:35 and SEQ ID NO:39, respectively, and
anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:483 and SEQ ID NO:487,
20 respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains
corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and
anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:483 and SEQ ID NO:487,
25 respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains
corresponding to SEQ ID NO:43 and SEQ ID NO:47, respectively, and
30 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:483 and SEQ ID NO:487,
respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains
corresponding to SEQ ID NO:3 and SEQ ID NO:7, respectively, and
anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471,
35 respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:3 and SEQ ID NO:7, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:475 and SEQ ID NO:479, respectively.

- 5 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:11 and SEQ ID NO:15, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:459 and SEQ ID NO:463, respectively.

- 10 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:35 and SEQ ID NO:39, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:459 and SEQ ID NO:463, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:43 and SEQ ID NO:47, respectively, and
15 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:459 and SEQ ID NO:463, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and
20 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:459 and SEQ ID NO:463, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:67 and SEQ ID NO:71, respectively, and
anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:459 and SEQ ID NO:463, respectively.

- 25 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:35 and SEQ ID NO:39, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains
30 corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:59 and SEQ ID NO:63, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:19 and SEQ ID NO:23, respectively, and

- 5 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:27 and SEQ ID NO:31, respectively, and

- 10 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:75 and SEQ ID NO:79, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:83 and SEQ ID NO:87, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 20 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:91 and SEQ ID NO:95, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains

- 25 corresponding to SEQ ID NO:99 and SEQ ID NO:103, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:107 and SEQ ID NO:111, respectively, and

- 30 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:115 and SEQ ID NO:119, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 35

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:211 and SEQ ID NO:215, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 5 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:219 and SEQ ID NO:223, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 10 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:227 and SEQ ID NO:231, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:235 and SEQ ID NO:239, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 20 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:251 and SEQ ID NO:255, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:243 and SEQ ID NO:247, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 25 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:259 and SEQ ID NO:263, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 30 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:267 and SEQ ID NO:271, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:123 and SEQ ID NO:127, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:275 and SEQ ID NO:279, respectively, and

- 5 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:283 and SEQ ID NO:287, respectively, and

- 10 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:299 and SEQ ID NO:303, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:291 and SEQ ID NO:295, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:187 and SEQ ID NO:191, respectively, and

- 20 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:139 and SEQ ID NO:143, respectively, and

- 25 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:203 and SEQ ID NO:207, respectively, and

- 30 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:179 and SEQ ID NO:183, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:195 and SEQ ID NO:199, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 5 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:171 and SEQ ID NO:175, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 10 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:163 and SEQ ID NO:167, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:147 and SEQ ID NO:151, respectively, and
15 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:155 and SEQ ID NO:159, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471,
20 respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:499 and SEQ ID NO:503, respectively.

- 25 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:507 and SEQ ID NO:511, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and
30 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:515 and SEQ ID NO:519, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:523 and SEQ ID NO:527, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 5 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:531 and SEQ ID NO:535, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 10 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:539 and SEQ ID NO:543, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:555 and SEQ ID NO:559, respectively.

- 15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:563 and SEQ ID NO:567, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 20 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:571 and SEQ ID NO:575, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 25 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:579 and SEQ ID NO:583, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 30 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:491 and SEQ ID NO:495, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:587 and SEQ ID NO:591, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:595 and SEQ ID NO:599, respectively.

- 5 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:603 and SEQ ID NO:607, respectively.

- 10 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:611 and SEQ ID NO:615, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and
15 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:619 and SEQ ID NO:623, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and
20 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:627 and SEQ ID NO:631, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and
anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:635 and SEQ ID NO:639, respectively.

- 25 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:643 and SEQ ID NO:647, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains
30 corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:651 and SEQ ID NO:655, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:659 and SEQ ID NO:663, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

5 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:667 and SEQ ID NO:671, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

10 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:675 and SEQ ID NO:679, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:683 and SEQ ID NO:687, respectively.

15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:691 and SEQ ID NO:695, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

20 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:699 and SEQ ID NO:703, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:307 and SEQ ID NO:311, respectively, and

25 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:315 and SEQ ID NO:319, respectively, and

30 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:339 and SEQ ID NO:343, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:323 and SEQ ID NO:327, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 5 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:331 and SEQ ID NO:335, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 10 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:355 and SEQ ID NO:359, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:347 and SEQ ID NO:351, respectively, and
15 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:363 and SEQ ID NO:367, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471,
20 respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:371 and SEQ ID NO:375, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 25 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:379 and SEQ ID NO:383, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:387 and SEQ ID NO:391, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.
30

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:403 and SEQ ID NO:407, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:395 and SEQ ID NO:399, respectively, and

- 5 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:419 and SEQ ID NO:423, respectively, and

- 10 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:411 and SEQ ID NO:415, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:427 and SEQ ID NO:431, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:131 and SEQ ID NO:135, respectively, and

- 20 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:435 and SEQ ID NO:439, respectively, and

- 25 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:443 and SEQ ID NO:447, respectively, and

- 30 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:451 and SEQ ID NO:455, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:771 and SEQ ID NO:775, respectively.

- 5 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:707 and SEQ ID NO:711, respectively.

- 10 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:779 and SEQ ID NO:783, respectively.

- 15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:763 and SEQ ID NO:767, respectively.

- 20 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:787 and SEQ ID NO:791, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:795 and SEQ ID NO:799, respectively.

- 25 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:819 and SEQ ID NO:823, respectively.

- 30 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:803 and SEQ ID NO:807, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:827 and SEQ ID NO:831, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

5 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:811 and SEQ ID NO:815, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

10 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:835 and SEQ ID NO:839, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:715 and SEQ ID NO:719, respectively.

15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:843 and SEQ ID NO:847, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

20 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:851 and SEQ ID NO:855, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

25 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:875 and SEQ ID NO:879, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:859 and SEQ ID NO:863, respectively.

30 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:883 and SEQ ID NO:887, respectively. In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:867 and SEQ ID NO:871, respectively. In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:891 and SEQ ID NO:895, respectively. In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:723 and SEQ ID NO:727, respectively. In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:899 and SEQ ID NO:903, respectively. In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:923 and SEQ ID NO:927, respectively.
- 15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:907 and SEQ ID NO:911, respectively.
- 20 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:731 and SEQ ID NO:735, respectively.
- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:915 and SEQ ID NO:919, respectively.
- 25 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:931 and SEQ ID NO:935, respectively.
- 30 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:939 and SEQ ID NO:943, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:963 and SEQ ID NO:967, respectively.

- 5 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:971 and SEQ ID NO:975, respectively.

- 10 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:947 and SEQ ID NO:951, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and
15 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:739 and SEQ ID NO:743, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:955 and SEQ ID NO:959,
20 respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:979 and SEQ ID NO:983, respectively.

- 25 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:987 and SEQ ID NO:991, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains
30 corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1011 and SEQ ID NO:1015, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1019 and SEQ ID NO:1023, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 5 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:995 and SEQ ID NO:999, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 10 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:747 and SEQ ID NO:751, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1003 and SEQ ID NO:1007, respectively.

- 15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1027 and SEQ ID NO:1031, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 20 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1051 and SEQ ID NO:1055, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 25 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1035 and SEQ ID NO:1039, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 30 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1059 and SEQ ID NO:1063, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1043 and SEQ ID NO:1047, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1067 and SEQ ID NO:1071, respectively.

- 5 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1075 and SEQ ID NO:1079, respectively.

- 10 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1099 and SEQ ID NO:1103, respectively.

- 15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:755 and SEQ ID NO:759, respectively.

- 20 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1107 and SEQ ID NO:1111, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1083 and SEQ ID NO:1087, respectively.

- 25 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1115 and SEQ ID NO:1119, respectively.

- 30 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1091 and SEQ ID NO:1095, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1123 and SEQ ID NO:1127, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 5 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1131 and SEQ ID NO:1135, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 10 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1155 and SEQ ID NO:1159, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1163 and SEQ ID NO:1167, respectively.

- 15 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1139 and SEQ ID NO:1143, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains

- 20 corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1171 and SEQ ID NO:1175, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 25 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1147 and SEQ ID NO:1151, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

- 30 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1179 and SEQ ID NO:1183, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and

anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:1187 and SEQ ID NO:1191, respectively.

In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:51 and SEQ ID NO:55, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:547 and SEQ ID NO:551, respectively.

- 5 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:1202 and SEQ ID NO:1206, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 10 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:1210 and SEQ ID NO:1214, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:1218 and SEQ ID NO:1222, respectively, and
15 anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:1226 and SEQ ID NO:1230, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471,
20 respectively.

- In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:1234 and SEQ ID NO:1238, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- 25 In one embodiment the bispecific antibody comprises anti-FIX(a) arm VH and VL domains corresponding to SEQ ID NO:1242 and SEQ ID NO:1246, respectively, and anti-FX(a) arm VH and VL domains corresponding to SEQ ID NO:467 and SEQ ID NO:471, respectively.

- In one embodiment the paratope of an anti-FIX(a) antibody or antigen-binding fragment
30 thereof of the invention comprises amino acid residues H30, D31, W53, D56, S102, S104, Y106 and N107 in the heavy chain variable domain (SEQ ID NO:67) and residues Y91 and S92 in the light chain variable domain (SEQ ID NO:71).

- In one embodiment an anti-FIX(a) antibody or antigen-binding fragment thereof of the invention comprises one, two or three amino acid substitutions or deletions within the group
35 of paratope amino acid residues H30, D31, W53, D56, S102, S104, Y106 and N107 in the

heavy chain variable domain (SEQ ID NO:67) and residues Y91 and S92 in the light chain variable domain (SEQ ID NO:71).

In another embodiment the paratope of an anti-FIX(a) antibody or antigen-binding fragment thereof of the invention comprises amino acid residues D30, D31, W53, S102, S104 and
 5 N107 in the heavy chain variable domain (SEQ ID NO:35) and residues Y91 and S92 in the light chain variable domain (SEQ ID NO:39).

In another embodiment an anti-FIX(a) antibody of the invention comprises one, two or three amino acid substitutions or deletions within the group of paratope amino acid residues: D30, D31, W53, S102, S104 and N107 in the heavy chain variable domain (SEQ ID NO:35) and
 10 residues Y91 and S92 in the light chain variable domain (SEQ ID NO:39).

In one embodiment the CDR sequences of an antibody or antigen-binding fragment thereof of the invention may be described by anti-FIX(a) paratope amino acid residues being part of the CDRs.

In one such embodiment the anti-FIX(a) paratope CDRs are

15 VH CDR1 (based on SEQ ID NO:68): **DXXXX**
 VH CDR2 (based on SEQ ID NO:69): **XXXWXXDXXXXXXXXXX**
 VH CDR3 (based on SEQ ID NO:70): **XXXSXSXYNXXXX**
 VL CDR1 (based on SEQ ID NO:72): **XXXXXXXXXXXX**
 VL CDR2 (based on SEQ ID NO:73): **XXXXXXX**
 20 VL CDR3 (based on SEQ ID NO:74): **XXYSXXXXX**

wherein paratope amino acid residues are in bold, and X represents a naturally occurring amino acid residue.

In another such embodiment the anti-FIX(a) paratope CDRs are

VH CDR1 (based on SEQ ID NO:36): **DXXXX**
 25 VH CDR2 (based on SEQ ID NO:37): **XXXWXXXXXXXXXXXXXXXX**
 VH CDR3 (based on SEQ ID NO:38): **XXXSXSXXNXXXX**
 VL CDR1 (based on SEQ ID NO:40): **XXXXXXXXXXXX**
 VL CDR2 (based on SEQ ID NO:41): **XXXXXXX**
 VL CDR3 (based on SEQ ID NO:42): **XXYSXXXXX**

30 wherein paratope amino acid residues are in bold, and X represents a naturally occurring amino acid residue.

In another such embodiment the anti-FIX(a) paratope CDRs are

VH CDR1 (based on SEQ ID NO:52): **DXXXX**
 VH CDR2 (based on SEQ ID NO:53): **XXXWXXXXXXXXXXXXXXXX**
 35 VH CDR3 (based on SEQ ID NO:54): **XXXSXSXYNXXXX**

VL CDR1 (based on SEQ ID NO:56): XXXXXXXXXXXX

VL CDR2 (based on SEQ ID NO:57): XXXXXXXX

VL CDR3 (based on SEQ ID NO:58): **XXYS**XXXXXX

wherein paratope amino acid residues are in bold, and X represents a naturally occurring amino acid residue.

5 In one embodiment the paratope of an anti-FX(a) antibody of the invention comprises residues K23, S25, G26, Y27, F29, W33, D52, S54, D55, F57, S77, H100, Y101, Y102, N103 and S104 in the heavy chain variable domain (SEQ ID NO:467) and residues V29, S30, S31, Y33, Y50, Q52, S54, R55, R57 and D94 in the light chain variable domain (SEQ
10 ID NO:471).

In another embodiment an anti-FX(a) antibody of the invention comprises one, two or three amino acid substitutions or deletions within the group of paratope residues K23, S25, G26, Y27, F29, W33, D52, S54, D55, F57, S77, H100, Y101, Y102, N103 and S104 in the heavy chain variable domain (SEQ ID NO:467) and residues V29, S30, S31, Y33, Y50, Q52, S54,
15 R55, R57 and D94 in the light chain variable domain (SEQ ID NO:471).

In another embodiment the paratope of an anti-FX(a) antibody of the invention comprises residues K23, G24, S25, G26, Y27, W33, D52, S54, D55, Y57, S77, L99, H100, Y101, Y102, N103 and S104 in the variable heavy chain domain (SEQ ID NO:483) and residues S30, S31, Y33, Y50, Q52, S54, R55, R57, Y92 and D94 in the light chain variable domain (SEQ
20 ID NO:487).

In another embodiment an anti-FX(a) antibody of the invention comprises one, two or three amino acid substitutions or deletions within the group of paratope residues K23, G24, S25, G26, Y27, W33, D52, S54, D55, Y57, S77, L99, H100, Y101, Y102, N103 and S104 in the variable heavy chain domain (SEQ ID NO:483) and residues S30, S31, Y33, Y50, Q52, S54,
25 R55, R57, Y92 and D94 in the light chain variable domain (SEQ ID NO:487).

In one embodiment the CDR sequences of such an antibody may be described by anti-FX(a) paratope amino acid residues being part of the CDRs.

30 In one such embodiment the anti-FX(a) paratope CDRs are

VH CDR1 (based on SEQ ID NO:468): **XXW**XX

VH CDR2 (based on SEQ ID NO:469): **XXDXSDX**XXXXXXXXXX

VH CDR3 (based on SEQ ID NO:470): **XHYNS**XXXXXX

VL CDR1 (based on SEQ ID NO:472): XXXXX**VSS**YXX

35 VL CDR2 (based on SEQ ID NO:473): **XQXSR**XR

VL CDR3 (based on SEQ ID NO:474): **XXXXDXXXXX**

wherein paratope amino acid residues are in bold, and X represents a naturally occurring amino acid residue.

- 5 In another such embodiment the anti-FX(a) paratope CDRs are

VH CDR1 (based on SEQ ID NO:484): **XXWXX**

VH CDR2 (based on SEQ ID NO:485): **XXDXSDXYXXXXXXXXXX**

VH CDR3 (based on SEQ ID NO:486): **LHYNSXXXXX**

VL CDR1 (based on SEQ ID NO:488): **XXXXXXXXSSXYXX**

- 10 VL CDR2 (based on SEQ ID NO:489): **XQXSRXR**

VL CDR3 (based on SEQ ID NO:490): **XXYXDXXXXX**

wherein paratope amino acid residues are in bold, and X represents a naturally occurring amino acid residue.

- 15 In one embodiment an antibody of the invention is a multispecific antibody or antigen-binding fragment thereof capable of stimulating the enzymatic activity of FIXa towards FX comprising a first antigen-binding site capable of binding to FIX (SEQ ID NO:1) and/or the activated form thereof (FIXa), and a second antigen-binding site capable of binding to FX (SEQ ID NO:2) and/or the activated form thereof (FXa).

- 20 In one such embodiment the first antigen-binding site comprises a paratope comprising amino acid residues D30, D31, W53, S102, S104 and N107 in the heavy chain variable domain (SEQ ID NO:35) and amino acid residues Y91 and S92 in the light chain variable domain (SEQ ID NO:39), and the second antigen-binding site comprises a paratope comprising amino acid residues K23, G24, S25, G26, Y27, W33, D52, S54, D55, Y57, S77,
25 L99, H100, Y101, Y102, N103 and S104 in the variable heavy chain domain (SEQ ID NO:483) and amino acid residues S30, S31, Y33, Y50, Q52, S54, R55, R57, Y92 and D94 in the light chain variable domain (SEQ ID NO:487).

- In one such embodiment the first antigen-binding site comprises a paratope comprising amino acid residues H30, D31, W53, D56, S102, S104, Y106 and N107 in the heavy chain
30 variable domain (SEQ ID NO:67) and amino acid residues Y91 and S92 in the light chain variable domain (SEQ ID NO:71), and the second antigen-binding site comprises a paratope comprising amino acid residues K23, G24, S25, G26, Y27, W33, D52, S54, D55, Y57, S77, L99, H100, Y101, Y102, N103 and S104 in the variable heavy chain domain (SEQ ID NO:483) and amino acid residues S30, S31, Y33, Y50, Q52, S54, R55, R57, Y92 and D94 in
35 the light chain variable domain (SEQ ID NO:487).

In one such embodiment the first antigen-binding site comprises a paratope comprising amino acid residues H30, D31, W53, D56, S102, S104, Y106 and N107 in the heavy chain variable domain (SEQ ID NO:67) and amino acid residues Y91 and S92 in the light chain variable domain (SEQ ID NO:71), and the second antigen-binding site comprises a paratope
5 comprising amino acid residues K23, S25, G26, Y27, F29, W33, D52, S54, D55, F57, S77, H100, Y101, Y102, N103 and S104 in the heavy chain variable domain (SEQ ID NO:467) and amino acid residues V29, S30, S31, Y33, Y50, Q52, S54, R55, R57 and D94 in the light chain variable domain (SEQ ID NO:471).

In one such embodiment the first antigen-binding site comprises a paratope comprising
10 amino acid residues D30, D31, W53, S102, S104 and N107 in the heavy chain variable domain (SEQ ID NO:35) and amino acid residues Y91 and S92 in the light chain variable domain (SEQ ID NO:39), and the second antigen-binding site comprises a paratope comprising amino acid residues K23, S25, G26, Y27, F29, W33, D52, S54, D55, F57, S77, H100, Y101, Y102, N103 and S104 in the heavy chain variable domain (SEQ ID NO:467)
15 and amino acid residues V29, S30, S31, Y33, Y50, Q52, S54, R55, R57 and D94 in the light chain variable domain (SEQ ID NO:471).

In one such embodiment the first antigen-binding site comprises a paratope comprising amino acid residues H30, D31, W53, S102, S104, Y106 and N107 in the heavy chain variable domain (SEQ ID NO:51) and amino acid residues Y91 and S92 in the light chain
20 variable domain (SEQ ID NO:55), and the second antigen-binding site comprises a paratope comprising amino acid residues K23, S25, G26, Y27, F29, W33, D52, S54, D55, F57, S77, H100, Y101, Y102, N103 and S104 in the heavy chain variable domain (SEQ ID NO:467) and amino acid residues V29, S30, S31, Y33, Y50, Q52, S54, R55, R57 and D94 in the light chain variable domain (SEQ ID NO:471).

25

In one embodiment the antibody is a bispecific antibody capable of binding to FIX(a) and FX(a).

In one embodiment an antibody of the invention is capable of binding FIXa with a higher affinity than that with which it binds FIX.

30 In one embodiment an antibody of the invention is capable of increasing the enzymatic activity of FIXa towards FX.

In one such embodiment an antibody of the invention is capable of increasing the enzymatic activity of FIXa towards FX as measured in a FXa generation assay using monovalent one-armed antibodies as described herein.

In one embodiment an antibody of the invention is capable of increasing the enzymatic activity of FIXa towards FX as measured in a FXa generation assay using bivalent antibodies as described herein.

In one embodiment the multispecific antibodies, such as bispecific antibodies, of the invention do not interfere with the effect of FVIII, such as recombinant FVIII administered to a patient suffering from haemophilia A, when said antibodies are used in clinically relevant dosages in the treatment of haemophilia A.

In one embodiment an antibody of the invention is not the anti-FIX antibody CLB-FIX 13 as described in Rohlena *et al.* (2003) J. Biol. Chem. 278(11):9394–9401. In one embodiment an antibody of the invention is not the anti-FIX antibody HIX-1 (IgG1 murine) (Merck KGaA, SigmaAldrich). In one embodiment an antibody or antigen-binding fragment thereof of the invention is not the anti-FIX antibody AHIX-5041 (IgG1) (Haematologic Technologies, Inc.).

In one embodiment an antibody or antigen-binding fragment thereof of the invention has reduced immunogenicity as compared to procoagulant antibodies of the art.

In a preferred embodiment antibodies of the invention were - unless otherwise stated or contradicted by context - expressed in the IgG4/kappa format.

The heavy chain constant domain regions (C_H1-C_H2-C_H3) were for the anti-FIX(a) arm human IgG4 with a S228P (EU-numbering) substitution and with truncation of the C-terminal lysine:

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKISKAKGQPREPQVYTLPPSQEEMTKNQV
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLGLG (SEQ ID NO:1195).

In one embodiment the heavy chain constant domain regions (C_H1-C_H2-C_H3) were for the anti-FX(a) arm human IgG4 with the S228P substitution and with two additional substitutions, F405L and R409K (EU numbering), in the C_H3 domain to facilitate hetero-dimerization of the heavy chains (described in example 4) and with truncation of the C-terminal lysine:

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKISKAKGQPREPQVYTLPPSQEEMTKNQV
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFLLYSKLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLGLG (SEQ ID NO:1196).

and, the light chain constant region (CL) was human kappa:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:1197).

5

In another embodiment antibodies can also be expressed in the IgG4 format with heavy chain constant domain regions (C_H1-C_H2-C_H3) for the anti-FIX(a) arm carrying S228P, F405L and R409K substitutions and with heavy chain constant domain regions for the anti-FX(a) arm carrying the S228P substitution, with or without C-terminal lysine deletion.

10

In one embodiment antibodies can also be expressed in the IgG1/kappa format. In that case the heavy chain constant domain regions of the anti-FIX(a) arm is human IgG1 F405L with truncation of the C-terminal lysine:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
15 LYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVELTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFLLYSKLTVDKSRWQQGNVFS
CSVMHEALHNHYTQKSLSLSPG (SEQ ID NO:1198).

20

and the heavy chain constant domain regions of the anti-FX(a) arm is human IgG1 K409R with truncation of the C-terminal lysine:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV
25 FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVELTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQQGNVFS
CSVMHEALHNHYTQKSLSLSPG (SEQ ID NO:1199).

30

Antibodies can also be expressed in the IgG1 format with heavy chain constant domain regions (C_H1-C_H2-C_H3) for the anti-FIX(a) arm carrying the K409R substitution and with heavy chain constant domain regions for the anti-FX(a) arm carrying the F405L substitution, with or without C-terminal lysine deletion.

The constant domain regions may further comprise additional substitutions or other

35

modifications e.g. to modulate effector functions, half-life or other properties.

The present disclosure also provides kits that comprise antibodies or antigen-binding fragments thereof as disclosed herein suitable for treatment as described herein. In some embodiments, a kit comprises (i) an antibody, such as a bispecific antibody or antigen-binding fragment thereof, pharmaceutical composition, nucleic acid, vector, or cell (e.g., a host cell) as disclosed herein, or a combination thereof, and (ii) instructions for use. A skilled person will readily recognize that the antibodies, bispecific molecules (e.g., bispecific antibodies), pharmaceutical compositions, nucleic acids, vectors, or cells (e.g., a host cell) disclosed herein, or combinations thereof can be readily incorporated into one of the established kit formats which are well known in the art.

EXAMPLES**List of Abbreviations**

	ACN:	Acetonitrile
	bimAb:	Bispecific monoclonal Antibody
5	CDR:	Complementarity Determining Region
	EGR-CK:	EGR-chloromethylketone
	LC-MS	Liquid chromatography-mass spectrometry
	FACS:	Fluorescence-activated cell sorting
	FIX:	Coagulation Factor IX
10	FIXa:	Coagulation Factor IXa
	FX:	Coagulation Factor X
	FXa:	Coagulation Factor Xa
	HA:	Haemophilia A
	HA-PPP:	HA-induced human platelet-poor plasma
15	HA-PRP:	HA-induced human platelet-rich plasma
	hFIXa:	human Coagulation Factor IXa
	ITC:	Isothermal Titration Calorimetry
	MACS:	Magnetic-activated cell sorting
	OA:	One-armed
20	PCR:	Polymerase Chain Reaction
	SPR:	Surface Plasmon Resonance

References to ACE910 should be understood as referring to an antibody having an amino acid sequence which is identical to that of ACE910.

Example 1: Development of anti-FIX(a) and anti-FX(a) antibodies

FIX(a) and FX(a) binding antibodies as disclosed herein were identified using various antibody development methods. In order to generate a diverse set of antibodies, immunisations of mice and rabbits were performed and phage display and Adimab yeast
5 antibody expression platforms were also utilized.

Adimab yeast antibody platform

The Adimab platform is a yeast antibody expression system encompassing a fully human naïve IgG1/kappa library with a diversity of 10^{10} . The antibody selection process was directed
10 using MACS and FACS based methods which allowed monitoring of applied selection criteria in real time. Since selections were based on MACS and FACS, labelled antigens (e.g. biotin) were needed. Selection campaigns were performed using biotin-labelled active-site inhibited hFIXa (FIXa-EGR-biotin), or antibody mediated immobilization of hFIXa. Hits were evaluated for binding using Bio-layer interferometry (Octet fortebio systems).

15

Phage display

The utilized antibody phage display platform is a proprietary fully human Fab display library. The library has a size of 10^{10} and was constructed by a combinatorial approach utilizing chemical synthesis of the light chain, as well as the heavy chain CDR1 and CDR2,
20 complemented with PCR amplification of the heavy chain CDR3 from human peripheral blood mononuclear cells. To maximise epitope diversity, different panning strategies were explored, including panning using biotinylated FIXa-EGR, FX, active-site inhibited FXa, or antigen capture using anti-FIXa antibodies. Initial hits were identified by phage ELISA. After sequence analysis, unique hits were cloned and recombinantly expressed as IgG1
25 antibodies, and ranked using SPR (Biacore) or Bio-layer interferometry (Octet fortebio systems).

In vivo platforms

Mice and rabbits were used for the generation of antibodies using in vivo platforms. For the
30 generation of anti-FIX/FIXa antibodies, mice or rabbits were immunized with human FIXa, FIXa-EGR or FIX using standard protocols. The spleen cells from mice were fused with myeloma cells using standard techniques and the resulting antibody containing hybridoma supernatants were screened for binding to FIXa using ELISA. FIXa binding rabbit B-cells were single cell sorted using FACS by gating on cells binding randomly biotinylated FIXa-
35 EGR (detected by streptavidin conjugated fluorophore). Sorted rabbit B cells were cultured

for seven days in 384w plates using feeder cells and conditioned medium from splenocytes, prior to screening against FIXa in ELISA. Rabbit B-cells and mouse hybridoma clones, expressing FIXa binding antibody hits, were either used for VH/VL sequencing followed by recombinant expression (for rabbit or hybridoma mAbs) or further propagated for mAb
5 production (mouse hybridomas).

For the generation of anti-FX antibodies, mice and rabbits were immunised with FX using standard protocols. Rabbit B-cells were isolated by FACS based single-cell sorting and using randomly biotinylated FX (detected by streptavidin conjugated flourophore) while spleen cells
10 from immunized mice were used for standard hybridoma development. Resulting antibody producing B-cell or mouse hybridoma clones were screened for FX binding using ELISA and Octet fortebio systems. Rabbit B-cell or mouse hybridoma clones expressing antibody hits were either used for VH/VL sequencing followed by recombinant expression (for rabbit or hybridoma mAbs) or further propagated for mAb production (mouse hybridomas)

15

Sequencing of hybridoma-derived antibodies

Anti-FIXa and anti-FX antibody producing hybridomas were sequenced and expressed in HEK293 cells using standard techniques. Expressed antibodies were evaluated for antigen binding using Octet fortebio systems.

20

Total RNA was extracted from antibody producing clones and the variable domain (V_H and V_L) encoding DNA sequences were amplified using RT-PCR. V_H and V_L sequences were determined and inserted into a pTT-based mammalian expression vector (Durocher *et al* (2002) Nucleic Acid Res. 30: E9) or into a pcDNA3.4 mammalian expression vector
25 (Invitrogen) containing antibody constant region encoding DNA sequences. For pTT/pcDNA3.4 mAb expression vectors, the V_H and V_L DNA sequences were inserted in-frame with human IgG1 or IgG₄ S228P ($C_H1C_H2C_H3$, optionally with additional amino acid substitutions and deletions, e.g. substitutions in the C_H3 domain and deletion of the C-terminal lysine) or human C_L kappa constant region encoding DNA sequences, respectively.
30 For the corresponding pTT/pcDNA3.4 Fab expression vectors the V_H DNA sequences were inserted in-frame with human IgG₄ C_H1 encoding DNA sequences.

Example 2: Recombinant expression of antibodies and antibody Fab fragments

Antibodies and antibody Fab fragments were expressed using transient transfection of HEK293 suspension cells (293Expi, Invitrogen) essentially following manufacturer's instructions. 293Expi cells were typically subcultivated every 3-4 days in Expi293F

- 5 expression medium (Invitrogen, catalogue number A1435104) supplemented with 1% P/S (GIBCO catalogue number 15140-122). Expi293F cells were transfected at a cell density of 2.5-3 mill/mL using Expifectamine. For each litre of Expi293F cells, the transfection was performed by diluting a total of 1 mg of plasmid DNA (V_H - C_H1 (for Fab) or V_H - C_H1 - C_H2 - C_H3 (for mAb) and LC plasmids in 1:1 ratio) into 50 mL Optimem (GIBCO, cat. no. 51985-026, dilution A) and by diluting 2.7 mL Expifectamine into 50 mL Optimem (dilution B). For Fab and mAb producing co-transfections, V_H - C_H1 and LC plasmids (Fab) and V_H - C_H1 - C_H2 - C_H3 and LC plasmids (mAb), respectively, were used in a 1:1 ratio. Dilution A and B were mixed and incubated at room temperature for 10-20 minutes. The transfection mix was hereafter added to the Expi293F cells and cells were incubated at 37°C in a humidified incubator with orbital rotation (85-125 rpm). One day post-transfection, transfected cells were supplemented with 5 ml of ExpiFectamine 293 Transfection Enhancer 1 and 50 ml of ExpiFectamine 293 Transfection Enhancer 2. Cell culture supernatants were typically harvested 4-5 days post-transfection by centrifugation followed by filtration.

20 **Example 3: Fab and antibody purification and characterization**

All purification steps were carried out at 4°C. For lab scale, Milli-Q water was used for buffer preparation. The HPLC system used for SE-HPLC analysis was Agilent 1100. Aggregation and LC/MS were assessed for QC.

- 25 Capturing of Fab was performed with HiTrap Protein G HP affinity chromatography with binding buffer in 1× PBS (10mM Na₂HPO₄, 1.8mM KH₂PO₄, 137mM NaCl, 2.7mM KCl), pH 7.4. One step elution was performed with 0.1M Glycine, pH 2.8. The final product was desalted via 52mL GE Hiprep 16 desalting column into formulation buffer (25mM HEPES, 150mM NaCl) with pH 7.4 and concentrated by centrifugal ultrafilter (30KD C.O.) for storage at -80 °C.

- 30 To assess the quality of the purified Fab, SDS-PAGE and high-performance size-exclusion chromatography (SE-HPLC) analysis were performed. Batches that did not meet the quality standards (e.g., <95% monomeric by SE-HPLC) were further purified by size-exclusion chromatography. LC/MS was carried out to verify identity of Fab protein. Molecular weights (MWs) of all Fab's were shown to be consistent with theoretical MW of heavy chain and light chain, respectively.
- 35

Antibody purification and characterization

Purification of the antibodies was conducted by affinity chromatography using a Protein A MabSelect SuRe resins (GE Healthcare, cat. no. 17-5438-01). For small-scale antibody productions, protein A based purification was performed in 96 well plates while for larger

5 productions, the ÄktaExplorer chromatography system (GE Healthcare, cat. no. 18-1112-41) was used. The buffer systems used for the affinity purification step were 1) an equilibration buffer composed of 20 mM NaPhosphate pH 7.2, 150 mM NaCl and 2) an elution buffer composed of 10 mM Formic acid pH 3.5 and 3) a pH-adjustment buffer composed of 0.4 M NaPhosphate pH 9.0. Cell supernatants were applied directly without any adjustments onto a

10 pre-equilibrated MabSelect SuRe column. The column was washed with approximately 10 column volumes of equilibration buffer and the antibodies were eluted isocratically in approx. 2-5 column volume of elution buffer. The pH of the pooled fractions was adjusted to neutral using the described pH-adjustment buffer immediately after elution.

The purified antibodies were characterized using different methods such as SDS-

15 PAGE/Coomassie, size-exclusion high-pressure liquid-chromatography (SE-HPLC) and liquid-chromatography mass spectrometry (LC-MS) analyses. The SDS-PAGE/Coomassie analysis was performed using NuPage 4–12% Bis-Tris gels (Invitrogen, cat. no. NP0321BOX). Here, all antibodies displayed expected light chain and heavy chain components. Intact molecular mass determinations were performed using a Liquid

20 Chromatography Electrospray Ionisation Time-of-Flight Mass Spectrometry method setup on an Agilent 6210 instrument and a desalting column MassPREP (Waters, cat. no. USRM10008656). The buffer system used was an equilibration buffer composed of 0.1% Formic acid in LC-MS graded-H₂O and an elution buffer composed of 0.1% formic acid in LC-MS graded-ACN. Analyses were performed with and without N-Glycosidase F (Roche

25 Diagnostics, cat. no. 11365177001) and reducing agent (i.e. mercaptoethanol or DTT). All antibodies displayed expected intact molecular masses in accordance with sequence and one heavy chain N-glycan. Purity was determined based on SE-HPLC. The final protein purity was analysed based on SE-HPLC method setup on an Agilent LC 1100/1200 system and using a BIOSep-SEC-S3000 300×7.8mm column (Phenomenex, cat. no. 00H-2146-K0)

30 and a running buffer composed of 200 mM NaPhosphate pH 6.9, 300 mM NaCl and 10% isopropanol. UV280 and fluorescence (Ex 280nm / Em 354nm) detectors was used for detection. The antibodies eluted as single symmetric peaks with retention times reflecting the size of the antibodies. Purity estimates were all between 95-99% for the different antibodies. To measure the final protein concentrations, a NanoDrop spectrophotometer (Thermo

35 Scientific) was used together with specific extinction coefficients for each of the antibodies.

Example 4: Bispecific antibodies prepared by *in vitro* assembly

Bispecific antibodies were generated by *in vitro* assembly of a first and a second antibody by the Duobody® method (Genmab) described (Labrijn *et al.* PNAS 2013, vol. 110, pp. 5145–5150) for bispecific human IgG1 antibodies and using a slightly modified variant for bispecific

5 human IgG4 antibodies as detailed in the following.

For IgG1 the heavy chain constant region of the first antibody is human IgG1 K409R (anti-FIX/FIXa) and the heavy chain constant region of the second antibody is human IgG1 F405L (anti-FX/FXa). The IgG1 may be a IgG1 variant with reduced effector functions, as referred to earlier.

10 For human IgG4, the heavy chain constant region of the first antibody is IgG4 S228P (anti-FIX/FIXa) and the heavy chain constant region of the second antibody is IgG4 S228P F405L+R409K (anti-FX). The two parental antibodies are produced as described in Examples 1-3. The Fab arm exchange reaction is carried out in HEPES buffer (pH 7.4) under reducing conditions using 75 mM 2-mercaptoethylamine (2-MEA) and incubation at 30 °C for
15 4 hours.

Example 5: Preparation of monovalent (one-armed) antibodies

To avoid any potential avidity effects associated with conventional monospecific and bivalent antibodies, e.g. in FXa generation assays (Example 12) and in certain SPR-based

20 experiments (Examples 10 and 11), a monovalent one-armed (OA) antibody format was used, as described by Martens *et al.*: A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo. *Clin. Cancer Res.* 12, 6144-6152 (2006), where a full heavy chain, a truncated heavy chain (lacking the Fab region) and a light chain are co-expressed. Instead of co-expression of the three chains described by Martens *et al.* monovalent
25 antibodies of the present invention were prepared using the Duobody® principle as described for bispecific antibodies (Example 4). Thus, monovalent antibodies were prepared by mixing a full monospecific and bivalent antibody and a truncated heavy chain dimer (formally derived from a full antibody by removing the Fab region) and allow exchange of chains to proceed under the same experimental conditions as described in Example 4. Formation of
30 the monovalent antibody requires that the antibody and truncated heavy chain dimer carry appropriate complementary mutations to promote hetero-dimerization, i.e. F405L/K409R for human IgG1 and F405L+R409K/WT for human IgG4, as described in Example 4.

In case of monovalent antibodies of the IgG1 subtype the truncation of the heavy chain can be from the N-terminus to a position in-between Cys 220 and the upper hinge Cys 226 (EU

numbering). A specific example of a truncated human IgG1 heavy chain is one where residues 1-220 are truncated.

- In case of monovalent antibodies of the human IgG4 subtype the truncation of the heavy chain can be from the N-terminus to a position in-between Cys 200 and the upper hinge Cys 226 (EU numbering). A specific example of a truncated human IgG4 heavy chain is one where residues 1-214 are truncated.
- 5

Example 6: Overview of bispecific antibody (component) IDs and SEQ ID NOs

Table 1: Overview of bispecific antibody components and corresponding VH/VL SEQ ID NOs

BimAb ID	Component anti-FIX antibody		Component anti-FX antibody	
	ID	# VH VL	ID	# VH VL
bimAb05-0745	mAb01-9994	67 71	mAb01-8174	467 471
bimAb05-0746	mAb01-9978	43 47	mAb01-8174	467 471
bimAb05-1229	mAb01-9016	3 7	mAb01-6723	459 463
bimAb05-2112	mAb01-9994	67 71	mAb01-9772	483 487
bimAb05-2113	mAb01-9933	35 39	mAb01-9772	483 487
bimAb05-2114	mAb01-9985	51 55	mAb01-9772	483 487
bimAb05-2115	mAb01-9978	43 47	mAb01-9772	483 487
bimAb05-2375	mAb01-9016	3 7	mAb01-8174	467 471
bimAb05-2379	mAb01-9016	3 7	mAb01-8913	475 479
bimAb05-2532	mAb01-9373	11 15	mAb01-6723	459 463
bimAb05-3279	mAb01-9933	35 39	mAb01-6723	459 463
bimAb05-3409	mAb01-9978	43 47	mAb01-6723	459 463
bimAb05-3416	mAb01-9985	51 55	mAb01-6723	459 463
bimAb05-3755	mAb01-9994	67 71	mAb01-6723	459 463
bimAb05-3761	mAb01-9933	35 39	mAb01-8174	467 471
bimAb05-3769	mAb01-9985	51 55	mAb01-8174	467 471
bimAb05-3770	mAb01-9986	59 63	mAb01-8174	467 471
bimAb05-3862	mAb01-9696	19 23	mAb01-8174	467 471
bimAb05-3863	mAb01-9697	27 31	mAb01-8174	467 471
bimAb05-3880	mAb11-0047	75 79	mAb01-8174	467 471

BimAb ID	Component anti-FIX antibody		Component anti-FX antibody	
	ID	# VH VL	ID	# VH VL
bimAb05-3886	mAb11-0049	83 87	mAb01-8174	467 471
bimAb05-3955	mAb11-0107	91 95	mAb01-8174	467 471
bimAb05-4100	mAb11-0149	99 103	mAb01-8174	467 471
bimAb05-4114	mAb11-0160	107 111	mAb01-8174	467 471
bimAb05-4121	mAb11-0164	115 119	mAb01-8174	467 471
bimAb05-4220	mAb11-0962	211 215	mAb01-8174	467 471
bimAb05-4226	mAb11-0965	219 223	mAb01-8174	467 471
bimAb05-4283	mAb11-1021	227 231	mAb01-8174	467 471
bimAb05-4289	mAb11-1024	235 239	mAb01-8174	467 471
bimAb05-4292	mAb11-1033	251 255	mAb01-8174	467 471
bimAb05-4293	mAb11-1030	243 247	mAb01-8174	467 471
bimAb05-4387	mAb11-1039	259 263	mAb01-8174	467 471
bimAb05-4392	mAb11-1042	267 271	mAb01-8174	467 471
bimAb05-4419	mAb11-0174	123 127	mAb01-8174	467 471
bimAb05-4422	mAb11-1073	275 279	mAb01-8174	467 471
bimAb05-4428	mAb11-1076	283 287	mAb01-8174	467 471
bimAb05-4443	mAb11-1094	299 303	mAb01-8174	467 471
bimAb05-4444	mAb11-1091	291 295	mAb01-8174	467 471
bimAb05-4601	mAb11-0937	187 191	mAb01-8174	467 471
bimAb05-4604	mAb11-0923	139 143	mAb01-8174	467 471
bimAb05-4608	mAb11-0939	203 207	mAb01-8174	467 471
bimAb05-4611	mAb11-0935	179 183	mAb01-8174	467 471
bimAb05-4612	mAb11-0938	195 199	mAb01-8174	467 471
bimAb05-4613	mAb11-0933	171 175	mAb01-8174	467 471
bimAb05-4615	mAb11-0932	163 167	mAb01-8174	467 471

BimAb ID	Component anti-FIX antibody		Component anti-FX antibody	
	ID	# VH VL	ID	# VH VL
bimAb05-4617	mAb11-0929	147 151	mAb01-8174	467 471
bimAb05-4618	mAb11-0931	155 159	mAb01-8174	467 471
bimAb05-4684	mAb01-9985	51 55	mAb11-1114	499 503
bimAb05-4685	mAb01-9985	51 55	mAb11-1115	507 511
bimAb05-4686	mAb01-9985	51 55	mAb11-1116	515 519
bimAb05-4687	mAb01-9985	51 55	mAb11-1117	523 527
bimAb05-4688	mAb01-9985	51 55	mAb11-1118	531 535
bimAb05-4689	mAb01-9985	51 55	mAb11-1119	539 543
bimAb05-4690	mAb01-9985	51 55	mAb11-1121	555 559
bimAb05-4692	mAb01-9985	51 55	mAb11-1122	563 567
bimAb05-4693	mAb01-9985	51 55	mAb11-1123	571 575
bimAb05-4694	mAb01-9985	51 55	mAb11-1124	579 583
bimAb05-4695	mAb01-9985	51 55	mAb01-9778	491 495
bimAb05-4696	mAb01-9985	51 55	mAb11-1125	587 591
bimAb05-4697	mAb01-9985	51 55	mAb11-1127	595 599
bimAb05-4698	mAb01-9985	51 55	mAb11-1128	603 607
bimAb05-4699	mAb01-9985	51 55	mAb11-1129	611 615
bimAb05-4700	mAb01-9985	51 55	mAb11-1130	619 623
bimAb05-4701	mAb01-9985	51 55	mAb11-1131	627 631
bimAb05-4702	mAb01-9985	51 55	mAb11-1132	635 639
bimAb05-4703	mAb01-9985	51 55	mAb11-1133	643 647
bimAb05-4704	mAb01-9985	51 55	mAb11-1416	651 655
bimAb05-4705	mAb01-9985	51 55	mAb11-1417	659 663
bimAb05-4706	mAb01-9985	51 55	mAb11-1418	667 671
bimAb05-4707	mAb01-9985	51 55	mAb11-1419	675 679

BimAb ID	Component anti-FIX antibody		Component anti-FX antibody	
	ID	# VH VL	ID	# VH VL
bimAb05-4708	mAb01-9985	51 55	mAb11-1420	683 687
bimAb05-4709	mAb01-9985	51 55	mAb11-1421	691 695
bimAb05-4710	mAb01-9985	51 55	mAb11-1422	699 703
bimAb05-4788	mAb11-1233	307 311	mAb01-8174	467 471
bimAb05-4884	mAb11-1254	315 319	mAb01-8174	467 471
bimAb05-4895	mAb11-1262	339 343	mAb01-8174	467 471
bimAb05-4896	mAb11-1259	323 327	mAb01-8174	467 471
bimAb05-4898	mAb11-1260	331 335	mAb01-8174	467 471
bimAb05-4903	mAb11-1268	355 359	mAb01-8174	467 471
bimAb05-4906	mAb11-1266	347 351	mAb01-8174	467 471
bimAb05-4910	mAb11-1273	363 367	mAb01-8174	467 471
bimAb05-4914	mAb11-1275	371 375	mAb01-8174	467 471
bimAb05-4915	mAb11-1276	379 383	mAb01-8174	467 471
bimAb05-4919	mAb11-1278	387 391	mAb01-8174	467 471
bimAb05-4920	mAb11-1282	403 407	mAb01-8174	467 471
bimAb05-4921	mAb11-1279	395 399	mAb01-8174	467 471
bimAb05-4924	mAb11-1288	419 423	mAb01-8174	467 471
bimAb05-4927	mAb11-1286	411 415	mAb01-8174	467 471
bimAb05-5092	mAb11-1344	427 431	mAb01-8174	467 471
bimAb05-5095	mAb11-0723	131 135	mAb01-8174	467 471
bimAb05-5204	mAb11-1358	435 439	mAb01-8174	467 471
bimAb05-5205	mAb11-1360	443 447	mAb01-8174	467 471
bimAb05-5240	mAb11-1389	451 455	mAb01-8174	467 471
bimAb05-5339	mAb01-9985	51 55	mAb11-1440	771 775
bimAb05-5340	mAb01-9985	51 55	mAb11-1431	707 711

BimAb ID	Component anti-FIX antibody		Component anti-FX antibody	
	ID	# VH VL	ID	# VH VL
bimAb05-5341	mAb01-9985	51 55	mAb11-1441	779 783
bimAb05-5342	mAb01-9985	51 55	mAb11-1439	763 767
bimAb05-5343	mAb01-9985	51 55	mAb11-1442	787 791
bimAb05-5344	mAb01-9985	51 55	mAb11-1443	795 799
bimAb05-5345	mAb01-9985	51 55	mAb11-1446	819 823
bimAb05-5346	mAb01-9985	51 55	mAb11-1444	803 807
bimAb05-5347	mAb01-9985	51 55	mAb11-1447	827 831
bimAb05-5348	mAb01-9985	51 55	mAb11-1445	811 815
bimAb05-5349	mAb01-9985	51 55	mAb11-1448	835 839
bimAb05-5350	mAb01-9985	51 55	mAb11-1432	715 719
bimAb05-5351	mAb01-9985	51 55	mAb11-1449	843 847
bimAb05-5352	mAb01-9985	51 55	mAb11-1450	851 855
bimAb05-5353	mAb01-9985	51 55	mAb11-1453	875 879
bimAb05-5354	mAb01-9985	51 55	mAb11-1451	859 863
bimAb05-5355	mAb01-9985	51 55	mAb11-1454	883 887
bimAb05-5356	mAb01-9985	51 55	mAb11-1452	867 871
bimAb05-5357	mAb01-9985	51 55	mAb11-1455	891 895
bimAb05-5358	mAb01-9985	51 55	mAb11-1433	723 727
bimAb05-5359	mAb01-9985	51 55	mAb11-1456	899 903
bimAb05-5361	mAb01-9985	51 55	mAb11-1459	923 927
bimAb05-5362	mAb01-9985	51 55	mAb11-1457	907 911
bimAb05-5363	mAb01-9985	51 55	mAb11-1434	731 735
bimAb05-5364	mAb01-9985	51 55	mAb11-1458	915 919
bimAb05-5365	mAb01-9985	51 55	mAb11-1460	931 935
bimAb05-5366	mAb01-9985	51 55	mAb11-1461	939 943

BimAb ID	Component anti-FIX antibody		Component anti-FX antibody	
	ID	# VH VL	ID	# VH VL
bimAb05-5367	mAb01-9985	51 55	mAb11-1465	963 967
bimAb05-5369	mAb01-9985	51 55	mAb11-1466	971 975
bimAb05-5370	mAb01-9985	51 55	mAb11-1463	947 951
bimAb05-5371	mAb01-9985	51 55	mAb11-1435	739 743
bimAb05-5372	mAb01-9985	51 55	mAb11-1464	955 959
bimAb05-5373	mAb01-9985	51 55	mAb11-1467	979 983
bimAb05-5374	mAb01-9985	51 55	mAb11-1468	987 991
bimAb05-5375	mAb01-9985	51 55	mAb11-1472	1011 1015
bimAb05-5377	mAb01-9985	51 55	mAb11-1473	1019 1023
bimAb05-5378	mAb01-9985	51 55	mAb11-1470	995 999
bimAb05-5379	mAb01-9985	51 55	mAb11-1436	747 751
bimAb05-5380	mAb01-9985	51 55	mAb11-1471	1003 1007
bimAb05-5381	mAb01-9985	51 55	mAb11-1474	1027 1031
bimAb05-5383	mAb01-9985	51 55	mAb11-1477	1051 1055
bimAb05-5384	mAb01-9985	51 55	mAb11-1475	1035 1039
bimAb05-5385	mAb01-9985	51 55	mAb11-1478	1059 1063
bimAb05-5386	mAb01-9985	51 55	mAb11-1476	1043 1047
bimAb05-5387	mAb01-9985	51 55	mAb11-1479	1067 1071
bimAb05-5388	mAb01-9985	51 55	mAb11-1480	1075 1079
bimAb05-5389	mAb01-9985	51 55	mAb11-1483	1099 1103
bimAb05-5390	mAb01-9985	51 55	mAb11-1437	755 759
bimAb05-5391	mAb01-9985	51 55	mAb11-1484	1107 1111
bimAb05-5392	mAb01-9985	51 55	mAb11-1481	1083 1087
bimAb05-5393	mAb01-9985	51 55	mAb11-1485	1115 1119
bimAb05-5394	mAb01-9985	51 55	mAb11-1482	1091 1095

BimAb ID	Component anti-FIX antibody		Component anti-FX antibody	
	ID	# VH VL	ID	# VH VL
bimAb05-5395	mAb01-9985	51 55	mAb11-1486	1123 1127
bimAb05-5396	mAb01-9985	51 55	mAb11-1487	1131 1135
bimAb05-5397	mAb01-9985	51 55	mAb11-1490	1155 1159
bimAb05-5399	mAb01-9985	51 55	mAb11-1491	1163 1167
bimAb05-5400	mAb01-9985	51 55	mAb11-1488	1139 1143
bimAb05-5401	mAb01-9985	51 55	mAb11-1492	1171 1175
bimAb05-5402	mAb01-9985	51 55	mAb11-1489	1147 1151
bimAb05-5403	mAb01-9985	51 55	mAb11-1493	1179 1183
bimAb05-5406	mAb01-9985	51 55	mAb11-1494	1187 1191
bimAb05-5413	mAb01-9985	51 55	mAb11-1120	547 551
bimAb05-4271	mAb11-0173	1202 1206	mAb01-8174	467 471
bimAb05-4756	mAb11-1204	1210 1214	mAb01-8174	467 471
bimAb05-0396	mAb11-1495	1218 1222	mAb01-8174	467 471
bimAb05-0417	mAb11-1501	1226 1230	mAb01-8174	467 471
bimAb05-0438	mAb11-1502	1234 1238	mAb01-8174	467 471

Table 2: Overview of anti-FIX(a) antibody VH, VL and CDR sequences

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb01-9016	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFDDYAMH WVRQVPGKGLEWVSGIS WRGDIGGYVDSVKGRFTI SRDNAKNSLYQLNSLRA EDTALYYCVKSYGSGSFY NAFDSWGQGTLLVTVSS	3	DYAMH	4	GISWRGDIIGGYV DSVKG	5	SYGSGSFYNAFDS	6
mAb01-9016	VL	DIQMTQSPSTLSASAGDR VTITCRASQSISSWLAWY QQKPGKAPKFLYKASRL ERGVPSRFSGSGSGTEF SLTISSLQPEDDFATYYCLE YSSYRTFGQGTKEIK	7	RASQSISSW LA	8	KASRLER	9	LEYSSYIRT	10
mAb01-9373	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WRGDIIGYVDSVKGRFTIS RDNAKNSLYQLNSLRAE DTALYYCVKSYGSGSFYN AFDSWGQGTLLVTVSS	11	DYAMH	12	GISWRGDIIGYVD SVKG	13	SYGSGSFYNAFDS	14
mAb01-9373	VL	DIQMTQSPSTLSASAGDE VTITCRASKSISSWLAWY QQKPGKAPRFLYKASRL DRGTPSRFSGSGSGTEF TLTISHLQPEDDFATYYCLE YSSYRTFGQGTKEIK	15	RASKSISSW LA	16	KASRLDR	17	LEYSSYIRT	18
mAb01-9696	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFDDYAMH	19	DYAMH	20	GISWRGDIIGGYV DSVKG	21	SYGSGSFYNAFDS	22

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
		WVRQVPGKGLEWVSGIS WRGDIGGYVDSVKGRFTI SRDNKNSLYQLNSLRA EDTALYVCVKSYSYSGSFY NAFDSWGQGTSLVTSS							
mAb01-9696	VL	DIQMTQSPSTLSASAGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGSGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	23	RASQSISSW LA	24	KASRLDR	25	LEYSSYIRT	26
mAb01-9697	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFDDYAMH WVRQVPGKGLEWVSGIS WRGDIGGYVDSVKGRFTI SRDNKNSLYQLNSLRA EDTALYVCVKSYSYSGSFY NAFDSWGQGTSLVTSS	27	DYAMH	28	GISWRGDIIGGYV DSVKG	29	SYGSGSFYNAFDS	30
mAb01-9697	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL ERGTPSRFSGSGSGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	31	RASQSISSW LA	32	KASRLER	33	LEYSSYIRT	34
mAb01-9933	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFDDYAMH WVRQVPGKGLEWVSGIS WKGDIIGGYVDSVKGRFTI SRDNKNSLYQLNSLRA EDTALYCAKSYSGSFY	35	DYAMH	36	GISWKGDIGGYV DSVKG	37	SYGSGSFYNAFDS	38

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb01-9933	VL	NAFDSWGQGLVTSS DIQMTQSPSTLSASAGDE VTITCRASQSISSWLAWY QQKPGKAPKLLIYKASKL DRGVPSRFSGSGSGTEF SLTISDLQPDFFATYYCLE YSSYIRTFGQGTKEIK	39	RASQSISSW LA	40	KASKLDR	41	LEYSSYIRT	42
mAb01-9978	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGLVTSS	43	DYAMH	44	GISWKGDIGGYV DSVKG	45	SYGSGSFYNAFDS	46
mAb01-9978	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKLLIYKASRL ERGTSPSRFSGSGSGTEF SLTISDLQPDFFATYYCLE YSSYIRTFGQGTKEIK	47	RASQSISSW LA	48	KASRLER	49	LEYSSYIRT	50
mAb01-9985	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WRGDIGGYVKS VKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGLVTSS	51	DYAMH	52	GISWRGDIGGYV KSVKG	53	SYGSGSFYNAFDS	54
mAb01-9985	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL	55	RASQSISSW LA	56	KASKLER	57	LEYSSYIRT	58

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb01-9986		ERGTPSRFSGSGSGTEF SLTISSLQPDFFATYCYCLE YSSYIRTFGQGTKEIK							
	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WRGDIGGYVKSVKGRFTI SRDNAKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLLVTVSS	59	DYAMH	60	GISWRGDIGGYV KSVKG	61	SYGSGSFYNAFDS	62
mAb01-9986	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLYKASRL ERGTPSRFSGSGSGTEF SLTISSLQPDFFATYCYCLE YSSYIRTFGQGTKEIK	63	RASQSISSW LA	64	KASRLR	65	LEYSSYIRT	66
mAb01-9994	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLLVTVSS	67	DYAMH	68	GISWKGDIGGYV DSVKG	69	SYGSGSFYNAFDS	70
	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLYKASRL DRGTPSRFSGSGSGTEF SLTISSLQPDFFATYCYCLE YSSYIRTFGQGTKEIK	71	RASQSISSW LA	72	KASRLR	73	LEYSSYIRT	74
mAb11-	VH	EVQLVESGGGLVQPGRS	75	DYAMH	76	GISWRGDIGGYVD	77	SYGSGSFYNAFDS	78

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	Sequence	#
0047		LRLSCAASGFTFHDYAMH WVRQAPGKGLEWVSGIS WRGDIKGYVDSVKGRFTI SRDNAKNSLYQLNSLRA EDTALYYCAKSYGSGSFY NAFDSWGQGTLVTVSS				SVKG		
mAb11-0047	VL	DIQMTQSPSTLSASAGDR VTITCRASKSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPQRFSGSGGTEF SLTISSLQPDDEFATYYCLE YSSYIRTFGQGTKEIK	79	RASKSISSW LA	80	KASRLDR	LEYSSYIRT	82
mAb11-0049	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQAPGKGLEWVSGIS WRGDIKGYVDSVKGRFTI SRDNAKNSLYQLNSLRA EDTALYYCAKSYGSGSFY NAFDSWGQGTLVTVSS	83	DYAMH	84	GISWRGDIKGYVD SVKG	SYGSGSFYNAFDS	86
mAb11-0049	VL	DIQMTQSPSTLSASAGDR VTISCRASQSISSWLAWY QQKPGKAPKLLIYKASRL DRGTPSRFSGSGGTEF TLTISSLQPDDEFATYYCLE YNSYIRTFGQGTKEIK	87	RASQSISSW LA	88	KASRLDR	LEYSYIRT	90
mAb11-0107	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WRGDIGGYVKSVKGRFTI SRDNAKNSLYQLNSLRA	91	DYAMH	92	GISWRGDIGGYV KSVKG	SYGSGSFYNAFDS	94

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-0107	VL	EDTALYYCVKSYGSGSFY NAFDSWGQGLTVSS	95	RASQSISSW LA	96	KAQRLDR	97	LEYSSYIRT	98
mAb11-0149	VH	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKAQRL DRGTPQRFSGSGGTEF TLTISLQPDFFATYYCLE YSSYIRTFGGQGTKVEIK	99	DYAMH	100	GISWKGDIGGYV DSVKG	101	SYGSGSFYNAFDS	102
mAb11-0149	VL	EVQLVESGGGLVQPGRS LKLSCAASGFTFDDYAMH WVRQAPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNAKNSLYLQMNLSR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVSS	103	RASQSIKSW LA	104	KASRLDR	105	LEYSSYIRT	106
mAb11-0160	VH	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPQRFSGSGGTEF SLTISRLQPDFFATYYCLE YSSYIRTFGGQGTKVEIK	107	DYAMH	108	GISWKGDIGGYA DSVKG	109	SYGSGSFYNAFDS	110
mAb11-0160	VL	EVQLVESGGGLVQPGRS LKLSCAASGFRFDDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYADSVKGRFTI SRDNAKNSLYLQNLRA EDTALYYCVKSYGSGSFY NAFDSWGQGLTVSS	111	RASKSISSW LA	112	KASRLER	113	LEYSSYIRT	114

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
		QQKPGKAPRFLIYKASRL ERGTPQRFSGSGGTEF TLTYSLPDDFATYYCLE YSSYIRTFGGQGTKVEIK							
mAb11-0164	VH	EVQLVESGGGLVQPGRS LKLSCAASGFRFDDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYADSVKGRFTI SRDNAKNSLYQLNSLR EDTALYYCVKSYGSGSFY NAFDWGQGLTVTVSS	115	DYAMH	116	GISWKGDIGGYA DSVKG	117	SYGSGSFYNAFDS	118
mAb11-0164	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL ERGTPSRFSGSGGTEF SLTISLPDDFATYYCLE YSSYIRTFGGQGTKVEIK	119	RASQSISSW LA	120	KASRLER	121	LEYSSYIRT	122
mAb11-0174	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFHDYAMH WVRQAPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNAKNSLYLQMNLSR AEDTALYYCAKSYGSGSF YNAFDWGQGLTVTVSS	123	DYAMH	124	GISWKGDIGGYV DSVKG	125	SYGSGSFYNAFDS	126
mAb11-0174	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL DRGTPSRFSGSGGTEF TLTISLPDDFATYYCLE YSSYIRTFGGQGTKVEIK	127	RASQSISSW LA	128	KASKLDR	129	LEYSSYIRT	130

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	Sequence	#
mAb11-0723	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFDDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNAKNSLYQLNSLRA EDTALYYCAKSYGSGSFY NAFDSWGQGTLVTVSS	131	DYAMH	132	GISWKGDIGGYV DSVKG	SYGSGSFYNAFDS	134
mAb11-0723	VL	DIQMTQSPSTLSASAGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGSGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	135	RASQSISSW LA	136	KASRLDR	LEYSSYIRT	138
mAb11-0923	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLVTVSS	139	DYAMH	140	GISWKGDIGGYV DSVKG	SYGSGSFYNAFDS	142
mAb11-0923	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGCPSPRFSGSGSGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	143	RASQSISSW LA	144	KASRLDR	LEYSSYIRT	146
mAb11-0929	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI	147	DYAMH	148	GISWKGDIGGYV DSVKG	SYGSGSFYNAFDS	150

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-0929	VL	SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS							
		DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGIPSRFSGSGSGTEFS LTISLQPDDEFATYYCLEY SSYIRTFGQGTKVEIK	151	RASQSISSW LA	152	KASRLDR	153	LEYSSYIRT	154
mAb11-0931	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS	155	DYAMH	156	GISWKGDIGGYV DSVKG	157	SYGSGSFYNAFDS	158
		DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGLPSRFSGSGSGTEF SLTISLQPDDEFATYYCLE YSSYIRTFGQGTKVEIK	159	RASQSISSW LA	160	KASRLDR	161	LEYSSYIRT	162
mAb11-0932	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS	163	DYAMH	164	GISWKGDIGGYV DSVKG	165	SYGSGSFYNAFDS	166
		DIQMTQSPSTLSASVGD	167	RASQSISSW	168	KASRLDR	169	LEYSSYIRT	170

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
0932		VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGMPSPRFSGSGGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGQTKVEIK		LA					
mAb11-0933	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLVTVSS	171	DYAMH	172	GISWKGDIGGYV DSVKG	173	SYGSGSFYNAFDS	174
mAb11-0933	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGNPSRFSGSGGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGQTKVEIK	175	RASQSISSW LA	176	KASRLDR	177	LEYSSYIRT	178
mAb11-0935	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLVTVSS	179	DYAMH	180	GISWKGDIGGYV DSVKG	181	SYGSGSFYNAFDS	182
mAb11-0935	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGQPSRFSGSGGTEF SLTISSLQPDFFATYYCLE	183	RASQSISSW LA	184	KASRLDR	185	LEYSSYIRT	186

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-0937	VH	YSSYIRTFGQGTKEIK							
		EVQLVESGGGLVQPGRS LRLSCAASGFTFHDIYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNLSR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS	187	DYAMH	188	GISWKGDIGGYV DSVKG	189	SYGSGSFYNAFDS	190
mAb11-0937	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGSPSRFSGSGSTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	191	RASQSISSW LA	192	KASRLDR	193	LEYSSYIRT	194
mAb11-0938	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDIYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNLSR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS	195	DYAMH	196	GISWKGDIGGYV DSVKG	197	SYGSGSFYNAFDS	198
		DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGVPSPRFSGSGSTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	199	RASQSISSW LA	200	KASRLDR	201	LEYSSYIRT	202
mAb11-0939	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDIYAMH WVRQVPGKGLEWVSGIS	203	DYAMH	204	GISWKGDIGGYV DSVKG	205	SYGSGSFYNAFDS	206

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
		WKGDIGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLLTVSS							
mAb11-0939	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGWPSRFRSGSGSGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGGGTKVEIK	207	RASQSISSW LA	208	KASRLDR	209	LEYSSYIRT	210
mAb11-0962	VH	EVQLVESGGGLVQPGRS LRLSCAASKFTFDHYAMH WVRQAPGKGLEWVSGIS WKGDIGYADSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCAKSYGSGSF YNAFDSWGQGTLLTVSS	211	DYAMH	212	GISWKGDIGGYA DSVKG	213	SYGSGSFYNAFDS	214
mAb11-0962	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL DRGTPSRFRSGSGSGTEF TLTISSLQPDFFATYYCLE YSSYIRTFGGGTKVEIK	215	RASQSISSW LA	216	KASKLDR	217	LEYSSYIRT	218
mAb11-0965	VH	EVQLVESGGGLVQPGRS LRLSCAASKFTFDHYAMH WVRQAPGKGLEWVSGIS WKGDIGYADSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCAKSYGSGSF YNAFDSWGQGTLLTVSS	219	DYAMH	220	GISWKGDIGGYA DSVKG	221	SYGSGSFYNAFDS	222

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1030	VH	TLTISSLQPDQDFATYYCLE YSSYIRTFGQGTKEIK							
		EVQLVESGGGLVQPGRS LRLSCAASKFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRTI SRDNAKNSLYLQMNSLR AEDTALYYCAKSYGSGSF YNAFDSWGQGTLVTVSS	243	DYAMH	244	GISWKGDIGGYV DSVKG	245	SYGSGSFYNAFDS	246
mAb11-1030	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL DRGTPSRFSGSGGTEF TLTISSLQPDQDFATYYCLE YSSYIRTFGQGTKEIK	247	RASQSISSW LA	248	KASKLDR	249	LEYSSYIRT	250
		EVQLVESGGGLVQPGRS LRLSCAASKFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRTI SRDNAKNSLYLQMNSLR AEDTALYYCAKSYGSGSF YNAFDSWGQGTLVTVSS	251	DYAMH	252	GISWKGDIGGYV DSVKG	253	SYGSGSFYNAFDS	254
mAb11-1033	VH	TLTISSLQPDQDFATYYCLE YSSYIRTFGQGTKEIK							
		EVQLVESGGGLVQPGRS LRLSCAASKFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRTI SRDNAKNSLYLQMNSLR AEDTALYYCAKSYGSGSF YNAFDSWGQGTLVTVSS	255	RASQSISSW LA	256	KASKLER	257	LEYSSYIRT	258
mAb11-1039	VH	EVQLVESGGGLVQPGRS LRLSCAASKFTFHDYAMH	259	DYAMH	260	GISWKGDIGGYV DSVKG	261	SYGSGSFYNAFDS	262

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
		WVRQAPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNKNSLYLQMNSLR AEDTALYYCAKSYGSGSF YNAFDSWGQGTTLVTSS							
mAb11-1039	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL DRGTPSRFSGSGGTEF TLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	263	RASQSISSW LA	264	KASKLDR	265	LEYSSYIRT	266
mAb11-1042	VH	EVQLVESGGGLVQPGRS LKLSCAASKFTFDYAMH WVRQAPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNKNSLYLQMNSLR AEDTALYYCAKSYGSGSF YNAFDSWGQGTTLVTSS	267	DYAMH	268	GISWKGDIGGYV DSVKG	269	SYGSGSFYNAFDS	270
mAb11-1042	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL ERGTPSRFSGSGGTEF TLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	271	RASQSISSW LA	272	KASKLER	273	LEYSSYIRT	274
mAb11-1073	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNKNSLYLQMNSLR AEDTALYYCAKSYGSGSF	275	DYAMH	276	GISWKGDIGGYV DSVKG	277	SYGSGSFYNAFDS	278

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1073	VL	YNAFDSWGQGLVTSS DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL DRGTPSRFSGSGGTEF TLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	279	RASQSISSW LA	280	KASKLDR	281	LEYSSYIRT	282
mAb11-1076	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNAKNSLYLQMNSLR AEDTALYYCAKSYGSGSF YNAFDSWGQGLVTSS	283	DYAMH	284	GISWKGDIGGYV DSVKG	285	SYGSGSFYNAFDS	286
mAb11-1076	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL ERGTPSRFSGSGGTEF TLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	287	RASQSISSW LA	288	KASKLER	289	LEYSSYIRT	290
mAb11-1091	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNAKNSLYLQMNSLR AEDTALYYCAKSYGSGSF YNAFDSWGQGLVTSS	291	DYAMH	292	GISWKGDIGGYV DSVKG	293	SYGSGSFYNAFDS	294
mAb11-1091	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL	295	RASQSISSW LA	296	KASKLDR	297	LEYSSYIRT	298

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1094		DRGTPSRFSGSGGTEF TLTISSLQPDFFATYCYCLE YSSYRTFGQGTKEIK							
	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNKNSLYLQMNLSR AEDTALYYCAKSYGSGSF YNAFDSWGQGTLLVTVSS	299	DYAMH	300	GISWKGDIGGYV DSVKG	301	SYGSGSFYNAFDS	302
mAb11-1094	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLYKASKL ERGTSPSRFSGSGGTEF TLTISSLQPDFFATYCYCLE YSSYRTFGQGTKEIK	303	RASQSISSW LA	304	KASKLER	305	LEYSSYIRT	306
mAb11-1233		EVQLVESGGGLVQPGRS LRLSCAASGFKFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNLSR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLLVTVSS							
	VH	EVQLVESGGGLVQPGRS LRLSCAASGFKFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNLSR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLLVTVSS	307	DYAMH	308	GISWKGDIGGYV DSVKG	309	SYGSGSFYNAFDS	310
mAb11-1233		DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLYKASKL ERGTSPSRFSGSGGTEF SLTISSLQPDFFATYCYCLE YSSYRTFGQGTKEIK							
	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLYKASKL ERGTSPSRFSGSGGTEF SLTISSLQPDFFATYCYCLE YSSYRTFGQGTKEIK	311	RASQSISSW LA	312	KASRLDR	313	LEYSSYIRT	314
mAb11-1233	VH	EVQLVESGGGLVQPGRS	315	DYAMH	316	GISWKGDIGGYV	317	SYGSGSFYNAFDS	318

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1254		LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNDKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLVTVSS				DSVKG		
mAb11-1254	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGSGTEF SLTISSLQPDDEFATYYCLE YSSYIRTFGGGTKVEIK	319	RASQSISSW LA	320	KASRLDR	321	LEYSSYIRT
mAb11-1259	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLVTVSS	323	DYAMH	324	GISWKGDIGGYV DSVKG	325	SYGSGSFYNAFDS
mAb11-1259	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGSGTEF SLTISSLQPDDEFATYYCLE YSSYIRTFGGGTKVEIK	327	RASQKISSW LA	328	KASRLDR	329	LEYSSYIRT
mAb11-1260	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR	331	DYAMH	332	GISWKGDIGGYV DSVKG	333	SYGSGSFYNAFDS

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1260	VL	AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS							
		DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGTVEIK	335	RASQSISS WLA	336	KASRLDR	337	LEYSSYIRT	338
mAb11-1262	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNLSR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS	339	DYAMH	340	GISWKGDIGGYV DSVKG	341	SYGSGSFYNAFDS	342
		DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGTVEIK	343	RASQSISS WLA	344	KASRLDR	345	LEYSSYIRT	346
mAb11-1266	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNLSR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS	347	DYAMH	348	GISWKGDIGGYV DSVKG	349	SYGSGSFYNAFDS	350
		DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY	351	RASQSISSW LA	352	KASRLDK	353	LEYSSYIRT	354

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
		QQKPGKAPKFLIYKASRL DKGTPSRFSGSGGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGKVEIK							
mAb11-1268	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDIYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS	355	DYAMH	356	GISWKGDIGGYV DSVKG	357	SYGSGSFYNAFDS	358
mAb11-1268	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPKRFSGSGGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGKVEIK	359	RASQSISSW LA	360	KASRLDR	361	LEYSSYIRT	362
mAb11-1273	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDIYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS	363	DYAMH	364	GISWKGDIGGYV DSVKG	365	SYGSGSFYNAFDS	366
mAb11-1273	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGGTEF SLTISELPDFFATYYCLE YSSYIRTFGQGKVEIK	367	RASQSISSW LA	368	KASRLDR	369	LEYSSYIRT	370

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1275	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDIYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYCVKSYGSGSF YNAFDSWGQGLTVTVSS	371	DYAMH	372	GISWKGDIGGYV DSVKG	373	SYGSGSFYNAFDS
mAb11-1275	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGSTEF SLTISLTPDDFATYYCLE YSSYIRTFGQGTKEIK	375	RASQSISSW LA	376	KASRLDR	377	LEYSSYIRT
mAb11-1276	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDIYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYCVKSYGSGSF YNAFDSWGQGLTVTVSS	379	DYAMH	380	GISWKGDIGGYV DSVKG	381	SYGSGSFYNAFDS
mAb11-1276	VL	DIQMTQSPSTLSASVGD VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGSTEF SLTISLTPDDFATYYCLE YSSYIRTFGQGTKEIK	383	RASQSISSW LA	384	KASRLDR	385	LEYSSYIRT
mAb11-1278	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDIYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI	387	DYAMH	388	GISWKGDIGGYV DSVKG	389	SYGSGSFYNAFDS

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1278		SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS							
	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFRFSGSGSTEF SLTISSLQPDFFATYYCLE YQSYIRTFGQGTKEIK	391	RASQSISSW LA	392	KASRLDR	393	LEYQSYIRT	394
mAb11-1279		EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS	395	DYAMH	396	GISWKGDIGGYV DSVKG	397	SYGSGSFYNAFDS	398
	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFRFSGSGSTEF SLTISSLQPDFFATYYCLE YKSYIRTFGQGTKEIK	399	RASQSISSW LA	400	KASRLDR	401	LEYQSYIRT	402
mAb11-1282		EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGLTVTVSS	403	DYAMH	404	GISWKGDIGGYV DSVKG	405	SYGSGSFYNAFDS	406
	VL	DIQMTQSPSTLSASVGDR	407	RASQSISSW	408	KASRLDR	409	LEYSSWIRT	410

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
1282		VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGSGTEF SLTISSLQPDFFATYYCLE YSSWIRTFGQGTKEIK		LA					
mAb11-1286	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDIYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLVTVSS	411	DYAMH	412	GISWKGDIGGYV DSVKG	413	SYGSGSFYNAFDS	414
mAb11-1286	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGSGTEF SLTIYDLQPDFFATYYCLE YRSYIRTFGQGTKEIK	415	RASQSISSW LA	416	KASRLDR	417	LEYRSYIRT	418
mAb11-1288	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDIYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNEKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLVTVSS	419	DYAMH	420	GISWKGDIGGYV DSVKG	421	SYGSGSFYNAFDS	422
mAb11-1288	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGSGTEF SLTIYSLQPDFFATYYCLE	423	RASQSISSW LA	424	KASRLDR	425	LEYNSYIRT	426

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1344	VH	YNSYIRTFGQGTKEIK EVQLVESGGGLVQPGRS LKLSCAASGFTFDDYAMH WVRQVPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNAKNSLYQLNSLRA EDTALYYCAKSYGSGSFY NAFDSWGQGLTVSS	427	DYAMH	428	GISWKGDIGGYV DSVKG	429	SYGSGSFYNAFDS
mAb11-1344	VL	DIQMTQSPSTLSASAGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL DRGTPSRFSGSGSTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	431	RASQSISSW LA	432	KASKLDR	433	LEYSSYIRT
mAb11-1358	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFDDYAMH WVRQVPGKGLEWVSGIS WRGDIGGYVDSVKGRFTI SRDNAKNSLYQLNSLRA EDTALYYCVKSYGSGSFY NAFDSWGQGLTVSS	435	DYAMH	436	GISWRGDIGGYV DSVKG	437	SYGSGSFYNAFDS
mAb11-1358	VL	DIQMTQSPSTLSASAGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL DRGTPSRFSGSGSTEF SLTISSLQPDFFATYYCLE YSSYIRTFGQGTKEIK	439	RASQSISSW LA	440	KASKLDR	441	LEYSSYIRT
mAb11-1360	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFDDYAMH WVRQVPGKGLEWVSGIS	443	DYAMH	444	GISWRGDIGGYV DSVKG	445	SYGSGSFYNAFDS

mAb ID	Domain	VH/ML		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
		WRGDIGGYVDSVKGRFTI SRDNKNSLYQLNSLRA EDTALYYCVKSYGSGSFY NAFDSWGQGTLLVTSS							
mAb11-1360	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKLLIYKASRL ERGTPSRFSGSGSGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGGGTKVEIK	447	RASQSISSW LA	448	KASRLER	449	LEYSSYIRT	450
mAb11-1389	VH	EVQLVESGGGLVQPGRS LKLSCAASGFTFHDYAMH WVRQAPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNKNSLYLQMNSLR AEDTALYYCAKSYGSGSF YNAFDSWGQGTLLVTSS	451	DYAMH	452	GISWKGDIGGYV DSVKG	453	SYGSGSFYNAFDS	454
mAb11-1389	VL	DIQMTQSPSTLSASAGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASRL DRGTPSRFSGSGSGTEF SLTISSLQPDFFATYYCLE YSSYIRTFGGGTKVEIK	455	RASQSISSW LA	456	KASRLDR	457	LEYSSYIRT	458
mAb11-0173	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQAPGKGLEWVSGIS WKGDIGGYVDSVKGRFTI SRDNKNSLYLQMNSLR AEDTALYYCAKSYGSGSF YNAFDSWGQGTLLVTSS	1202	DYAMH	1203	GISWKGDIGGYV DSVKG	1204	SYGSGSFYNAFDS	1205

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	#
mAb11-0173	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL DRGTPSRFSGSGSGTEF TLTISSLQPDDFATYYCLE YSSYIRTFGGQGTKVEIK	1206	RASQSISSW LA	1207	KASKLDR	1208	LEYSYIRT 1209
mAb11-1204	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WRGDIGGYVKSIVKGRFTI SRDNKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLVTVSS	1210	DYAMH	1211	GISWRGDIGGYV KSVKG	1212	SYGSGSFYNAFDS 1213
mAb11-1204	VL	DIQMTQSPSTLSASVGDE VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL ERGTPSRFSGSGSGTEF SLTISSLQPDDFATYYCLE YSSYIRTFGGQGTKVEIK	1214	RASQSISSW LA	1215	KASKLER	1216	LEYSYIRT 1217
mAb11-1495	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFHDYAMH WVRQVPGKGLEWVSGIS WRGDIGGYAKSVKGRFTI SRDNKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLVTVSS	1218	DYAMH	1219	GISWRGDIGGYA KSVKG	1220	SYGSGSFYNAFDS 1221
mAb11-1495	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLAWY QQKPGKAPKFLIYKASKL DRGTPSRFSGSGSGTEF	1222	RASQSISSW LA	1223	KASKLDR	1224	LEYSYIRT 1225

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1501	VH	TLTISSLQPDQDFATYYCLE YSSYIRTFGGQTKVEIK						
		EVQLVESGGGLVQPGRS LRLSCAASGFTFDDYAMH WVRQVPGKGLEWVSGIS WRGDIGGYVKSIVGRFTI SRDIAKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLVTVSS	1226	DYAMH	1227	GISWRGDIGGYV KSVKG	1228	SYGSGSFYNAFDS
mAb11-1501	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLA QQKPGKAPKFLIYKASKL DRGTPSRFSGSGGTEF TLTISSLQPDQDFATYYCLE YSSYIRTFGGQTKVEIK	1230	RASQSISSW LA	1231	KASKLDR	1232	LEYSSYIRT
mAb11-1502	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFDDYAMH WVRQVPGKGLEWVSGIS WRGDIGGYVKSIVGRFTI SRDIAKNSLYLQMNSLR AEDTALYYCVKSYGSGSF YNAFDSWGQGTLVTVSS	1234	DYAMH	1235	GISWRGDIGGYV KSVKG	1236	SYGSGSFYNAFDS
mAb11-1502	VL	DIQMTQSPSTLSASVGDR VTITCRASQSISSWLA QQKPGKAPKFLIYKASKL DRGTPSRFSGSGGTEF TLTISSLQPDQDFATYYCLE YSSYIRTFGGQTKVEIK	1238	RASQSISSW LA	1239	KASKLDR	1240	LEYSSYIRT
mAb11-1499	VH	EVQLVESGGGLVQPGRS LRLSCAASGFTFDDYAMH	1242	DYAMH	1243	GISWRGDIGGYV KSVKG	1244	SYGSGSFYNAFDS

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
		WVRQVPGKLEWVSGIS							
		WRGDIGGYVKS VKGRFTI							
		SRDNAKNSLYLQMNSLR							
		AEDTALYYCVKSYGSGSF							
		YNAFDSWGQGTLVTVSS							
mAb11-1499	VL	DIQMTQSPSTLSASVGDRTITCRASQSISSWLAWYQQKPGKAPKFLIYKASKLDRGTPSRFSGSGSGTEFTLTISSLQPDDFATYYCLEYSSYIRTEFGQGTKVEIK	1246	RASQSISSWLA	1247	KASKLDR	1248	LEYSSYIRT	1249

Table 3: Overview of anti-FX antibody VH, VL and CDR sequences

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb01-6723	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFDVWGQGT LVTSS	459	TSWIV	460	MIDPSDSFTSYSPSFQ G	461	LHYHSEEFDV	462
	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GASSRARGIPDRFSGS GSGTDFLTISRLEPED FAVYYCQQFGSSRLFTF GQGTKLEIK	463	RASQSVSSS YLA	464	GASSRAR	465	QQFGSSRLFT	466
mAb01-8174	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYNSEEFDVWGQGT LVTSS	467	TSWIV	468	MIDPSDSFTSYSPSFQ G	469	LHYNSEEFDV	470
mAb01-8174	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	471	RASQSVSSS YLA	472	GQSSRTR	473	QQFGDSQLFT	474

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb01-8913	VH	FAVYCCQFGDSQLFT FGGKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	475	TSWIV	476	MIDPSDSFTSYSPSFQ G	477	LHYYNSEEFDV 478
mAb01-8913	VL	EIVLTQSPGTLSSAGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GASSRARGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQFGSSRLFTF GGTKLEIK	479	RASQSVSSS YLA	480	GASSRAR	481	QQFGSSRLFT 482
mAb01-9772	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTSS	483	TSWIS	484	MIDPSDSYTSYSPSFQ G	485	LHYYNSEEFDV 486
		EIVLTQSPGTLSSAGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GASSRARGIPDRFSGS GSGTDFLTISRLEPED	487	RASQSVSSS YLA	488	GQSSRTR	489	QQYGDSQLFT 490

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb01-9778	VH	FAVYQCQYGDSQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVDVWGQGT LVTVSS	491	TSWIS	492	MIDPSDSFTSYSPSFQ G	493	LHYYNSEEFDV
mAb01-9778	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQYGDSQLFT FGQGTKLEIK	495	RASQSVSSS YLA	496	GQSSRTR	497	QQYGDSQLFT
mAb11-1114	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVDVWGQGT MVTVSS	499	TSWIS	500	MIDPSDSYTSYSPSFQ G	501	LHYYNSEEFDV
		EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	503	RASQSVSSS YLA	504	GQSSRTR	505	QQFGDSQLFT
mAb11-1114	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	503	RASQSVSSS YLA	504	GQSSRTR	505	QQFGDSQLFT

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1115	VH	FAVYCCQQFGDSLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWVGQGT MVTVSS	507	TSWIS	508	MIDPSDSFTSYSPSFQ G	509	LHYHSEEFDV
mAb11-1115	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYCCQQFGDSLFT FGQGTKLEIK	511	RASQSVSSS YLA	512	GQSSRTR	513	QQFGDSLFT
mAb11-1116	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWVGQGT LVTVSS	515	TSWIS	516	MIDPSDSYTSYSPSFQ G	517	LHYHSEEFDV
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWVGQGT LVTVSS	515	TSWIS	516	MIDPSDSYTSYSPSFQ G	517	LHYHSEEFDV
mAb11-1116	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	519	RASQSVSSS YLA	520	GQSSRTR	521	QQFGDSLFT

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1117	VH	FAVYQCQFGDSLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTVSS	523	TSWIS	524	MIDPSDSYTSYSPSFQ G	525	LHYHSEEFDV
mAb11-1117	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYQCQFGDSLFT FGQGTKLEIK	527	RASQSVSS YLA	528	GQSSRTR	529	QQFGDSLFT
mAb11-1118	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT LVTVSS	531	TSWIS	532	MIDPSDSYTSYSPSFQ G	533	LHYHSEEFDV
mAb11-1118	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	535	RASQSVSS YLA	536	GQSSRTR	537	QQFGDSLFT

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1119	VH	FAVYQCQFGDSQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTVSS	539	TSWIV	540	MIDPDSYTSYSPSFQ G	541	LHYYNSEEFDV 542
mAb11-1119	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQFGDSQLFT FGQGTKLEIK	543	RASQSVSSS YLA	544	GQSSRTR	545	QQFGDSQLFT 546
mAb11-1120	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	547	TSWIV	548	MIDPDSYTSYSPSFQ G	549	LHYYNSEEFDV 550
mAb11-1120	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	551	RASQSVSSS YLA	552	GQSSRTR	553	QQFGDSQLFT 554

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1121	VH	FAVYCCQQFGDSQLFT FGQGTKLEIK							
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVDVWGQGT LVTVSS	555	TSWIV	556	MIDPSDSFTSYSPSFQ G	557	LHYYNSEEFDV	558
mAb11-1121	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQQYGDSQLFT FGQGTKLEIK	559	RASQSVSSS YLA	560	GQSSRTR	561	QQYGDSQLFT	562
mAb11-1122	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVDVWGQGT MVTVSS	563	TSWIS	564	MIDPSDSFTSYSPSFQ G	565	LHYHSEEFDV	566
		EIVLTQSPGTLSPGE RATLSCRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	567	RASQSVSSS YLA	568	GQSSRTR	569	QQYGDSQLFT	570

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1123	VH	FAVYQCQYGDSQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVVGQGT LVTSS	571	TSWIS	572	MIDPDSYTSYSPSFQ G	573	LHYHSEEFDV
mAb11-1123	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYQCQYGDSQLFT FGQGTKLEIK	575	RASQSVSSS YLA	576	GQSSRTR	577	QQYGDSQLFT
mAb11-1124	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVVGQGT MVTSS	579	TSWIS	580	MIDPDSYTSYSPSFQ G	581	LHYHSEEFDV
		EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	583	RASQSVSSS YLA	584	GQSSRTR	585	QQYGDSQLFT
mAb11-1124	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	583	RASQSVSSS YLA	584	GQSSRTR	585	QQYGDSQLFT

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1125	VH	FAVYQCQYGDSQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	587	TSWIV	588	MIDPDSYTSYSPSFQ G	589	LHYYNSEEFDV 590
mAb11-1125	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQYGDSQLFT FGQGTKLEIK	591	RASQSVSSS YLA	592	GQSSRTR	593	QQYGDSQLFT 594
mAb11-1127	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	595	TSWIV	596	MIDPDSYTSYSPSFQ G	597	LHYYNSEEFDV 598
mAb11-1127	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	599	RASQSVSSS YLA	600	GASSRAR	601	QQYGDSRLFT 602

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1128	VH	FAVYQCQYGDRLFT FGQGTKLEIK							
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	603	TSWIS	604	MIDPSDSYTSYSPSFQ G	605	LHYYNSEEFDV	606
mAb11-1128	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GASSRARGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQYGDRLFT FGQGTKLEIK	607	RASQSVSSS YLA	608	GASSRAR	609	QQYGDSRLFT	610
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTVSS	611	TSWIS	612	MIDPSDSYTSYSPSFQ G	613	LHYHSEEFDV	614
mAb11-1129	VH	FAVYQCQYGDRLFT FGQGTKLEIK							
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTVSS	603	TSWIS	604	MIDPSDSYTSYSPSFQ G	605	LHYHSEEFDV	606
mAb11-1129	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GASSRARGIPDRFSGS GSGTDFLTISRLEPED	615	RASQSVSSS YLA	616	GASSRAR	617	QQYGDSRLFT	618
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTVSS	611	TSWIS	612	MIDPSDSYTSYSPSFQ G	613	LHYHSEEFDV	614

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1130	VH	FAVYQCQYQSDSLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVVGQGT LVTSS	619	TSWIS	620	MIDPSDSYTSYSPSFQ G	621	LHYHSEEFDV 622
mAb11-1130	VL	EIVLTQSPGTLSPGE RATLSKRASQSVSSYL AWYQQKPGQAPRLIY GASSRARGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQYQSDSLFT FGQGTKLEIK	623	RASQSVSSS YLA	624	GASSRAR	625	QQYGDSRLFT 626
mAb11-1131	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVVGQGT MVTSS	627	TSWIS	628	MIDPSDSYTSYSPSFQ G	629	LHYHSEEFDV 630
		EIVLTQSPGTLSPGE RATLSKRASQSVSSYL AWYQQKPGQAPRLIY GASSRARGIPDRFSGS GSGTDFLTISRLEPED	631	RASQSVSSS YLA	632	GASSRAR	633	QQYGDSRLFT 634

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1132	VH	FAVYQCQYQYGDRLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	635	TSWIS	636	MIDPSDSFTSYSPSFQ G	637	LHYYNSEEFDV 638
mAb11-1132	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GASSRARGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQYQYGDRLFT FGQGTKLEIK	639	RASQSVSSS YLA	640	GASSRAR	641	QQYGDSRLFT 642
mAb11-1133	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	643	TSWIV	644	MIDPSDSYTSYSPSFQ G	645	LHYYNSEEFDV 646
		EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GASSRARGIPDRFSGS GSGTDFLTISRLEPED	647	RASQSVSSS YLA	648	GASSRAR	649	QQYGDSRLFT 650

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1416	VH	FAVYQCQYQGSRLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSIStayLQ WSSLKASDTAMYCAR LHYYNSEEFVDVWGQGT LVTSS	651	TSWIV	652	MIDPSDSFTSYSPSFQ G	653	LHYYNSEEFDV
mAb11-1416	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQYQGSRLFT FGQGTKLEIK	655	RASQSVSSS YLA	656	GQSSRTR	657	QQFGDSRLFT
mAb11-1417	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSIStayLQ WSSLKASDTAMYCAR LHYYNSEEFVDVWGQGT MVTSS	659	TSWIS	660	MIDPSDSYTSYSPSFQ G	661	LHYYNSEEFDV
		EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	663	RASQSVSSS YLA	664	GQSSRTR	665	QQFGDSRLFT
mAb11-1417	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	663	RASQSVSSS YLA	664	GQSSRTR	665	QQFGDSRLFT

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1418		FAVYQCQFGDSRLFT FGQGTKLEIK						
	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFDVWGQGT MVTVSS	667	TSWIS	668	MIDPSDSFTSYSPSFQ G	669	LHYHSEEFDV 670
mAb11-1418	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQFGDSRLFT FGQGTKLEIK	671	RASQSVSSS YLA	672	GQSSRTR	673	QQFGDSRLFT 674
mAb11-1419		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFDVWGQGT LVTVSS	675	TSWIS	676	MIDPSDSYTSYSPSFQ G	677	LHYHSEEFDV 678
	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	679	RASQSVSSS YLA	680	GQSSRTR	681	QQFGDSRLFT 682

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1420	VH	FAVYCCQQFGDSRLFT FGQGTKLEIK							
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTVSS	683	TSWIS	684	MIDPSDSYTSYSPSFQ G	685	LHYHSEEFDV	686
mAb11-1420	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYCCQQFGDSRLFT FGQGTKLEIK	687	RASQSVSSS YLA	688	GQSSRTR	689	QQFGDSRLFT	690
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYNSEEFVWGQGT LVTVSS	691	TSWIS	692	MIDPSDSYTSYSPSFQ G	693	LHYNSEEFDV	694
mAb11-1421	VH	FAVYCCQQFGDSRLFT FGQGTKLEIK							
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYNSEEFVWGQGT LVTVSS	691	TSWIS	692	MIDPSDSYTSYSPSFQ G	693	LHYNSEEFDV	694
mAb11-1421	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	695	RASQSVSSS YLA	696	GQSSRTR	697	QQFGDSRLFT	698
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYNSEEFVWGQGT LVTVSS	695	RASQSVSSS YLA	696	GQSSRTR	697	QQFGDSRLFT	698

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1422	VH	FAVYQCQFGDSRLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	699	TSWIV	700	MIDPDSYTSYSPSFQ G	701	LHYYNSEEFDV 702
mAb11-1422	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQFGDSRLFT FGQGTKLEIK	703	RASQSVSSS YLA	704	GQSSRTR	705	QQFGDSRLFT 706
mAb11-1431	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	707	TSWIV	708	MIDPDSYTSYSPSFQ G	709	LHYYNSEEFDV 710
mAb11-1431	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	711	RASQSVSSS YLA	712	GQSSRTR	713	QQFGSSQLFT 714

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1432	VH	FAVYCCQFGSSQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	715	TSWIV	716	MIDPSDSFTSYSPSFQ G	717	LHYYNSEEFDV 718
mAb11-1432	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQFGESQLFT FGQGTKLEIK	719	RASQSVSSS YLA	720	GQSSRTR	721	QQFGESQLFT 722
mAb11-1433	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	723	TSWIV	724	MIDPSDSFTSYSPSFQ G	725	LHYYNSEEFDV 726
mAb11-1433	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	727	RASQSVSSS YLA	728	GQSSRTR	729	QQFGNSQLFT 730

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1434	VH	FAVYQCQFGNSQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	731	TSWIV	732	MIDPSDSFTSYSPSFQ G	733	LHYYNSEEFDV 734
mAb11-1434	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQFGQSQLFT FGQGTKLEIK	735	RASQSVSSS YLA	736	GQSSRTR	737	QQFGQSQLFT 738
mAb11-1435	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	739	TSWIV	740	MIDPSDSFTSYSPSFQ G	741	LHYYNSEEFDV 742
mAb11-1435	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	743	RASQSVSSS YLA	744	GQSSRTR	745	QQFGDAQLFT 746

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1436	VH	FAVYCCQQFGDAQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVVGQGT LVTSS	747	TSWIV	748	MIDPSDSFTSYSPSFQ G	749	LHYYNSEEFDV
mAb11-1436	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQQFGDTQLFT FGQGTKLEIK	751	RASQSVSSS YLA	752	GQSSRTR	753	QQFGDTQLFT
mAb11-1437	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVVGQGT LVTSS	755	TSWIV	756	MIDPSDSFTSYSPSFQ G	757	LHYYNSEEFDV
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVVGQGT LVTSS	755	TSWIV	756	MIDPSDSFTSYSPSFQ G	757	LHYYNSEEFDV
mAb11-1437	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	759	RASQSVSSS YLA	760	GQSSRTR	761	QQFGDNQLFT

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1439	VH	FAVYYCQQFGDNQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFDVWGQGT MVTVSS	763	TSWIS	764	MIDPDSYTSYSPSFQ G	765	LHYHSEEFDV
mAb11-1439	VL	EIVLTQSPGTLISLSPGE RATLSCRASQSVSSSYL AWYQQKPGQAPRLLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYYCQQFGSSQLFT FGQGTKLEIK	767	RASQSVSSS YLA	768	GQSSRTR	769	QQFGSSQLFT
mAb11-1440	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFDVWGQGT MVTVSS	771	TSWIS	772	MIDPDSFTSYSPSFQ G	773	LHYHSEEFDV
mAb11-1440	VL	EIVLTQSPGTLISLSPGE RATLSCRASQSVSSSYL AWYQQKPGQAPRLLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	775	RASQSVSSS YLA	776	GQSSRTR	777	QQFGSSQLFT

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1441	VH	FAVYCCQKFGSSQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVVGQGT LVTSS	779	TSWIS	780	MIDPDSYTSYSPSFQ G	781	LHYHSEEFDV 782
mAb11-1441	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYCCQKFGSSQLFT FGQGTKLEIK	783	RASQSVSSS YLA	784	GQSSRTR	785	QQFGSSQLFT 786
mAb11-1442	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVVGQGT MVTSS	787	TSWIS	788	MIDPDSYTSYSPSFQ G	789	LHYHSEEFDV 790
mAb11-1442	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	791	RASQSVSSS YLA	792	GQSSRTR	793	QQFGSSQLFT 794

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	#
mAb11-1443	VH	FAVYCCQFGSSQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYNSEEFDVWGQGT LVTSS	795	TSWIS	796	MIDPSDSFTSYSPSFQ G	LHYNSEEFDV	798
mAb11-1443	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQFGSSQLFT FGQGTKLEIK	799	RASQSVSSS YLA	800	GQSSRTR	QQFGSSQLFT	802
mAb11-1444	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYNSEEFDVWGQGT LVTSS	803	TSWIV	804	MIDPSDSYTSYSPSFQ G	LHYNSEEFDV	806
		EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	807	RASQSVSSS YLA	808	GQSSRTR	QQFGSSQLFT	810

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1445	VH	FAVYCCQQFGSSQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	811	TSWIV	812	MIDPDSYTSYSPSFQ G	813	LHYYNSEEFDV 814
mAb11-1445	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQQFGSSQLFT FGQGTKLEIK	815	RASQSVSSS YLA	816	GQSSRTR	817	QQFGSSQLFT 818
mAb11-1446	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	819	TSWIS	820	MIDPDSYTSYSPSFQ G	821	LHYYNSEEFDV 822
mAb11-1446	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	823	RASQSVSSS YLA	824	GQSSRTR	825	QQFGESQLFT 826

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1447	VH	FAVYQCQGFGEQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWVGQGT MVTVSS	827	TSWIS	828	MIDPSDSFTSYSPSFQ G	829	LHYHSEEFDV 830
mAb11-1447	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQGFGEQLFT FGQGTKLEIK	831	RASQSVSSS YLA	832	GQSSRTR	833	QQFGESQLFT 834
mAb11-1448	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWVGQGT LVTVSS	835	TSWIS	836	MIDPSDSYTSYSPSFQ G	837	LHYHSEEFDV 838
mAb11-1448	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	839	RASQSVSSS YLA	840	GQSSRTR	841	QQFGESQLFT 842

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1449	VH	FAVYQCQFGESQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVVGQGT MVTVSS	843	TSWIS	844	MIDPDSYTSYSPSFQ G	845	LHYHSEEFDV 846
mAb11-1449	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQFGESQLFT FGQGTKLEIK	847	RASQSVSSS YLA	848	GQSSRTR	849	QQFGESQLFT 850
mAb11-1450	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVVGQGT LVTVSS	851	TSWIS	852	MIDPDSYTSYSPSFQ G	853	LHYHSEEFDV 854
mAb11-1450	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	855	RASQSVSSS YLA	856	GQSSRTR	857	QQFGESQLFT 858

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1451	VH	FAVYQCQGFGEQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVVGQGT LVTVSS	859	TSWIV	860	MIDPDSYTSYSPSFQ G	861	LHYYNSEEFDV 862
mAb11-1451	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQGFGEQLFT FGQGTKLEIK	863	RASQSVSSS YLA	864	GQSSRTR	865	QQFGESQLFT 866
mAb11-1452	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVVGQGT MVTVSS	867	TSWIV	868	MIDPDSYTSYSPSFQ G	869	LHYYNSEEFDV 870
mAb11-1452	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	871	RASQSVSSS YLA	872	GQSSRTR	873	QQFGESQLFT 874

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1453	VH	FAVYCCQGFGEQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	875	TSWIS	876	MIDPDSYTSYSPSFQ G	877	LHYYNSEEFDV 878
mAb11-1453	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQGFGEQLFT FGQGTKLEIK	879	RASQSVSSS YLA	880	GQSSRTR	881	QQFGNSQLFT 882
mAb11-1454	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTVSS	883	TSWIS	884	MIDPDSYTSYSPSFQ G	885	LHYHSEEFDV 886
		EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	887	RASQSVSSS YLA	888	GQSSRTR	889	QQFGNSQLFT 890

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1455	VH	FAVYQCQFGNSQLFT FGQGTKLEIK							
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT LVTSS	891	TSWIS	892	MIDPDSYTSYSPSFQ G	893	LHYHSEEFDV	894
mAb11-1455	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY QSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYQCQFGNSQLFT FGQGTKLEIK	895	RASQSVSSS YLA	896	GQSSRTR	897	QQFGNSQLFT	898
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTSS	899	TSWIS	900	MIDPDSYTSYSPSFQ G	901	LHYHSEEFDV	902
mAb11-1456	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY QSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	903	RASQSVSSS YLA	904	GQSSRTR	905	QQFGNSQLFT	906
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTSS	903	RASQSVSSS YLA	904	GQSSRTR	905	QQFGNSQLFT	906

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1457	VH	FAVYQCQFGNSQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	907	TSWIS	908	MIDPSDSFTSYSPSFQ G	909	LHYYNSEEFDV 910
mAb11-1457	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQFGNSQLFT FGQGTKLEIK	911	RASQSVSSS YLA	912	GQSSRTR	913	QQFGNSQLFT 914
mAb11-1458	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	915	TSWIV	916	MIDPSDSYTSYSPSFQ G	917	LHYYNSEEFDV 918
mAb11-1458	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	919	RASQSVSSS YLA	920	GQSSRTR	921	QQFGNSQLFT 922

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1459	VH	FAVYCCQQFGNSQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	923	TSWIV	924	MIDPDSYTSYSPSFQ G	925	LHYYNSEEFDV
mAb11-1459	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQQFGNSQLFT FGQGTKLEIK	927	RASQSVSSS YLA	928	GQSSRTR	929	QQFGNSQLFT
mAb11-1460	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	931	TSWIS	932	MIDPDSYTSYSPSFQ G	933	LHYYNSEEFDV
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	931	TSWIS	932	MIDPDSYTSYSPSFQ G	933	LHYYNSEEFDV
mAb11-1460	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	935	RASQSVSSS YLA	936	GQSSRTR	937	QQFGNSQLFT

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1461	VH	FAVYCCQQFGQSQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVDVWGQGT MVTVSS	939	TSWIS	940	MIDPDSFTSYSPSFQ G	941	LHYHSEEFDV 942
mAb11-1461	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYCCQQFGQSQLFT FGQGTKLEIK	943	RASQSVSSS YLA	944	GQSSRTR	945	QQFGQSQLFT 946
mAb11-1463	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVDVWGQGT MVTVSS	947	TSWIS	948	MIDPDSYTSYSPSFQ G	949	LHYHSEEFDV 950
mAb11-1463	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	951	RASQSVSSS YLA	952	GQSSRTR	953	QQFGQSQLFT 954

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1464	VH	FAVYCCQFGGSQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	955	TSWIS	956	MIDPDSFTSYSPSFQ G	957	LHYNSEEFDV 958
mAb11-1464	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQFGGSQLFT FGQGTKLEIK	959	RASQSVSSS YLA	960	GQSSRTR	961	QQFGQSQLFT 962
mAb11-1465	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	963	TSWIV	964	MIDPDSYTSYSPSFQ G	965	LHYNSEEFDV 966
mAb11-1465	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	967	RASQSVSSS YLA	968	GQSSRTR	969	QQFGQSQLFT 970

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1466	VH	FAVYCCQQFGQSQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	971	TSWIV	972	MIDPDSYTSYSPSFQ G	973	LHYYNSEEFDV 974
mAb11-1466	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYCCQQFGQSQLFT FGQGTKLEIK	975	RASQSVSSS YLA	976	GQSSRTR	977	QQFGQSQLFT 978
mAb11-1467	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	979	TSWIS	980	MIDPDSYTSYSPSFQ G	981	LHYYNSEEFDV 982
mAb11-1467	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	983	RASQSVSSS YLA	984	GQSSRTR	985	QQFGDAQLFT 986

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1468	VH	FAVYCCQQFGDAQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWVGQGT MVTVSS	987	TSWIS	988	MIDPSDSFTSYSPSFQ G	989	LHYHSEEFDV 990
mAb11-1468	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYCCQQFGDAQLFT FGQGTKLEIK	991	RASQSVSSS YLA	992	GQSSRTR	993	QQFGDAQLFT 994
mAb11-1470	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWVGQGT MVTVSS	995	TSWIS	996	MIDPSDSYTSYSPSFQ G	997	LHYHSEEFDV 998
		EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	999	RASQSVSSS YLA	1000	GQSSRTR	1001	QQFGDAQLFT 1002

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1471	VH	FAVYCCQQFGDAQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFDVWGQGT LVTVSS	1003	TSWIS	1004	MIDPDSFTSYSPSFQ G	1005	LHYYNSEEFDV
mAb11-1471	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQQFGDAQLFT FGQGTKLEIK	1007	RASQSVSSS YLA	1008	GQSSRTR	1009	QQFGDAQLFT
mAb11-1472	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFDVWGQGT LVTVSS	1011	TSWIV	1012	MIDPDSYTSYSPSFQ G	1013	LHYYNSEEFDV
		EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	1015	RASQSVSSS YLA	1016	GQSSRTR	1017	QQFGDAQLFT
mAb11-1472	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED						

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1473	VH	FAVYCCQQFGDAQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	1019	TSWIV	1020	MIDPDSYTSYSPSFQ G	1021	LHYYNSEEFDV
mAb11-1473	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQQFGDAQLFT FGQGTKLEIK	1023	RASQSVSSS YLA	1024	GQSSRTR	1025	QQFGDAQLFT
mAb11-1474	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	1027	TSWIS	1028	MIDPDSYTSYSPSFQ G	1029	LHYYNSEEFDV
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	1027	TSWIS	1028	MIDPDSYTSYSPSFQ G	1029	LHYYNSEEFDV
mAb11-1474	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	1031	RASQSVSSS YLA	1032	GQSSRTR	1033	QQFGDTQLFT

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1475	VH	FAVYCCQQFGDTQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTVSS	1035	TSWIS	1036	MIDPSDSFTSYSPSFQ G	1037	LHYHSEEFDV
mAb11-1475	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYCCQQFGDTQLFT FGQGTKLEIK	1039	RASQSVSSS YLA	1040	GQSSRTR	1041	QQFGDTQLFT
mAb11-1476	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT LVTVSS	1043	TSWIS	1044	MIDPSDSYTSYSPSFQ G	1045	LHYHSEEFDV
		EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	1047	RASQSVSSS YLA	1048	GQSSRTR	1049	QQFGDTQLFT
mAb11-1476	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED						

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1477	VH	FAVYCCQQFGDTQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTVSS	1051	TSWIS	1052	MIDPDSYTSYSPSFQ G	1053	LHYHSEEFDV
mAb11-1477	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQQFGDTQLFT FGQGTKLEIK	1055	RASQSVSSS YLA	1056	GQSSRTR	1057	QQFGDTQLFT
mAb11-1478	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT LVTVSS	1059	TSWIS	1060	MIDPDSYTSYSPSFQ G	1061	LHYHSEEFDV
mAb11-1478	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	1063	RASQSVSSS YLA	1064	GQSSRTR	1065	QQFGDTQLFT

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1479	VH	FAVYQCQQFGDTQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVVGQGT LVTSS	1067	TSWIV	1068	MIDPDSYTSYSPSFQ G	1069	LHYYNSEEFDV
mAb11-1479	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQQFGDTQLFT FGQGTKLEIK	1071	RASQSVSSS YLA	1072	GQSSRTR	1073	QQFGDTQLFT
mAb11-1480	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVVGQGT MVTSS	1075	TSWIV	1076	MIDPDSYTSYSPSFQ G	1077	LHYYNSEEFDV
mAb11-1480	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	1079	RASQSVSSS YLA	1080	GQSSRTR	1081	QQFGDTQLFT

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1481	VH	FAVYCCQQFGDTQLFT FGQGTKLEIK							
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	1083	TSWIS	1084	MIDPDSYTSYSPSFQ G	1085	LHYYNSEEFDV	1086
mAb11-1481	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYCCQQFGDNQLFT FGQGTKLEIK	1087	RASQSVSSS YLA	1088	GQSSRTR	1089	QQFGDNQLFT	1090
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTVSS	1091	TSWIS	1092	MIDPDSFTSYSPSFQ G	1093	LHYHSEEFDV	1094
mAb11-1482	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	1095	RASQSVSSS YLA	1096	GQSSRTR	1097	QQFGDNQLFT	1098

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1483	VH	FAVYQCQFGDNQLFT FGQGTKLEIK							
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT LVTSS	1099	TSWIS	1100	MIDPDSYTSYSPSFQ G	1101	LHYHSEEFDV	1102
mAb11-1483	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQFGDNQLFT FGQGTKLEIK	1103	RASQSVSSS YLA	1104	GQSSRTR	1105	QQFGDNQLFT	1106
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTSS	1107	TSWIS	1108	MIDPDSYTSYSPSFQ G	1109	LHYHSEEFDV	1110
mAb11-1484	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	1111	RASQSVSSS YLA	1112	GQSSRTR	1113	QQFGDNQLFT	1114
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTSS	1107	TSWIS	1108	MIDPDSYTSYSPSFQ G	1109	LHYHSEEFDV	1110

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1485	VH	FAVYQCQFGDNQLFT FGQGTKLEIK							
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	1115	TSWIS	1116	MIDPSDSFTSYSPSFQ G	1117	LHYNSEEFDV	1118
mAb11-1485	VL	EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQFGDNQLFT FGQGTKLEIK	1119	RASQSVSSS YLA	1120	GQSSRTR	1121	QQFGDNQLFT	1122
mAb11-1486	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT LVTSS	1123	TSWIV	1124	MIDPSDSYTSYSPSFQ G	1125	LHYNSEEFDV	1126
		EIVLTQSPGTLSPGE RATLSCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	1127	RASQSVSSS YLA	1128	GQSSRTR	1129	QQFGDNQLFT	1130

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1487	VH	FAVYQCQFGDNQLFT FGQGTKLEIK EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	1131	TSWIV	1132	MIDPDSYTSYSPSFQ G	1133	LHYYNSEEFDV 1134
mAb11-1487	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYQCQFGDNQLFT FGQGTKLEIK	1135	RASQSVSSS YLA	1136	GQSSRTR	1137	QQFGDNQLFT 1138
mAb11-1488	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVWGQGT MVTVSS	1139	TSWIS	1140	MIDPDSYTSYSPSFQ G	1141	LHYYNSEEFDV 1142
mAb11-1488	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	1143	RASQSVSSS YLA	1144	GQSSRTR	1145	QQFGDDQLFT 1146

mAb ID	Domain	VH/VL		CDR1		CDR2		CDR3	
		Sequence	#	Sequence	#	Sequence	#	Sequence	#
mAb11-1489	VH	FAVYCCQQFGDDQLFT FGQGTKLEIK							
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSFTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT MVTVSS	1147	TSWIS	1148	MIDPSDSFTSYSPSFQ G	1149	LHYHSEEFDV	1150
mAb11-1489	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED FAVYCCQQFGDDQLFT FGQGTKLEIK	1151	RASQSVSSS YLA	1152	GQSSRTR	1153	QQFGDDQLFT	1154
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT LVTVSS	1155	TSWIS	1156	MIDPSDSYTSYSPSFQ G	1157	LHYHSEEFDV	1158
mAb11-1490	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGDTFTLTISRLEPED	1159	RASQSVSSS YLA	1160	GQSSRTR	1161	QQFGDDQLFT	1162
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVWGQGT LVTVSS	1159	RASQSVSSS YLA	1160	GQSSRTR	1161	QQFGDDQLFT	1162

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1491	VH	FAVYCCQQFGDDQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFTTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYHSEEFVVGQGT MVTVSS	1163	TSWIS	1164	MIDPSDSYTSYSPSFQ G	1165	LHYHSEEFDV
mAb11-1491	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED FAVYCCQQFGDDQLFT FGQGTKLEIK	1167	RASQSVSSS YLA	1168	GQSSRTR	1169	QQFGDDQLFT
mAb11-1492	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFTSW ISWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYNSEEFVVGQGT LVTVSS	1171	TSWIS	1172	MIDPSDSYTSYSPSFQ G	1173	LHYNSEEFDV
mAb11-1492	VL	EIVLTQSPGTLSPGE RATLSRASQSVSSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFLTISRLEPED	1175	RASQSVSSS YLA	1176	GQSSRTR	1177	QQFGDDQLFT

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
mAb11-1493	VH	FAVYCCQQFGDDQLFT FGQGTKLEIK						
		EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVVGQGT LVTVSS	1179	TSWIV	1180	MIDPDSYTSYSPSFQ G	1181	LHYYNSEEFDV
mAb11-1493	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFTLTISRLEPED FAVYCCQQFGDDQLFT FGQGTKLEIK	1183	RASQSVSSS YLA	1184	GQSSRTR	1185	QQFGDDQLFT
mAb11-1494	VH	EVQLVQSGAEVKKPGE SLRISCKGSGYSFSTSW IVWVRQMPGKGLEWM GMIDPSDSYTSYSPSFQ GHVTISADKSISTAYLQ WSSLKASDTAMYCAR LHYYNSEEFVVGQGT MVTVSS	1187	TSWIV	1188	MIDPDSYTSYSPSFQ G	1189	LHYYNSEEFDV
		EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFTLTISRLEPED	1191	RASQSVSSS YLA	1192	GQSSRTR	1193	QQFGDDQLFT
mAb11-1494	VL	EIVLTQSPGTLSPGE RATLSRCRASQSVSSYL AWYQQKPGQAPRLIY GQSSRTRGIPDRFSGS GSGTDFTLTISRLEPED						

mAb ID	VH/VL		CDR1		CDR2		CDR3	
	Domain	Sequence	#	Sequence	#	Sequence	#	Sequence
		FAVYCCQQFGDDQLFT FGQGTKLEIK						

Example 7a: Binning of anti-FIX/FIXa stimulating antibodies

Antibodies capable of stimulating the enzymatic activity of FIXa towards FX were analysed in binning experiments to determine the binding characteristics for the identified antibodies using the method described below. Both parent antibodies and engineered variants were
 5 analysed, and compared to other known antibodies.

Method for binning of antibodies

Binning experiments were performed using Octet fortebio systems (HTX, Red384), based on the principle of Bio-Layer Interferometry, and equipped with streptavidin sensors (Pall Life
 10 Sciences, Menlo Park, CA), and using 8-channel mode. The binning assays were performed using a modified in-tandem setup. Briefly, (1) 370 nM randomly biotinylated human FIXa (biotinylated using NHS-d-biotin from Sigma H1759 and human FIXa obtained from Haematologic Technologies, Essex Junction, VT) was captured by streptavidin tips (dip and read biosensors Part NO:18-5019, Pall Life Sciences, Menlo Park, CA) for 5 minutes, (2) 330
 15 nM of a first bivalent anti-FIXa antibody was then offered to the streptavidin tips, and incubated for 10 minutes until the biotinylated FIXa were fully saturated and (3) the tips were then offered to an equimolar solution of 330 nM of the first antibody and 330 nM of a second bivalent anti-FIXa antibody for 5 minutes. This modified in-tandem set-up, with inclusion of an equimolar concentration of the first antibody in the second antibody incubation step, were
 20 preferred due to the very low affinity (and fast koff rates) of some of the used antibodies. Unspecific binding were evaluated by including an unrelated human IgG4 bivalent antibody as first and second antibody control. As seen in Table 4, where the response values from step (3) are reported, the analysis identified three different bins, represented by the bivalent anti-FIXa antibodies 224F3 (mAb01-1582), mAb01-1767 and mAb01-2434 (ACE910 anti-FIX(a) arms). From Table 4 it is also clear, that the engineered antibodies mAb01-9933, mAb01-9978, mAb01-9985, and mAb01-9994 show the same binning pattern as their parent antibody mAb01-1767 and consequently belong to BinB (as indicated in Table 4).
 25

Table 4: Interferometry response values

1st antibody	224F3 (BinA)	mAb01-1767 (BinB)	mAb01-2434 (BinC)	hIgG4 (control)
2nd antibody				
224F3	0.11	1.60	1.69	2.11
mAb01-1767	0.95	0.02	1.11	1.41

mAb01-2434	0.41	0.49	0.14	0.85
mAb01-9933	0.34	0.02	0.46	0.59
mAb01-9978	0.24	0.01	0.34	0.40
mAb01-9985	0.44	0.02	0.60	0.83
mAb01-9994	0.40	0.01	0.56	0.75
hIgG4 (control)	0.08	-0.02	-0.04	-0.03

As seen from Table 4, the control antibody human IgG4 was not able to bind to FIXa when used as second antibody (Table 4 last row) and did not prevent binding of the second antibody to FIXa when used as first antibody (Table 4 last column). 224F3 and mAb01-2434 had self-competition response values higher than zero, namely 0.11 and 0.14, respectively, still well beyond the lowest response values among the second antibodies belonging to a different bin, e.g. 0.24 for mAb01-9978 (2nd antibody)/224F3 (1st antibody) and 0.34 for the mAb01-9978 (2nd antibody)/mAb01-2434 (1st antibody). Some examples of the full binding curves are shown in Figures 4A and 4B (C, D, E and F)

Example 7b: Binning of anti-FX/FXa stimulating antibodies

Anti-FX(a) antibodies were analysed in binning experiments to determine the binding characteristics for the identified antibodies using the method described below. Both parent antibodies and engineered variants were analysed, and compared to other known antibodies.

Method for binning of antibodies

Binning experiments were performed using Octet fortebio systems (HTX, Red384) equipped with streptavidin sensors (Pall Life Sciences, Menlo Park, CA), and using 8-channel mode (Red384 and HTX). The binning assays were performed using a modified in-tandem setup. Briefly, (1) 363 nM randomly biotinylated human FXa (obtained from Haematologic technologies and biotinylated using NHS-d-biotin) was captured by streptavidin tips for 5 minutes (dip and read biosensors Part NO:18-5019, Pall Life Sciences, Menlo Park, CA), (2) 330 nM of a first bivalent anti-FX(a) antibody was then offered to the streptavidin tips, and incubated for 10 minutes until the biotinylated FXa were fully saturated and (3) the tips were then offered to an equimolar solution of 330 nM of the first antibody and 330 nM of a second bivalent anti-FX(a) antibody for 5 minutes. The set-up with inclusion of an equimolar concentration of the first antibody in the second antibody incubation step, were preferred due to the very low affinity (and fast koff rates) of some of the used antibodies. Unspecific binding

- were evaluated by including an unrelated human IgG4 bivalent antibody as first and second antibody control. As seen in Table 5, where the response values from step (3) are reported, the analysis identified two different bins, represented by the bivalent anti-FX(a) antibodies mAb01-2435 (ACE910 anti-FX(a) arms) and mAb01-6723. From Table 5 it is also clear, that
- 5 the engineered antibodies mAb01-8174 and mAb01-9772 show the same binning pattern as their parent antibody mAb01-6723 and consequently belong to Bin2 (as indicated in Table 5). Some examples of the full binding curves are shown in Figure 5 (A and B).

Table 5: Interferometry response values

1st antibody	mAb01-2435 (Bin1)	mAb01-6723 (Bin2)	hIgG4 (control)
2nd antibody			
mAb01-2435	-0.05	0.85	2.63
mAb01-6723	0.79	-0.02	2.59
mAb01-8174	0.62	0.05	2.29
mAb01-9772	0.22	-0.01	1.49
hIgG4 (control)	-0.08	-0.03	-0.09

Example 8: Crystallization and epitope/paratope mapping of anti-FIX(a) antibodies using X-ray crystallography

Crystallization and epitope/paratope mapping of anti-FIX(a) antibody mAb01-9994

5 Crystallization

Fab fragment corresponding to mAb01-9994 was mixed in a 1:1 molar ratio with human EGR-CK-inhibited Factor IXa Gla-domainless (wild-type) bacterial expression, Lot# hGDFIXAWTEGR_05 (purchased from Cambridge ProteinWorks) and crystals of the Fab/FIXa complex were grown using the sitting drop vapour diffusion technique at 18 °C. A protein solution of 100 nl 5.5 mg/ml complex in 20mM Tris-HCl, pH 7.4, 50mM NaCl, and 2.5mM CaCl₂ was mixed with 100 nl of 0.1M Bicine, pH 9.0, 2 % (v/v) 1,4-dioxane, 10 % PEG 20000 as precipitant and incubated over 60 µl precipitant.

Diffraction data collection

15 The crystal was cryo protected by addition of 1 µl of precipitant added 20 % of ethylene glycol to the crystallization drop prior to flash cooling in liquid nitrogen. Diffraction data were collected at 100K at the Diamond Light Source beamline i03 (0.9763 Å wavelength) using a Pilatus3 6M pixel detector from Dectris. Autoindexing, integration and scaling of the data were performed with programmes from the XDS package (diffracting data statistics are summarised in Table 6).

Structure determination and refinement

The asymmetric unit contains one Fab:FIXa complex as judged from Matthews coefficient analysis. The structure was determined by molecular replacement using Phaser as implemented in the programme suite Phenix using a structure of a predetermined Fab:FIXa complex as search model. The correct amino acid sequence was model built using COOT and thereafter the structure was refined using steps of Phenix refinement and manual rebuilding in COOT. The refinement statistics are found in Table 6.

30 Table 6: Data collection and refinement statistics

Wavelength (Å)	0.9763
Resolution range (Å)	43.06 - 2.7 (2.797 - 2.7)
Space group	P4 ₃ 2 ₁ 2
Unit cell (Å, deg)	87.65 87.65 231.8 90 90 90
Total reflections	327518 (33655)

Unique reflections	25718 (2511)
Multiplicity	12.7 (13.4)
Completeness (%)	99.94 (100.00)
Mean I/sigma(I)	13.21 (1.28)
Wilson B-factor (Å ²)	77.47
R-merge	0.15 (2.05)
R-meas	0.1565 (2.13)
R-pim	0.04391 (0.5757)
CC1/2	0.998 (0.447)
CC*	1 (0.786)
Reflections used in refinement	25715 (2511)
Reflections used for R-free	968 (93)
R-work	0.1978 (0.3407)
R-free	0.2494 (0.4171)
CC(work)	0.933 (0.554)
CC(free)	0.988 (0.575)
Number of non-hydrogen atoms	5597
macromolecules	5540
ligands	25
solvent	32
Protein residues	719
RMS(bonds) (Å)	0.012
RMS(angles) (deg)	1.92
Ramachandran favored (%)	90.24
Ramachandran allowed (%)	7.92
Ramachandran outliers (%)	1.84
Rotamer outliers (%)	0.00
Clashscore	12.93
Average B-factor (Å ²)	82.66
Macromolecules	82.77
Ligands	85.42
Solvent	61.00

Statistics for the highest-resolution shell are shown in parentheses.

Determination of the epitope of mAb01-9994

The epitope of mAb01-9994, defined as FIX(a) residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å from a heavy atom in the Fab, comprises the following residues L337, R338, T340, K341 and T343, according to SEQ ID NO:1.

Determination of the paratope of mAb01-9994

The paratope for mAb01-9994 defined as Fab residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å from a heavy atom in FIXa, comprises the residues (consecutive numbering): H30, **D31**, **W53**, **D56**, **S102**, **S104**, **Y106** and **N107** in the heavy chain variable domain (SEQ ID NO:67) and residues **Y91** and **S92** in the light chain variable domain (SEQ ID NO:71).

Residues in bold are located in the CDR sequences, as defined using the Kabat definition, while the remaining paratope residues H30 (in the heavy chain variable domain) is a framework residue.

Crystallization and epitope/paratope mapping of anti-FIX/FIXa antibody mAb01-9933

Crystallization

Fab fragment corresponding to mAb01-9933 was mixed in a 1:1 molar ratio with human EGR-CK-inhibited Factor IXa Gla-domainless (wild-type) bacterial expression, Lot# hGDFIXAWTEGR_05 (purchased from Cambridge ProteinWorks) and crystals of the Fab/FIXa complex were grown using the sitting drop vapour diffusion technique at 18 °C. A protein solution of 150 nl 8.1 mg/ml complex in 20mM Tris-HCl, pH 7.4, 50mM NaCl, and 2.5mM CaCl₂ was mixed with 50 nl of 0.1 M Bis-Tris, pH 6.5, 20 % (w/v) PEG 5000 MME as precipitant and incubated over 60 µl precipitant.

Diffraction data collection

The crystal was cryo protected by addition of 1 µl of precipitant added 20 % of ethylene glycol to the crystallization drop prior to flash cooling in liquid nitrogen. Diffraction data were collected at 100K at the Diamond Light Source beamline i03 (0.9763 Å wavelength) using a Pilatus3 6M pixel detector from Dectris. Autoindexing, integration and scaling of the data were performed with programmes from the XDS package (diffracting data statistics are summarised in Table 7).

Structure determination and refinement

- The asymmetric unit contains one Fab:FIXa complex as judged from Matthews coefficient analysis. The structure was determined by molecular replacement using Phaser as implemented in the programme suite Phenix using a structure of a predetermined Fab:FIXa
- 5 complex as search model . The correct amino acid sequence was model built using COOT and thereafter the structure was refined using steps of Phenix refinement and manual rebuilding in COOT. The refinement statistics are found in Table 7.

Table 7: Data collection and refinement statistics

Wavelength (Å)	0.9763
Resolution range (Å)	47.16 - 2.4 (2.486 - 2.4)
Space group	P 4 ₃ 2 ₁ 2
Unit cell (Å, deg)	85.7 85.7 225.95 90 90 90
Total reflections	433016 (39929)
Unique reflections	33886 (3317)
Multiplicity	12.8 (12.0)
Completeness (%)	99.95 (99.97)
Mean I/sigma(I)	13.85 (1.41)
Wilson B-factor	53.78
R-merge	0.1353 (1.658)
R-meas	0.1412 (1.732)
R-pim	0.03956 (0.4966)
CC1/2	0.999 (0.591)
CC*	1 (0.862)
Reflections used in refinement	33879 (3317)
Reflections used for R-free	1279 (128)
R-work	0.2171 (0.2721)
R-free	0.2623 (0.3245)
CC(work)	0.957 (0.764)
CC(free)	0.991 (0.670)
Number of non-hydrogen atoms	5624
macromolecules	5497
Ligands	25
Solvent	102

Protein residues	715
RMS(bonds) (Å)	0.011
RMS(angles) (deg)	1.36
Ramachandran favored (%)	90.70
Ramachandran allowed (%)	7.58
Ramachandran outliers (%)	1.72
Rotamer outliers (%)	0.49
Clashscore	9.45
Average B-factor (Å ²)	64.71
Macromolecules	64.92
Ligands	60.38
Solvent	54.67

Statistics for the highest-resolution shell are shown in parentheses.

Determination of the epitope of mAb01-9933

- 5 The epitope of mAb01-9933, defined as FIX(a) residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å from a heavy atom in the Fab, comprises the following residues L337, R338, T340, and K341, according to SEQ ID NO:1.

Determination of the paratope of mAb01-9933

- 10 Additionally, the paratope for mAb01-9933 defined as Fab residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å from a heavy atom in FIXa, comprises the residues (consecutive numbering): D30, **D31**, **W53**, **S102**, **S104**, **N107** in the heavy chain variable domain (SEQ ID NO:35) and residues: **Y91** and **S92** in the light chain variable domain (SEQ ID NO:39).

- 15 Residues in bold are located in the CDR sequences, as defined using the Kabat definition, while the remaining paratope residues D30 (in the heavy chain variable domain) is a framework residue.

Example 8a: Crystallization and epitope/paratope mapping of anti-FIX(a) antibody mAb01-9985

Crystallization

- Fab fragment corresponding to mAb01-9985 was mixed in a 1:1 molar ratio with human
- 5 EGR-CK-inhibited Factor IXa Gla-domainless (wild-type) bacterial expression, Lot# hGDFIXAWTEGR_11 (purchased from Cambridge ProteinWorks). The complex was subjected to size exclusion chromatography on a HiLoad 16/60 Superdex 200 pg column (GE Healthcare) run with 20mM Hepes, pH 7.5, 140mM NaCl, 1mM CaCl₂ buffer. The fractions containing the Fab/FIXa complex were pooled and concentrated to 10.1 mg/ml.
- 10 Crystals of the Fab/FIXa complex were grown using the microseed matrix screening technique as described in D'Arcy *et al.* (2014) *Acta Crystallographica Section F* 70, 1117-1126 using sitting drop vapour diffusion at 18 °C. The crystal used was grown using a protein solution of 200 nl 10.1 mg/ml complex in 20mM Hepes, pH 7.4, 140mM NaCl, 1 mM CaCl₂ mixed with 100 nl seed stock and 300 nl of 2 M ammonium sulphate, 0.1 M Hepes, pH 7.5 as
- 15 precipitant and incubated over 80 µl precipitant. The seed stock was prepared from crystals of the Fab fragment corresponding to mAb01-9933 in complex with human EGR-CK-inhibited Factor IXa Gla-domainless (wild-type).

Diffraction data collection

- 20 The crystal was cryo protected by addition of 1.5 µl of precipitant added 20 % of ethylene glycol to the crystallization drop prior to flash cooling in liquid nitrogen. Diffraction data were collected at 100K at the Swiss Light Source beamline X10SA (1.00 Å wavelength) using a Pilatus3 6M pixel detector from Dectris. Autoindexing, integration and scaling of the data were performed with programmes from the XDS package (diffracting data statistics are
- 25 summarised in Table 7a).

Structure determination and refinement

- The asymmetric unit contains one Fab:FIXa complex as judged from Matthews coefficient analysis. The structure was determined by molecular replacement using Phaser as
- 30 implemented in the programme suite Phenix using a structure of a predetermined Fab:FIXa complex as search model. The correct amino acid sequence was model built using COOT and thereafter the structure was refined using steps of Phenix refinement and manual rebuilding in COOT. The refinement statistics are found in Table 7a.

Table 7a: Data collection and refinement statistics

Wavelength (Å)	1.00
Resolution range (Å)	48.51 - 3.105 (3.216 - 3.105)
Space group	P 4 ₁ 22
Unit cell (Å, deg)	97.03 97.03 254.51 90 90 90
Total reflections	295893 (28675)
Unique reflections	22811 (2201)
Multiplicity	13.0 (13.0)
Completeness (%)	99.80 (99.19)
Mean I/sigma(I)	4.30 (0.95)
Wilson B-factor (Å²)	50.79
R-merge	0.692 (2.568)
R-meas	0.7205 (2.672)
R-pim	0.1985 (0.7295)
CC1/2	0.957 (0.476)
CC*	0.989 (0.803)
Reflections used in refinement	22786 (2193)
Reflections used for R-free	548 (53)
R-work	0.2240 (0.3283)
R-free	0.2794 (0.3814)
CC(work)	0.940 (0.725)
CC(free)	0.928 (0.614)
Number of non-hydrogen atoms	5690
macromolecules	5595
ligands	95
Protein residues	726
RMS(bonds) (Å)	0.012
RMS(angles) (deg)	1.70
Ramachandran favored (%)	97.21
Ramachandran allowed (%)	2.65
Ramachandran outliers (%)	0.14
Rotamer outliers (%)	0.16
Clashscore	3.58
Average B-factor (Å²)	43.84
Macromolecules	43.53

Ligands

61.76

Statistics for the highest-resolution shell are shown in parentheses.

Determination of the epitope of mAb01-9985

- 5 The epitope of mAb01-9985, defined as FIX(a) residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å from a heavy atom in the Fab, comprises the following residues L337, R338, S339, T340, and K341, according to SEQ ID NO:1.

Determination of the paratope of mAb01-9985

- 10 The paratope for mAb01-9985 defined as Fab residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å from a heavy atom in FIXa, comprises the residues (consecutive numbering): H30, **D31**, **W53**, **S102**, **S104**, **Y106** and **N107** in the heavy chain variable domain (SEQ ID NO:51) and residues **Y91** and **S92** in the light chain variable domain (SEQ ID NO:55). Residues in bold are located in the CDR
- 15 sequences, as defined using the Kabat definition, while the remaining paratope residue H30 (in the heavy chain variable domain) is a framework residue.

Example 9: Crystallization and epitope/paratope mapping of anti-FX antibodies using X-ray crystallography

- 20 **Crystallization and epitope/paratope mapping of anti-FXa antibody mAb01-8174**

Crystallization

- Fab fragment corresponding to mAb01-8174 was mixed in a 1:1 molar ratio with human EGR-CK-inhibited Factor Xa Gla-domainless (wild-type) bacterial expression, Lot# hGDFXAEGR_026 (purchased from Cambridge ProteinWorks) and crystals of the Fab/FXa
- 25 complex were grown using the sitting drop vapour diffusion technique at 18 °C. A protein solution of 150 nl 4.7 mg/ml complex in 20mM Tris-HCl, pH 7.4, 50mM NaCl, and 2.5mM CaCl₂ was mixed with 50 nl of 0.2 M sodium acetate, 0.1 M sodium cacodylate, pH 6.5, 18 % (w/v) PEG 8000 as precipitant and incubated over 60 µl precipitant.

- 30 Diffraction data collection

The crystal was cryo protected by addition of 1 µl of precipitant added 20 % of ethylene glycol to the crystallization drop prior to flash cooling in liquid nitrogen. Diffraction data were collected at 100K at the Swiss Light Source beamline X06DA (1.00 Å wavelength) using a Pilatus2M pixel detector from Dectris. Autoindexing, integration and scaling of the data were

performed with programmes from the XDS package (diffracting data statistics are summarised in Table 8).

Structure determination and refinement

- 5 The asymmetric unit contains two Fab:FXa complexes as judged from Matthews coefficient analysis. The structure was determined by molecular replacement with Molrep as implemented in the programme suite CCP4 using structures of predetermined Fab:FXa complexes as search models. The correct amino acid sequence for the Fab was model built using COOT and thereafter the structure was refined using steps of Phenix refinement and
- 10 manual rebuilding in COOT. The refinement statistics are found in Table 8.

Table 8: Data collection and refinement statistics

Wavelength (Å)	1.000
Resolution range (Å)	44.12 - 2.6 (2.693 - 2.6)
Space group	P2 ₁
Unit cell (Å, deg)	63.13 105.25 145.78 90 89.995 90
Total reflections	302807 (30703)
Unique reflections	58767 (5896)
Multiplicity	5.2 (5.2)
Completeness (%)	99.90 (99.97)
Mean I/sigma(I)	12.31 (1.56)
Wilson B-factor (Å²)	50.13
R-merge	0.1209 (1.024)
R-meas	0.1346 (1.138)
R-pim	0.05869 (0.4933)
CC1/2	0.996 (0.523)
CC*	0.999 (0.829)
Reflections used in refinement	58761 (5896)
Reflections used for R-free	1999 (202)
R-work	0.2033 (0.3027)
R-free	0.2623 (0.3140)
CC(work)	0.857 (0.463)
CC(free)	0.788 (0.347)
Number of non-hydrogen atoms	11641
macromolecules	11145

ligands	52
solvent	444
Protein residues	1447
RMS(bonds)	0.011
RMS(angles)	1.70
Ramachandran favored (%)	95.74
Ramachandran allowed (%)	3.70
Ramachandran outliers (%)	0.56
Rotamer outliers (%)	0.32
Clashscore	22.55
Average B-factor	46.64
macromolecules	46.94
ligands	46.66
solvent	39.14
Twin refinement	h,-k,-l

Statistics for the highest-resolution shell are shown in parentheses.

Determination of epitope of mAb01-8174

- 5 The epitope of mAb01-8174, defined as FXa residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å from a heavy atom in the Fab in one or both of the complexes in the asymmetric unit, comprises the following residues: E103, Q104, V108, R113, T116, L117, D119, I125, T127, E228, F229, Y230, E266, R287, P291, I292, P304, L419, K420, D423, R424, M426, K427 and T428 according to SEQ ID NO:2.

10 Determination of paratope of mAb01-8174

- The paratope for mAb01-8174 defined as Fab residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å from a heavy atom in FXa in one or both of the complexes in the asymmetric unit, comprises the residues (consecutive numbering): K23, S25, G26, Y27, F29, **W33, D52, S54, D55, F57, S77, H100, Y101, Y102,**
 15 **N103, S104** in the heavy chain variable domain (SEQ ID NO:467) and residues **V29, S30, S31, Y33, Y50, Q52, S54, R55, R57** and **D94** in the light chain variable domain (SEQ ID NO:471).

- Residues in bold are located in the CDR sequences, as defined using the Kabat definition, while the remaining paratope residues K23, S25, G26, Y27, F29 and S77 (in the heavy chain
 20 variable domain) and Y50 (in light chain variable domain) are framework residues.

Crystallization and epitope/paratope mapping of anti-FXa antibody mAb01-9772

- Fab fragment corresponding to mAb01-9772 was mixed in a 1:1 molar ratio with human
- 5 EGR-CK-inhibited Factor Xa Gla-domainless (wild-type) bacterial expression, Lot# hGDFXAEGR_026 (purchased from Cambridge ProteinWorks) and crystals of the Fab/FXa complex were grown using the sitting drop vapour diffusion technique at 18 °C. A protein solution of 150 nl 3.7 mg/ml complex in 20mM Tris-HCl, pH 7.4, 50mM NaCl, and 2.5mM CaCl₂ was mixed with 50 nl of 0.2 M sodium formate, 20 % (w/v) PEG 3350 as precipitant
- 10 and incubated over 60 µl precipitant.

Diffraction data collection

- The crystal was cryo protected by addition of 1 µl of precipitant added 20 % of ethylene glycol to the crystallisation drop prior to flash cooling in liquid nitrogen. Diffraction data were
- 15 collected at 100K at the Swiss Light Source beamline X06DA (1.00 Å wavelength) using a Pilatus2M pixel detector from Dectris. Autoindexing, integration and scaling of the data were performed with programmes from the XDS package (diffracting data statistics are summarised in Table 9).

20 Structure determination and refinement

- The asymmetric unit contains two Fab:FXa complexes as judged from Matthews coefficient analysis. The structure was determined by molecular replacement with Molrep as implemented in the programme suite CCP4 using structures of predetermined Fab:FXa complexes as search models. The correct amino acid sequence for the Fab was model built
- 25 using COOT and thereafter the structure was refined using steps of Phenix refinement and manual rebuilding in COOT. The refinement statistics are found in Table 9.

Table 9: Data collection and refinement statistics

Wavelength (Å)	1.000
Resolution range	48.33 - 3.15 (3.263 - 3.15)
Space group	P 2 ₁
Unit cell (Å, deg)	62.34 104.72 144.98 90 90.048 90
Total reflections	102910 (10275)
Unique reflections	31847 (3182)
Multiplicity	3.2 (3.2)

Completeness (%)	98.16 (98.45)
Mean I/sigma(I)	8.51 (1.45)
Wilson B-factor (Å²)	74.36
R-merge	0.126 (0.7224)
R-meas	0.1512 (0.8628)
R-pim	0.08262 (0.4665)
CC1/2	0.994 (0.571)
CC*	0.998 (0.853)
Reflections used in refinement	31824 (3182)
Reflections used for R-free	1083 (113)
R-work	0.2163 (0.2810)
R-free	0.2929 (0.2997)
CC(work)	0.849 (0.374)
CC(free)	0.736 (0.325)
Number of non-hydrogen atoms	11190
macromolecules	11138
ligands	52
Protein residues	1446
RMS(bonds)	0.013
RMS(angles)	1.98
Ramachandran favored (%)	95.03
Ramachandran allowed (%)	4.20
Ramachandran outliers (%)	0.77
Rotamer outliers (%)	0.00
Clashscore	26.08
Average B-factor (Å²)	73.74
macromolecules	73.78
ligands	65.77
Twin refinement	h,-k,-l

Statistics for the highest-resolution shell are shown in parentheses.

Determination of epitope of mAb01-9772

The epitope of mAb01-9772, defined as FXa residues characterized by having a heavy atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å from a heavy atom in the Fab in one or both of the complexes in the asymmetric unit, comprises the following residues: E103, Q104,
5 V108, R113, T116, L117, A118, D119, I125, T127, S227, E228, Y230, R287, I292, L303, P304, L419, K420, D423, R424, M426, K427 and T428 according to SEQ ID NO:2.

Determination of paratope of mAb01-9772

The paratope for mAb01-9772 defined as Fab residues characterized by having a heavy
10 atom (i.e. a non-hydrogen atom) within a distance of 3.5 Å from a heavy atom in FXa in one or both of the complexes in the asymmetric unit, comprises the residues (consecutive numbering): K23, G24, S25, G26, Y27, **W33, D52, S54, D55, Y57**, S77, **L99, H100, Y101, Y102, N103** and **S104** in the variable heavy chain domain (SEQ ID NO:483) and residues
15 **S30, S31, Y33**, Y50, **Q52, S54, R55, R57, Y92** and **D94** in the light chain variable domain (SEQ ID NO:487).

Residues in bold are located in the CDR sequences, as defined using the Kabat definition, while the remaining paratope residues K23, G24, S25, G26, Y27 and S77 (in the heavy chain variable domain) and Y50 (in light chain variable domain) are framework residues.

Example 10: Identification of hot-spot residues on FIX

In order to determine residues critical for the interaction (referred to as hot-spot) between the anti-FIX/FIXa mAb01-9994 and mAb01-9985 and FIX, a set of FIX variants was selected based on Fab/FIXa structure of the Fab fragment of mAb01-9994 and FIXa. As detailed
5 below the selected FIX variants were transiently expressed in mammalian cells, purified and characterized with respect to their binding to monovalent variants of mAb01-9994 and mAb01-9985 using Surface Plasmon Resonance (SPR).

Generation of FIX mutants

10 A DNA plasmid, suitable for transient mammalian expression, was constructed with an expression cassette encoding amino acids residues 1-461 of human FIX (uniprot P00740, except for a T194A mutation according to the UNIPROT numbering, corresponding to T148A of SEQ ID NO:1) directly followed by six Histidines (6×His-tag, for affinity purification). The secreted, mature FIX protein chain produced using this construct is identical to the A148
15 allelic form of human FIX (Anson *et al.* EMBO J. 1984 3:1053-1060, McGraw *et al.*, Proc Natl Acad Sci USA. 1985 82:2847-2851) except for the addition of the C-terminal His-tag.

Using the construct as template, selected mutations were introduced by PCR. For each single-point mutation listed in Table 10, a forward primer containing the desired amino acid
20 change and a reverse primer without amino acid mutations were designed. These primers were used in a standard PCR reaction with the vector described above as template to amplify the entire vector sequence. Ligation-free cloning was used to join the ends of the resulting amplified DNA fragment into a circular expression plasmid using overlap sequences introduced by the forward and the reverse primers.

The circularized plasmids were transformed into *E. coli* cells, grown on selective agar plates
25 to form colonies, and the colonies used to start liquid *E. coli* cultures. After overnight growth of the *E. coli* cultures, plasmid preparations were performed and the mutants identified by DNA sequencing.

Recombinant protein production was performed by transfecting expi293F cells growing in suspension culture in Expi293 Expression™ medium (ThermoFisher Scientific, cat#
30 A1435101) using the ExpiFectamine™ 293 Transfection Kit (ThermoFisher Scientific, cat# A14525) and plasmid DNA encoding each of the desired variants as well as wild-type FIX (corresponding to SEQ ID NO:1 with C-terminal His-tag). Vitamin K was added to a final concentration of 5 mg/mL at the time of transfection. Transfection Enhancers 1 and 2 from the ExpiFectamine™ 293 Transfection Kit were added the day after transfection. The cell
35 cultures were harvested 5 days after transfection by centrifugation.

- The C-terminal His-tag on each FIX variant was used for batch protein purification in a multi-well, robotic setup. Briefly, the harvested cell culture supernatants were adjusted to binding conditions, mixed with Ni Sepharose 6 Fast Flow affinity purification resin (GE Healthcare, cat# 17-5318-02, 50 µl sedimented resin/ml cell culture medium) and incubated while
- 5 shaking for 20 minutes. The resin/supernatant mixes were then transferred to a filter plate and the liquid drawn through the filter plate by application of vacuum. The resin remaining in the filter plate was washed three times before elution in a high-imidazole buffer.
- Concentration determination of the purified protein solutions was performed by ELISA, using an anti-FIX antibody for detection and high-purity recombinant wild-type FIX for standard
- 10 curves.
- The FIX variants were characterized with respect to their binding to mAb01-9994 and mAb01-9985 using surface plasmon resonance (SPR) by capturing the FIX variant via the C-terminal His-tag. To avoid avidity effects, i.e. ensure a 1:1 interaction, one-armed (OA) variants of mAb01-9994 and mAb01-9985 (prepared as described in Example 5), were used
- 15 as analytes.
- SPR analyses were carried out on Biacore T200 instruments (Biacore AB, Uppsala, Sweden). For the experiments on the T200 instrument the following conditions were applied: measurements were conducted at a temperature of 25 °C. Anti-His antibody at 25 µg/ml (R&D Systems, catalogue # MAB050) was immobilized on a CM5 sensor chip using standard
- 20 amine coupling chemistry. Anti-FIX variants at 25 nM were injected at a flow rate of 10 µl/min for 1 min and were captured via their His-tag by the immobilized anti-His antibody.
- Subsequently, 20 µM (with 2.5 fold dilution) of OA mAb01-9994 and OA mAb01-9985 were injected at a flow rate of 50 µl/min for 3 min to allow for binding to captured FIX variant followed by a 3 min buffer injection allowing for dissociation of the monovalent anti-FIX
- 25 antibodies. The running buffer used was 20 mM Tris, 150 mM NaCl, 5 mM CaCl₂, 0.05 % Tween-20, 10 mg/ml BSA, pH 7.4. This was also used for dilution of anti-FIX antibody and FIX samples. Regeneration of the chip was achieved using 10 mM Glycine pH 2.0. Binding data were analysed according to a 1:1 model using BiaEvaluation 4.1 supplied by the manufacturer (Biacore AB, Uppsala, Sweden).
- 30 Binding data are reported as % binding of the antibody to the FIX variant relative to binding of the antibody to wild-type FIX calculated according to the formula:
- $$\text{Binding (\%)} = 100 \% \times [(R_{\max_Ab, \text{FIX_var}})/(R_{\max_FIXvar})] / [(R_{\max_Ab, \text{FIX_wt}})/(R_{\max_FIXwt})]$$
- where $R_{\max_FIXvar}$ and $R_{\max_FIXwt}$ represent capture level (RU) of FIX variant and wild-type FIX, respectively, and where $R_{\max_Ab, \text{FIX_var}}$ and $R_{\max_Ab, \text{FIX_wt}}$ represent Rmax (RU) of the 20 µM

antibody to captured FIX variant and wild-type FIX, respectively. Results are shown in Tables 10 and 11.

Table 10: Results from SPR analysis (mAb01-9994)

5 Results from hot-spot analysis of OA variant of mAb01-9994

Residue#	FIX variant	Binding (%)
301	K301A	89
332	D332S	41
332	D332A	41
333	R333A	55
334	A334L	38
335	T335A	43
337	L337A	38
338	R338A	0
339	S339L	46
340	T340A	16
341	K341E	3
341	K341A	18
343	T343I	62
343	T343A	58
346	N346Q	101
346	N346A	92
NA	WT	100

Table 11: Results from SPR analysis (mAb01-9985)

Results from hot-spot analysis of OA variant of mAb01-9985

Residue#	FIX variant	Binding (%)
301	K301A	94
332	D332S	59
332	D332A	59
333	R333A	73
334	A334L	60

335	T335A	64
337	L337A	61
338	R338A	8
339	S339L	66
340	T340A	29
341	K341E	10
341	K341A	30
343	T343I	84
343	T343A	86
346	N346Q	93
346	N346A	100
NA	WT	100

Hot-spot residues for mAb01-9994 and mAb01-9985

Hot-spot residues for mAb01-9994 and mAb01-9985 are defined as positions where substitution of the wild-type residue with alanine reduces the binding of the antibody to 30% or less relative to binding of the antibody to wild-type FIX.

5 or less relative to binding of the antibody to wild-type FIX.

Hot-spot residues for mAb01-9994:

R338, T340 and K341

Hot-spot residues for mAb01-9985:

R338, T340 and K341

10

For both mAb01-9994 and mAb01-9985 the residue contributing most to binding is **R338**; substitution of R338 with alanine (R338A) in FIX exhibited the largest impact on antibody binding, which was greatly reduced to no observable binding and 8% for mAb01-9994 and mAb01-9985, respectively, relative to antibody binding to wild-type FIX.

15

Example 11: Identification of hot-spot residues on FX

The data provided in the present example determines the hot-spot epitope residues on FX for mAb01-8174. The FX variants used were single-site alanine variants (except for position 118, which is alanine in the wild-type, where an alanine to serine substitution was introduced) of desGla-desEGF1-FX, corresponding to residues 86-448 of SEQ ID NO:2, with a N-terminal His-tag (HHHHHH) (SEQ ID NO:1200), for affinity purification) attached via a short

20

GS-linker (GGGGSGGGGS) (SEQ ID NO:1201). The FX variants tested are listed in Table 12.

Table 12: List of generated desGla-desEGF1-FX mutants

Position ¹⁾	Variant	Domain ²⁾
101	H101A	EGF2
103	E103A	EGF2
113	R113A	EGF2
116	T116A	EGF2
118	A118S	EGF2
127	T127A	EGF2
227	S227A	PD
228	E228A	PD
229	F229A	PD
230	Y230A	PD
266	E266A	PD
287	R287A	PD
305	E305A	PD
419	L419A	PD
420	K420A	PD
423	D423A	PD
424	R424A	PD
427	K427A	PD
428	T428A	PD

5 ¹⁾ According to SEQ ID NO:2

²⁾ EGF2 and PD refer to second epidermal growth factor-like and protease domains, respectively

10 The wild-type desGla-desEGF1-FX and variants listed in Table 12 were expressed in the HEK293 system and purified via affinity chromatography. Identification of hot-spot epitope residues was done using a Biacore 4000 instrument at 25 °C. The wild-type desGla-desEGF1-FX and variants were immobilized on a Series-S Sensor Chip CM5 (GE Healthcare, Catalogue # BR100530) using standard amine coupling chemistry. 10 µM (with 2 fold serial dilutions) of the one-armed variant of mAb01-8174 was injected at the flow rate of 10 µL/min for 300 sec to allow for binding to the immobilized wild-type desGla-desEGF1-FX

- and variants followed by a 600 sec buffer injection to allow for dissociation of the monovalent antibody. The running buffer (also used for diluting the monovalent antibody and desGLA-desEGF1-hFX variants) contained 10 mM HEPES, 150 mM NaCl, 1 mg/mL BSA and 5 mM CaCl₂ (pH 7.4). No regeneration buffer was used because near complete dissociation of the antibody from the sensor chip was observed during the 600 sec dissociation stage. Binding data were analyzed according to the 1:1 model and the affinity (i.e. dissociation equilibrium constant) for each binding was derived from steady-state fitting of the binding curves in the Biacore 4000 Evaluation Software 1.0 supplied by GE Healthcare. Binding data are reported as fold of affinity of all the FX variants for the antibody with reference to that of the wild-type FX. Relative affinities measured for the FX variants are shown in table 13.

Table 13: Relative affinities ($K_D(\text{variant})/K_D(\text{wild-type})$) for binding of one-armed mAb01-8174 to FX variants

Variant	Relative affinity
Wild Type	1.0
H101A	3.6
E103A	3.5
R113A	2.3
T116A	0.55
A118S	1.5
T127A	0.85
S227A	2.8
E228A	0.85
F229A	0.95
Y230A	No Binding
E266A	0.65
R287A	> 5
E305A	2.1
L419A	4.5
K420A	> 5
D423A	No Binding
R424A	No Binding
K427A	No Binding
T428A	1.0

"No binding" means that binding was too weak to be detected

Hot-spot residues for mAb01-8174

As shown in Table 13 alanine-substitutions at positions 230, 423, 424 and 427 in FX completely abrogated binding to one-armed mAb01-8174. Thus, hot-spot residues on FX for binding to mAb01-8174 are:

5 **Y230, D423, R424 and K427**

Example 12: Activity of monovalent anti-FIX/FIXa antibodies in a FIXa generation assay

To avoid any potential avidity effects arising as a consequence of the bivalency of the conventional IgG antibody format, the stimulatory activity of anti-FIX(a) antibodies on FIXa enzymatic activity towards FX was determined following reformatting into a monovalent one-armed (OA) antibody format (see Example 5). Tested antibodies are listed in Table 14 below. The monovalent OA versions of the anti-FIXa antibodies 224F3 and ACE910 were included for comparison.

The stimulatory activity of OA antibodies was measured in assay buffer (50 mM HEPES, 100 mM NaCl, 5 mM CaCl₂, 0.1% (w/v) PEG8000, pH 7.3 + 1 mg/ml BSA) at fixed concentrations of phosphatidyl serine (PS):phosphatidyl choline (PC) phospholipid vesicles (final concentration of 500 µM; Haematologic Technologies Inc, USA) and plasma-derived FIXa (final concentrations of 0.04, 0.1, 0.17, 0.2, 0.3, 0.5 or 1 nM; Haematologic Technologies Inc, USA). The concentration of FIXa was chosen to ensure that less than 15% of the substrate FX was converted into FIXa. Following pre-incubation in the presence of monovalent OA antibody (final concentrations listed in Table 14), 100 nM plasma-derived FX (Haematologic Technologies Inc, USA) was added to give a final reaction volume of 50 µl, and activation was allowed to proceed for 20 min at room temperature. The reaction was then quenched by addition of 25 µl quench buffer (50 mM HEPES, 100 mM NaCl, 60 mM EDTA, 0.1% PEG8000, pH 7.3 + 1 mg/ml BSA) and the amount of FIXa generated was determined by further addition of 25 µl 2 mM S-2765 chromogenic substrate (Chromogenix, Sweden) and measurement of chromogenic substrate conversion by absorbance measurement at 405 nm (ΔOD/min) in a microplate reader. The measured activity was corrected for background activity by subtraction of the signal measured in the same assay but with FIXa and antibody replaced by assay buffer, and then normalized according to the concentration of FIXa present in the assay ([FIXa]_{total}). Dividing this number by the similarly normalized rate of FIXa generation in the absence of antibody ($A_{\text{FIXa, norm}}$), an antibody stimulation index was calculated providing the fold stimulation of FIXa activity by the antibody at the concentration used. Due to slow rate of FIXa generation by free FIXa, activation reactions in the absence of

antibody were carried out as described above but with 5, 10, or 20 nM FIXa present. Measured activities were then background subtracted and normalized according to the FIXa concentration in the assay. For the calculation of the stimulation index, the average of the three normalized activities of free FIXa was used.

5

Determination of Stimulation index

In summary, calculation of the stimulation index can be described as follows

$$\text{Stimulation index} = ((A_{\text{FIXa}+\text{OA}} - A_{\text{bckg}}) / [\text{FIXa}]_{\text{total}}) / A_{\text{FIXa, norm}}$$

10

where $A_{\text{FIXa}+\text{OA}}$ is the activity measured in the presence of OA antibody, A_{bckg} is the background activity measured in the absence of FIXa and OA antibody, $[\text{FIXa}]_{\text{total}}$ is the FIXa concentration in the assay, and $A_{\text{FIXa, norm}}$ is average normalized activity of free FIXa.

15 Determination of FIXa saturation

The fraction of FIXa saturated with OA antibody in the assay is determined by the concentrations of FIXa and OA antibody, and the equilibrium dissociation constant (K_d) governing their interaction. The latter can be measured by techniques known in the art, such as isothermal titration calorimetry (ITC).

20 Since the stimulation index will increase as the concentration of OA antibody is increased until saturation of FIXa is reached, the concentration of OA antibody in the assay should be chosen to ensure at least 80% saturation of FIXa in the assay to provide a proper determination of the stimulation index at full FIXa saturation.

The fraction of FIXa bound to OA antibody at equilibrium ($f_{\text{FIXa}+\text{OA}}$), can be calculated from the
25 total concentrations of FIXa ($[\text{FIXa}]_{\text{total}}$) and OA antibody ($[\text{OA}]_{\text{total}}$) in the assay and the equilibrium dissociation constant (K_d) for their interaction using the quadratic binding equation as described by Krishnaswamy *et al.* (1992) J. Biol. Chem., 267:23696-23706 and detailed in Eq. 1 and 2 below, wherein

30 $[\text{FIXa} + \text{OA}]_{\text{assay}}$ represents the calculated concentration of FIXa-OA antibody complex at equilibrium in the assay

$f_{\text{FIXa}+\text{OA}}$ represents the calculated fraction (in percent) of FIXa, which is bound to
OA antibody at equilibrium in the assay

35

Eq. 1:

$$\frac{[FIXa + OA]_{assay}}{= \frac{([FIXa]_{total} + [OA]_{total} + K_d) - \sqrt{([FIXa]_{total} + [OA]_{total} + K_d)^2 - 4 \times [FIXa]_{total} \times [OA]_{total}}}{2}}$$

5 Eq. 2:

$$f_{FIXa+OA} = 100\% \times \frac{[FIXa + OA]_{assay}}{[FIXa]_{total}}$$

The stimulation index for each OA antibody is provided in Table 14. With a concentration of OA 224F3 antibody of 3260 nM in the assay and a K_d for the interaction with FIXa of 0.477 nM as reported by Kerschbaumer *et al.* (US7297336B2), more than 95% of FIXa was bound to the OA 224F3 antibody in the assay. In the case of the OA ACE910 antibody, FIXa stimulation was determined at eight different antibody concentrations which allowed for the estimation of the stimulation index at full FIXa saturation using the quadratic binding equation as outlined above. This also provided an estimated equilibrium dissociation constant (K_d) for the interaction of ACE910 with FIXa of 1.1 μ M, which is in good agreement with the value of 1.52 μ M reported by Kitazawa *et al.* (2017) Thromb Haemost, 117:1348-1357 and the value of 1.97 μ M determined by ITC in Example 13. For the remaining antibodies, the degree of FIXa saturation was not known and the listed stimulation indices therefore represent conservative estimates of the stimulation that would be obtained at a degree of FIXa saturation of 80% or greater. For the tested antibodies the measured stimulation index was found to be higher than that measured for the OA 224F3 and OA ACE910 antibodies.

Table 14: Stimulation of FIXa activity by monovalent one-armed (OA) anti-FIXa antibodies

The anti-FIX mAb ID refers to the ID of the antibody used for reformatting into the OA format. Columns labelled 'OA antibody concentration (nM)' and 'Stimulation index' list the concentration of OA antibody (nM) used in the assay and the corresponding stimulation of FIXa activity measured relative to free FIXa. In the case of ACE910, the estimated stimulation index at full FIXa saturation is provided.

anti-FIX mAb ID	OA antibody concentration (nM)	Stimulation Index
ACE910	saturation	1372
224F3	3260	<10
01-9016	1600	5905

01-9373	1600	1392
01-9696	1600	5166
01-9697	3200	6539
01-9933	3600	6444
01-9978	3600	3667
01-9985	2400	13730
01-9986	800	5822
01-9994	3600	10593
11-0047	800	2856
11-0049	800	1509
11-0107	800	3264
11-0149	800	3315
11-0160	800	4549
11-0164	800	3269
11-0173	1600	8480
11-0174	800	3690
11-0723	800	3772
11-0923	800	2823
11-0929	800	1559
11-0931	800	1882
11-0932	800	1688
11-0933	800	1614
11-0935	800	1572
11-0937	800	2684
11-0938	800	1818
11-0939	800	2011
11-0962	800	3372
11-0965	800	2857
11-1021	800	4646
11-1024	800	3654
11-1030	800	5751
11-1033	800	5126
11-1039	800	3960
11-1042	800	4316

11-1073	800	6146
11-1076	800	3587
11-1091	800	5402
11-1094	800	4083
11-1204	1600	9099
11-1233	800	1700
11-1254	760	1890
11-1259	800	2005
11-1260	800	1757
11-1262	800	1952
11-1266	800	1696
11-1268	800	1796
11-1273	800	1540
11-1275	800	1835
11-1276	800	1739
11-1278	800	1694
11-1279	800	1562
11-1282	800	1461
11-1286	800	1816
11-1288	800	2534
11-1344	800	4662
11-1358	800	2831
11-1360	800	1114
11-1389	800	5786
11-1495	1600	7694
11-1499	1600	9013
11-1501	1600	10277
11-1502	1600	5853

Example 13: Binding affinities determined by isothermal titration calorimetry (ITC)

Binding affinities for anti-FIX(a) and anti-FX(a) antibodies were measured by isothermal
5 titration calorimetry (ITC) by using a PEAQ-ITC calorimeter (Malvern, UK). The experiments
were conducted at 37°C and pH 7.4 using 25 mM Tris, 150 mM NaCl, 5 mM CaCl₂ (Tris-

- buffer). The sample cell (200 μ l) contained either FIX, FIXa, or FX (macromolecule) and anti-FIX(a) and anti-FX(a) antibodies (ligand) were injected via a syringe (40 μ l). All proteins were extensively dialyzed in Tris-buffer prior to measurements to secure matched buffer conditions. A thermal equilibration step was followed by a 60 s delay and subsequently an
- 5 initial 0.2 μ l injection of antibody, followed by 12-16 injections of 1.5-3 μ l of antibody at an interval of 120 s. The stirring speed was maintained at 750 rpm, and the reference power is kept constant at 5-10 μ cal/s. The heat associated with each injection of antibody is integrated and plotted against the molar ratio of ligand to macromolecule. The resulting isotherm is fitted to a one-site binding model to obtain the affinity (K_D), stoichiometry (n), and enthalpy of
- 10 interaction (ΔH) using the software provided by the manufacturer. Experiments were performed in at least duplicates. K_D values in μ M units are reported in Table 15.

Table 15: Dissociation constant (K_D) values using ITC

	K_D , μ M		
	FIX	FIXa	FX
mAb01-9994	2.48 $\pm$ 0.23	1.8 $\pm$ 0.13	NA
mAb01-9933	2.39 $\pm$ 0.33	1.3 $\pm$ 0.12	NA
mAb01-9985	1.92 $\pm$ 0.18	1.26 $\pm$ 0.08	NA
mAb01-9978	5.6 $\pm$ 0.93	3.57 $\pm$ 0.52	NA
mAb01-8913	NA	NA	0.35 $\pm$ 0.19
mAb01-8174	NA	NA	0.75 $\pm$ 0.66
mAb01-9772	NA	NA	1.37 $\pm$ 0.39
ACE910	2.77 $\pm$ 1.44	1.97 $\pm$ 0.42	2.42 $\pm$ 0.2

NA: Not applicable since antibody is directed to different macromolecule

Example 14: Activity of anti-FIX(a)/FX(a) bispecific antibodies in a FXa generation assay

The procoagulant activity of anti-FIXa/FX bispecific antibodies was determined based on their ability to promote FX activation by FIXa in the presence of a procoagulant phospholipid membrane. The bispecific antibodies (BiAb) tested are listed in Table 16 and ACE910 was included for comparison.

The procoagulant activity of each bispecific antibody is reported as fold stimulation relative to FX activation by free FIXa at a given antibody concentration. Bispecific antibodies were tested at 8 concentrations (made by serial three fold dilutions in assay buffer) by pre-incubation with 35 or 125 pM human plasma-derived FIXa (Haematologic Technologies Inc, USA) and 500 μ M 25:75 phosphatidyl serine:phosphatidyl choline phospholipid vesicles (Haematologic Technologies Inc, USA) in assay buffer (50 mM HEPES, 100 mM NaCl, 5 mM CaCl_2 , 0.1% (w/v) PEG8000, pH 7.3 + 1 mg/ml BSA) for 10 min. Activation was then initiated by addition of human plasma-derived FX (Haematologic Technologies Inc, USA) to a concentration of 25 nM. Following 15 min activation at room temperature, the reaction (50 μ l) was quenched by addition of 25 μ l quench buffer (50 mM HEPES, 100 mM NaCl, 60 mM EDTA, 0.1% PEG8000, pH 7.3 + 1 mg/ml BSA). The amount of FXa generated was determined by addition of 25 μ l 2 mM S-2765 chromogenic substrate (Chromogenix, Sweden) and measurement of chromogenic substrate conversion by absorbance measurement at 405 nm (Δ OD/min) in a microplate reader. Similarly, FX activation by free FIXa was determined at a FIXa concentration of 25 nM and a reaction time of 60 min. The measured activity was normalized according to the concentration of FIXa present in the assay and the reaction time. By dividing this number by the similarly normalized rate of FXa generation in the absence of antibody, fold stimulation by the antibody at a given concentration was calculated.

In summary, calculation of biAb stimulation can be described as follows

$$\text{BiAb stimulation} = (A_{\text{FIXa+biAb}} / ([\text{FIXa}]_{\text{assay}} \times t_{\text{reaction}})) / A_{\text{FIXa,norm}}$$

where $A_{\text{FIXa+biAb}}$ is the activity measured in the presence of bispecific antibody, $[\text{FIXa}]_{\text{assay}}$ is the FIXa concentration in the assay, t_{reaction} is the reaction time, and $A_{\text{FIXa,norm}}$ is the normalized activity of free FIXa.

Table 16 lists the maximum stimulation determined for each bispecific antibody among the 8 antibody concentrations tested as well as the concentration at which maximum stimulation (fold) was observed. For all tested bispecific antibodies the maximum stimulation was found to be higher than that measured for ACE910, which was tested at a concentration interval

5 from 0 to 15300 nM.

Table 16: Maximum stimulation by bispecific anti-FIXa/FX antibodies

BiAb antibody ID	Concentration span tested (nM)	BiAb conc at maximum stimulation (nM)	Maximum stimulation (fold)
<i>ACE910</i>	<i>14.38-31440</i>	<i>10480</i>	<i>891</i>
bimAb05-0745	3.65-7980	7980	21143
bimAb05-3761	3.69-8070	2690	16332
bimAb05-3769	3.735-8170	8170	27417
bimAb05-0746	5.1-11150	3717	14595
bimAb05-2112	3.575-7820	7820	30426
bimAb05-2113	3.475-7600	7600	26321
bimAb05-2114	3.465-7580	7580	35222
bimAb05-2115	3.56-7790	7790	14921
bimAb05-3755	1.93-4212	156	7573

Example 15: TGT of anti-FIX(a)/FX(a) bispecific antibodies in haemophilia A (HA) plasma

Thrombin generation tests (TGT) were conducted in an automated HTP 384-well setup triggering with tissue factor. In brief, 10 µl antibodies were added to 30 µl haemophilia A (HA) plasma (George King). Then, 10 µl TissueFactor trigger (Thrombinoscope, #TS31.00) mixed with phospholipids was added, followed by addition of 10 µl thrombin substrate (FluCa, Thrombinoscope, #TS50.00) to a final assay volume of 60 µl. Fluorescence time series were measured at room temperature on a Perkin Elmer EnVision multi-label plate reader at 1-minute intervals for 2 hours. Thrombograms were calculated as the smoothed first derivative of the fluorescence time series. Peak height was calculated as the maximum value observed in the thrombogram, and normalized (peak ratio) to the peak height observed for the ACE910 reference at the highest concentration (333 nM). The test results for the bispecific antibodies (bimAb) are shown in Table 17. Peak ratio (fold) is the maximum value observed for the bimAb in the thrombogram relative to the value for ACE910 at 333 nM. The concentration (nM) at which the peak is observed is also listed.

Table 17: TGT activity of anti-FIX/FX bimAbs relative to ACE910

bimAb ID	anti-FIX mAb ID	anti-FX mAb ID	Concentration (nM)	Peak ratio (fold)
bimAb05-0396	mAb11-1495	mAb01-8174	111	1.18
bimAb05-0417	mAb11-1501	mAb01-8174	111	1.25
bimAb05-0438	mAb11-1502	mAb01-8174	333	1.10
bimAb05-0745	mAb01-9994	mAb01-8174	111	1.24
bimAb05-2114	mAb01-9985	mAb01-9772	333	1.07
bimAb05-2375	mAb01-9016	mAb01-8174	111	1.14
bimAb05-2379	mAb01-9016	mAb01-8913	666	1.26
bimAb05-2532	mAb01-9373	mAb01-6723	333	1.24
bimAb05-3416	mAb01-9985	mAb01-6723	111	1.13
bimAb05-3769	mAb01-9985	mAb01-8174	111	1.27
bimAb05-3770	mAb01-9986	mAb01-8174	333	1.23
bimAb05-3862	mAb01-9696	mAb01-8174	333	1.52
bimAb05-3880	mAb11-0047	mAb01-8174	333	1.4
bimAb05-3886	mAb11-0049	mAb01-8174	333	1.16
bimAb05-3955	mAb11-0107	mAb01-8174	333	1.34
bimAb05-4100	mAb11-0149	mAb01-8174	333	1.25
bimAb05-4114	mAb11-0160	mAb01-8174	333	1.26
bimAb05-4121	mAb11-0164	mAb01-8174	333	1.34
bimAb05-4220	mAb11-0962	mAb01-8174	333	1.39
bimAb05-4226	mAb11-0965	mAb01-8174	333	1.31

bimAb ID	anti-FIX mAb ID	anti-FX mAb ID	Concentration (nM)	Peak ratio (fold)
bimAb05-4271	mAb11-0173	mAb01-8174	111	1.32
bimAb05-4283	mAb11-1021	mAb01-8174	333	1.19
bimAb05-4289	mAb11-1024	mAb01-8174	333	1.06
bimAb05-4292	mAb11-1033	mAb01-8174	111	1.19
bimAb05-4293	mAb11-1030	mAb01-8174	111	1.35
bimAb05-4387	mAb11-1039	mAb01-8174	333	1.28
bimAb05-4392	mAb11-1042	mAb01-8174	111	1.24
bimAb05-4419	mAb11-0174	mAb01-8174	111	1.21
bimAb05-4422	mAb11-1073	mAb01-8174	333	1.2
bimAb05-4428	mAb11-1076	mAb01-8174	111	1.12
bimAb05-4443	mAb11-1094	mAb01-8174	333	1.14
bimAb05-4444	mAb11-1091	mAb01-8174	333	1.19
bimAb05-4601	mAb11-0937	mAb01-8174	111	1.17
bimAb05-4604	mAb11-0923	mAb01-8174	333	1.02
bimAb05-4611	mAb11-0935	mAb01-8174	333	1.02
bimAb05-4612	mAb11-0938	mAb01-8174	111	1.23
bimAb05-4613	mAb11-0933	mAb01-8174	333	1.03
bimAb05-4684	mAb01-9985	mAb11-1114	333	1.05
bimAb05-4685	mAb01-9985	mAb11-1115	111	1.12
bimAb05-4686	mAb01-9985	mAb11-1116	333	1.16
bimAb05-4687	mAb01-9985	mAb11-1117	333	1.12
bimAb05-4688	mAb01-9985	mAb11-1118	111	1.16
bimAb05-4689	mAb01-9985	mAb11-1119	333	1.26
bimAb05-4690	mAb01-9985	mAb11-1121	333	1.36
bimAb05-4693	mAb01-9985	mAb11-1123	333	1.02
bimAb05-4696	mAb01-9985	mAb11-1125	333	1.3
bimAb05-4704	mAb01-9985	mAb11-1416	333	1.17
bimAb05-4708	mAb01-9985	mAb11-1420	111	1.02
bimAb05-4710	mAb01-9985	mAb11-1422	333	1.1
bimAb05-4756	mAb11-1204	mAb01-8174	111	1.20
bimAb05-4788	mAb11-1233	mAb01-8174	333	1.13
bimAb05-4884	mAb11-1254	mAb01-8174	316	1.16
bimAb05-4895	mAb11-1262	mAb01-8174	111	1.28
bimAb05-4896	mAb11-1259	mAb01-8174	333	1.13
bimAb05-4898	mAb11-1260	mAb01-8174	333	1.17
bimAb05-4903	mAb11-1268	mAb01-8174	333	1.1
bimAb05-4906	mAb11-1266	mAb01-8174	111	1.38
bimAb05-4910	mAb11-1273	mAb01-8174	333	1.12
bimAb05-4914	mAb11-1275	mAb01-8174	333	1.16
bimAb05-4915	mAb11-1276	mAb01-8174	111	1.23
bimAb05-4919	mAb11-1278	mAb01-8174	333	1.17
bimAb05-4920	mAb11-1282	mAb01-8174	111	1.22

bimAb ID	anti-FIX mAb ID	anti-FX mAb ID	Concentration (nM)	Peak ratio (fold)
bimAb05-4921	mAb11-1279	mAb01-8174	333	1.14
bimAb05-4924	mAb11-1288	mAb01-8174	333	1.22
bimAb05-4927	mAb11-1286	mAb01-8174	333	1.22
bimAb05-5092	mAb11-1344	mAb01-8174	111	1.23
bimAb05-5095	mAb11-0723	mAb01-8174	111	1.31
bimAb05-5204	mAb11-1358	mAb01-8174	333	1.5
bimAb05-5205	mAb11-1360	mAb01-8174	111	1.38
bimAb05-5240	mAb11-1389	mAb01-8174	111	1.29
bimAb05-5340	mAb01-9985	mAb11-1431	111	1.28
bimAb05-5341	mAb01-9985	mAb11-1441	111	1.05
bimAb05-5342	mAb01-9985	mAb11-1439	333	1.14
bimAb05-5344	mAb01-9985	mAb11-1443	333	1.03
bimAb05-5346	mAb01-9985	mAb11-1444	158	1.17
bimAb05-5348	mAb01-9985	mAb11-1445	111	1.19
bimAb05-5353	mAb01-9985	mAb11-1453	333	1.15
bimAb05-5354	mAb01-9985	mAb11-1451	116	1.01
bimAb05-5356	mAb01-9985	mAb11-1452	111	1.16
bimAb05-5357	mAb01-9985	mAb11-1455	333	1.11
bimAb05-5358	mAb01-9985	mAb11-1433	111	1.22
bimAb05-5359	mAb01-9985	mAb11-1456	333	1.07
bimAb05-5361	mAb01-9985	mAb11-1459	111	1.21
bimAb05-5362	mAb01-9985	mAb11-1457	111	1.39
bimAb05-5363	mAb01-9985	mAb11-1434	333	1.56
bimAb05-5364	mAb01-9985	mAb11-1458	111	1.18
bimAb05-5365	mAb01-9985	mAb11-1460	333	1.04
bimAb05-5366	mAb01-9985	mAb11-1461	333	1.12
bimAb05-5367	mAb01-9985	mAb11-1465	333	1.15
bimAb05-5369	mAb01-9985	mAb11-1466	333	1.17
bimAb05-5370	mAb01-9985	mAb11-1463	333	1.06
bimAb05-5371	mAb01-9985	mAb11-1435	208	1.19
bimAb05-5372	mAb01-9985	mAb11-1464	333	1.05
bimAb05-5373	mAb01-9985	mAb11-1467	333	1.15
bimAb05-5374	mAb01-9985	mAb11-1468	333	1.07
bimAb05-5375	mAb01-9985	mAb11-1472	308	1.27
bimAb05-5377	mAb01-9985	mAb11-1473	111	1.27
bimAb05-5378	mAb01-9985	mAb11-1470	333	1.16
bimAb05-5379	mAb01-9985	mAb11-1436	111	1.07
bimAb05-5380	mAb01-9985	mAb11-1471	333	1.09
bimAb05-5381	mAb01-9985	mAb11-1474	333	1.15
bimAb05-5383	mAb01-9985	mAb11-1477	111	1.05
bimAb05-5385	mAb01-9985	mAb11-1478	333	1.03
bimAb05-5386	mAb01-9985	mAb11-1476	333	1.08

bimAb ID	anti-FIX mAb ID	anti-FX mAb ID	Concentration (nM)	Peak ratio (fold)
bimAb05-5387	mAb01-9985	mAb11-1479	333	1.27
bimAb05-5388	mAb01-9985	mAb11-1480	111	1.36
bimAb05-5389	mAb01-9985	mAb11-1483	111	1.19
bimAb05-5390	mAb01-9985	mAb11-1437	133	1.06
bimAb05-5396	mAb01-9985	mAb11-1487	111	1.07
bimAb05-5406	mAb01-9985	mAb11-1494	333	1.19

Example 16: Activity of bispecific anti-FIX(a)/FX(a) antibodies in a thrombin generation test (TGT) in human haemophilia A platelet-poor and platelet-rich mimic plasma

5 The procoagulant activity of the bispecific antibodies bimAb05-0745, bimAb05-3761, bimAb05-3769, bimAb05-0746, bimAb05-2112, bimAb05-2113 and bimAb005-2114 was determined based on their ability to promote thrombin generation in the presence of either a procoagulant synthetic phospholipid membrane or platelets according to the principles described by Hemker *et al.* (Pathophysiol Haemost Thromb, 2002;32:249-253). ACE910 was
10 included for comparison. Each antibody (test compound) was tested in a thrombin generation test (TGT) using commercially available Haemophilia A (HA) patient pooled platelet-poor plasma (HA-PPP) and HA-induced human platelet-rich plasma (HA-PRP) freshly prepared from healthy consenting donors.

15 Materials and methods:

Preparation of Haemophilia A-induced human platelet-rich plasma (HA-PRP)

Blood was obtained from healthy consenting donors by venipuncture. Six volumes of blood was collected into 1 volume acid citrate dextrose (ACD; 85 mM sodium citrate, 110 mM dextrose, and 62.3 mM citric acid, pH 4.9), final pH 6.5, and centrifuged for 20 min at 220 g
20 at room temperature (RT). Platelet-rich plasma (PRP) was collected and platelet concentrations were determined with a Medonic CA 620 hematology analyzer (Boule Diagnostics AB, Spånga, Sweden).

The red blood cell-containing plasma part was centrifuged for another 10 min at 600 g at RT. Platelet-poor plasma (PPP) was collected and used to dilute the PRP to ~300,000
25 platelets/ μ l. HA conditions were induced by addition of a FVIII-neutralising anti-human FVIII antibody (Sheep anti-Human Factor VIII - 5 mg, Haematologic Technologies, VT, USA) to a final concentration of 0.1 mg/ml and rotated gently at 2 rpm for 30 minutes at RT.

Thrombin generation test

Thrombin generation tests (TGT) in both HA-PPP (George King Bio-Medical Inc, KS, USA) (Exp. A) and HA-PRP (Exp. B) were performed by standard calibrated automated thrombography using a 96-well plate fluorometer (Fluoroscan Ascent FL, Thermolabsystems, Helsinki, Finland). Reaction mixtures contained 70 µl HA-PRP (~ 300,000 platelets/µl) or HA-PPP, 10 µl test compound dilution (diluted in 20 mM HEPES, 140 mM NaCl, pH 7.4, 2 % BSA), 20 µl CAT reagents containing tissue factor (TF) (PRP reagent; TF without synthetic phospholipids, PPP-reagent LOW; TF with synthetic phospholipids, 1 pM TF final, Thrombinoscope BV, Maastricht, the Netherlands) or Thrombin Calibrator (Thrombinoscope BV), and 20 µl of a mixture containing the fluorescently labelled thrombin substrate z-Gly-Gly-Arg-AMC (3 mM) and CaCl₂ (90 mM) (Thrombinoscope BV). TGT was performed at up to eight concentrations of test compound (0.3, 1.0, 3, 10, 30, 100, 300, and 900 nM, final plasma concentration) or added buffer (20 mM HEPES, 140 mM NaCl, pH 7.4, 2 % BSA) only (representing HA control). The concentration ranges were tested in at least three independent experiments in HA-PPP from the same stock or in blood from four different donors. Normal control levels in TGT were measured using untreated human PRP or CRYOcheck™ pooled normal human PPP plasma (Precision Biologic Inc., Dartmouth, Canada) added buffer (20 mM HEPES, 140 mM NaCl, pH 7.4, 2 % BSA) only. The TGT was allowed to proceed for a total of 90 minutes and the TGT parameter Peak Thrombin Height (nM) was analysed by Thrombinoscope software (Thrombinoscope BV).

Results and discussion

Exp. A: Figure 2 and Table 18 shows the measured peak thrombin generation rates for each bispecific antibody at the concentrations tested in HA-PPP. The data show that all test compounds increase the peak thrombin formation above the level observed in the absence of antibody, i.e. exhibit procoagulant activity. In addition, thrombin generation levels between 10 and 300 nM for bimAb05-0745, bimAb05-3761, bimAb05-3769, bimAb05-0746, bimAb05-2112, bimAb05-2113, and bimAb05-2114 are higher than that observed for ACE910, demonstrating superior potency. Moreover, thrombin generation levels at 300 to 900 nM of bimAb05-0745, bimAb05-3761, bimAb05-3769, bimAb05-2112, and bimAb05-2114 are higher than that observed with 900 nM ACE910, demonstrating higher potencies and efficacies of these compounds compared to ACE910.

Exp. B: Figure 3 and Table 19 shows the measured peak thrombin generation for each bispecific antibody at the concentrations tested in HA-PRP. Under these conditions,

bimAb05-0745, bimAb05-3761, bimAb05-3769, bimAb05-0746, bimAb05-2112, bimAb05-2113, and bimAb05-2114 also display better potencies and efficacies compared to ACE910.

Table 18: Thrombin generation test (TGT) in HA-PPP (Exp. A)

- 5 Thrombin generation test (TGT) of the bispecific antibodies bimAb05-0745, bimAb05-3761, bimAb05-3769, bimAb05-0746, bimAb05-2112, bimAb05-2113, bimAb05-2114, and ACE910 in human tissue factor activated haemophilia A platelet-poor plasma (PPP). Mean peak thrombin generation levels $\pm$ standard deviation measured at each of the tested compound concentrations in at least three independent experiments in HA-PPP (Exp. A).

10

<u>Exp. A</u> Compound concentration (nM)	Peak thrombin (mean $\pm$ SD in nM) for ACE910	Peak thrombin (mean $\pm$ SD in nM) for bimAb05-0745	Peak thrombin (mean $\pm$ SD in nM) for bimAb05-3761
0	15.5 $\pm$ 7.8	11.6 $\pm$ 0.9	11.6 $\pm$ 0.9
0.3	11.5 $\pm$ 1.1	11.6 $\pm$ 1.9	11.4 $\pm$ 0.7
1	12.6 $\pm$ 0.1	11.8 $\pm$ 1.2	13.5 $\pm$ 1.6
3	11.2 $\pm$ 2.5	14.0 $\pm$ 3.6	13.8 $\pm$ 2.7
10	13.3 $\pm$ 0.0	25.5 $\pm$ 5.8	18.1 $\pm$ 3.8
30	15.3 $\pm$ 4.3	44.8 $\pm$ 5.8	35.7 $\pm$ 5.4
100	22.0 $\pm$ 4.1	81.4 $\pm$ 9.2	64.1 $\pm$ 9.2
300	31.6 $\pm$ 4.0	105.7 $\pm$ 7.7	85.7 $\pm$ 7.0
900	45.6 $\pm$ 7.2	107.7 $\pm$ 14.1	78.4 $\pm$ 7.5
<u>Exp. A</u> Compound concentration (nM)	Peak thrombin (mean $\pm$ SD in nM) for bimAb05-3769	Peak thrombin (mean $\pm$ SD in nM) for bimAb05-0746	Peak thrombin (mean $\pm$ SD in nM) for bimAb05-2112
0	11.6 $\pm$ 0.9	11.6 $\pm$ 0.9	11.6 $\pm$ 0.9
0.3	14.6 $\pm$ 3.8	11.1 $\pm$ 1.2	9.4 $\pm$ 2.5
1	12.3 $\pm$ 0.8	12.4 $\pm$ 2.5	11.8 $\pm$ 1.0
3	14.7 $\pm$ 3.2	13.1 $\pm$ 3.2	12.0 $\pm$ 1.1
10	25.4 $\pm$ 4.8	12.6 $\pm$ 1.3	12.7 $\pm$ 1.2
30	50.8 $\pm$ 8.7	15.3 $\pm$ 0.9	17.0 $\pm$ 4.0
100	94.1 $\pm$ 7.5	29.0 $\pm$ 3.6	29.1 $\pm$ 5.7
300	117.5 $\pm$ 8.1	44.2 $\pm$ 5.2	51.2 $\pm$ 5.7
900	112.5 $\pm$ 11.0	47.8 $\pm$ 6.0	82.8 $\pm$ 7.5

<u>Exp. A</u> Compound concentration (nM)	Peak thrombin (mean ± SD in nM) for bimAb05-2113	Peak thrombin (mean ± SD in nM) for bimAb05-2114	
0	11.6 ± 0.9	11.6 ± 0.9	
0.3	14.2 ± 5.2	11.9 ± 0.5	
1	11.5 ± 1.2	12.3 ± 0.8	
3	11.8 ± 0.7	12.9 ± 1.2	
10	13.0 ± 2.7	15.7 ± 2.8	
30	15.7 ± 5.4	21.3 ± 5.1	
100	22.4 ± 5.5	41.9 ± 14.5	
300	40.7 ± 7.2	75.8 ± 17.0	
900	51.1 ± 4.0	103.7 ± 7.1	

Table 19: Thrombin generation test (TGT) in HA-PRP (Exp. B)

- Thrombin generation test (TGT) of the bispecific antibodies bimAb05-0745, bimAb05-3761, bimAb05-3769, bimAb05-0746, bimAb05-2112, bimAb05-2113, bimAb05-2114 and ACE910 in human tissue factor activated haemophilia A platelet-rich plasma (PRP). Mean peak thrombin generation ± standard deviation at each of the tested compound concentrations from four independent experiments in HA-PRP (Exp. B).

10

<u>Exp. B</u> Compound concentration (nM)	Peak thrombin (mean ± SD in nM) for ACE910	Peak thrombin (mean ± SD in nM) for bimAb05-0745	Peak thrombin (mean ± SD in nM) for bimAb05-3761
0	15.5 ± 7.8	15.5 ± 7.8	15.5 ± 7.8
0.3	15.2 ± 7.1	12.0 ± 2.1	11.6 ± 0.7
1	16.9 ± 7.5	11.9 ± 1.4	14.0 ± 1.6
3	15.0 ± 6.9	14.5 ± 4.2	14.3 ± 3.0
10	20.3 ± 7.0	23.5 ± 5.2	18.8 ± 4.2
30	23.3 ± 10.3	45.0 ± 7.1	36.1 ± 6.5
100	44.3 ± 10.0	79.9 ± 10.6	65.8 ± 10.4
300	64.9 ± 12.6	106.0 ± 9.4	86.0 ± 8.6
900	94.5 ± 21.3	108.9 ± 17.0	80.8 ± 7.2

<u>Exp. B</u> Compound concentration (nM)	Peak thrombin (mean ± SD in nM) for bimAb05-3769	Peak thrombin (mean ± SD in nM) for bimAb05-0746	Peak thrombin (mean ± SD in nM) for bimAb05-2112
0	15.5 ± 7.8	15.5 ± 7.8	15.5 ± 7.8
0.3	13.0 ± 2.6	11.3 ± 1.4	9.0 ± 2.9
1	12.6 ± 0.8	13.0 ± 2.7	12.0 ± 1.2
3	15.7 ± 3.1	13.7 ± 3.7	12.3 ± 1.1
10	24.8 ± 5.7	13.0 ± 1.2	12.9 ± 1.4
30	49.8 ± 10.4	15.5 ± 1.0	17.1 ± 4.8
100	95.6 ± 8.5	30.4 ± 2.8	30.8 ± 5.8
300	118.6 ± 9.6	45.3 ± 5.8	51.3 ± 6.9
900	114.4 ± 12.6	49.5 ± 5.9	83.3 ± 9.1
<u>Exp. B</u> Compound concentration (nM)	Peak thrombin (mean ± SD in nM) for bimAb05-2113	Peak thrombin (mean ± SD in nM) for bimAb05-2114	
0	15.5 ± 7.8	15.5 ± 7.8	
0.3	11.7 ± 1.1	11.9 ± 0.5	
1	11.6 ± 1.4	12.3 ± 0.8	
3	11.7 ± 0.9	12.9 ± 1.2	
10	13.6 ± 2.9	15.7 ± 2.8	
30	16.8 ± 6.1	21.3 ± 5.1	
100	24.2 ± 5.2	41.9 ± 14.5	
300	43.3 ± 6.2	75.8 ± 17.0	
900	52.3 ± 4.1	103.7 ± 7.1	

Example 17: *In vivo* efficacy of bispecific anti-FIX(a)/FX(a) antibodies in a Tail Vein Transection (TVT) model

In vivo efficacy was determined using a Tail Vein Transection (TVT) model in FVIII knockout-mice. The efficacy of a high dose (8 mg/kg) of antibody test compounds and ACE910 was investigated in a Tail Vein Transection (TVT) study in FVIII knockout mice (B6;129S-F8tm1Kaz/J, The Jackson Laboratory, Bar Harbor, ME, US) co-treated with human FIX (2 mg/kg) (Benefix, Pfizer, New York City, NY, US) and FX (1.5 mg/kg) (Haematologic Technologies, INC, Essex Junction, VT, US). In short, the mice were anaesthetized with isoflurane and placed on a heating pad, set to keep animal body temperature at 37°C, with their tails immersed in saline (37°C). Dosing was performed in the right lateral tail vein 5 minutes prior to the injury. In the present TVT model (Johansen *et al.*, Haemophilia, 2016, 625-31) the lateral vein was transected. If the bleeding stopped at 10, 20, or 30 min, the tail was taken up from the saline, and wound was gently wiped with a saline wetted gauze swab. Total blood loss was determined after 40 min by quantifying the amount of haemoglobin in the saline (see Table 20). The efficacy of the antibody test compound was compared with a One-way ANOVA followed by a Tukey multiple comparison test. A p-value < 0.05 was considered significant.

Table 20: Comparison of the efficacy in the bleeding models in F8 knockout mice

Bispecific antibody ID	Blood loss mean (nmol haemoglobin)
Vehicle (control)	4441
bimAb05-0745	1072*
bimAb05-0746	925*
bimAb05-3761	566*
bimAb05-3769	860*
bimAb05-2112	1301*
bimAb05-2113	450*
bimAb05-2114	1222*
ACE910	1462*

*Significantly different from vehicle treated FVIII knockout mice

While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.

CLAIMS

1. A multispecific antibody or antigen-binding fragment thereof capable of stimulating the enzymatic activity of FIXa towards FX comprising a first antigen-binding site capable of binding to FIX (SEQ ID NO:1) and/or the activated form thereof (FIXa), and a second
- 5 antigen-binding site capable of binding to FX (SEQ ID NO:2) and/or the activated form thereof (FIXa).
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof
- 10 competes with a reference antibody for binding to FIX(a) wherein the reference antibody comprises
- a) a heavy chain variable domain identified by SEQ ID NO:35 and a light chain variable domain identified by SEQ ID NO:39, or
 - b) a heavy chain variable domain identified by SEQ ID NO:43 and a light chain variable
 - 15 domain identified by SEQ ID NO:47, or
 - c) a heavy chain variable domain identified by SEQ ID NO:51 and a light chain variable domain identified by SEQ ID NO:55, or
 - d) a heavy chain variable domain identified by SEQ ID NO:67 and a light chain variable domain identified by SEQ ID NO:71,
- 20 and/or
- competes with a reference antibody for binding to FX(a) wherein the reference antibody comprises
- 25 e) a heavy chain variable domain identified by SEQ ID NO:467 and a light chain variable domain identified by SEQ ID NO:471, or
 - f) a heavy chain variable domain identified by SEQ ID NO:483 and a light chain variable domain identified by SEQ ID NO:487.
- 30 3. The antibody or antigen-binding fragment thereof according to claim 1, wherein the first antigen-binding site is capable of binding an epitope comprising amino acid residues R338, T340 and K341 of FIX(a).

4. The antibody or antigen-binding fragment thereof according to claim 3, wherein the first antigen-binding site is capable of binding an epitope comprising amino acid residues L337, R338, T340 and K341 and optionally T343 of FIX(a).
- 5 5. The antibody or antigen-binding fragment thereof according to claim 3, wherein the first antigen-binding site is capable of binding an epitope comprising amino acid residues L337, R338, S339, T340, and K341 of FIX(a).
- 10 6. The antibody or antigen-binding fragment thereof according to any of the previous claims, wherein the second antigen-binding site is capable of binding to the EGF-2 domain and/or the C-terminal trypsin-like serine protease domain of FX(a).
- 15 7. The antibody or antigen-binding fragment thereof according to any of the previous claims wherein the first antigen-binding site is capable of binding to an epitope comprising R338, T340, K341 of FIX(a), and wherein the second antigen-binding site is capable of binding an epitope comprising amino acid residues Y230, D423, R424 and K427 of FX(a).
- 20 8. The antibody or antigen-binding fragment thereof according to any of the previous claims wherein the first antigen-binding site is capable of binding to an epitope comprising R338, T340, K341, and optionally T343 of FIX(a), and wherein the second antigen-binding site is capable of binding an epitope comprising amino acid residues
- i) E103, Q104, V108, R113, T116, L117, D119, I125, T127, E228, F229, Y230, E266, R287, P291, I292, P304, L419, K420, D423, R424, M426, K427 and T428 of FX(a)
- or
- 25 ii) E103, Q104, V108, R113, T116, L117, A118, D119, I125, T127, S227, E228, Y230, R287, I292, L303, P304, L419, K420, D423, R424, M426, K427 and T428 of FX(a).
- 30 9. The antibody or antigen-binding fragment thereof according to any of the previous claims wherein the first antigen-binding site is capable of binding to an epitope comprising L337, R338, S339, T340 and K341 of FIX(a), and wherein the second antigen-binding site is capable of binding an epitope comprising amino acid residues
- i) E103, Q104, V108, R113, T116, L117, D119, I125, T127, E228, F229, Y230, E266, R287, P291, I292, P304, L419, K420, D423, R424, M426, K427 and T428 of FX(a)
- or

ii) E103, Q104, V108, R113, T116, L117, A118, D119, I125, T127, S227, E228, Y230, R287, I292, L303, P304, L419, K420, D423, R424, M426, K427 and T428 of FX(a).

- 10.** The antibody according to any of the previous claims, wherein the first antigen-binding site comprises
- i. a paratope comprising amino acid residues D30, D31, W53, S102, S104 and N107 in the heavy chain variable domain (SEQ ID NO:35) and amino acid residues Y91 and S92 in the light chain variable domain (SEQ ID NO:39), optionally comprising one or two substitution(s) in the eight recited paratope amino acid residues, or
 - 10 ii. a paratope comprising amino acid residues H30, D31, W53, D56, S102, S104, Y106 and N107 in the heavy chain variable domain (SEQ ID NO:67) and residues Y91 and S92 in the light chain variable domain (SEQ ID NO:71), optionally comprising one or two substitution(s) in the ten recited paratope amino acid residues, or
 - 15 iii. a paratope comprising amino acid residues H30, D31, W53, S102, S104, Y106 and N107 in the heavy chain variable domain (SEQ ID NO:51) and residues Y91 and S92 in the light chain variable domain (SEQ ID NO:55), optionally comprising one or two substitution(s) in the nine recited paratope amino acid residues,
- and the second antigen-binding site comprises
- a. a paratope comprising amino acid residues K23, G24, S25, G26, Y27, W33, D52, S54, D55, Y57, S77, L99, H100, Y101, Y102, N103 and S104 in the variable heavy chain domain (SEQ ID NO:483) and amino acid residues S30, S31, Y33, Y50, Q52, S54, R55, R57, Y92 and D94 in the light chain variable domain (SEQ ID NO:487), optionally comprising one, two, three, four or five substitutions in the 27 recited paratope amino acid residues, or
 - 25 b. a paratope comprising amino acid residues K23, S25, G26, Y27, F29, W33, D52, S54, D55, F57, S77, H100, Y101, Y102, N103 and S104 in the heavy chain variable domain (SEQ ID NO:467) and residues V29, S30, S31, Y33, Y50, Q52, S54, R55, R57 and D94 in the light chain variable domain (SEQ ID NO:471), optionally comprising one, two, three, four or five substitutions in the 26 recited paratope amino acid residues.
 - 30

11. The antibody or antigen-binding fragment thereof according to claim 10 wherein said substitutions are conservative substitutions.

12. The antibody or antigen-binding fragment thereof according to claim 1 wherein the first antigen-binding site is comprised by an anti-FIX(a) antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain, and wherein the second antigen-binding site is comprised by an anti-FX(a) antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain, wherein
- 5
- a. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID NOs:36, 37 and 38, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
- 10 the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID NOs:40, 41 and 42, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
- the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid
- 15 substitutions, and
- the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or
- b. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
- 20 NOs:36, 37 and 38, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
- the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID NOs:40, 41 and 42, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
- 25 the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID NOs:484, 485 and 486, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
- the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID NOs:488, 489 and 490, respectively, optionally comprising 1, 2 or 3 amino acid
- 30 substitutions, or
- c. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID NOs:44, 45 and 46, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
- the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
- 35 NOs:48, 49 and 50, respectively, optionally comprising 1, 2 or 3 amino acid

- substitutions, and
the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs: 468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
- 5 the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID NOs:
472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, or
- d. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs: 52, 53 and 54, respectively, optionally comprising 1, 2 or 3 amino acid
10 substitutions, and
the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID NOs:
56, 57 and 58, respectively, optionally comprising 1, 2 or 3 amino acid substitutions,
and
the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
15 NOs: 468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
NOs: 472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, or
- 20 e. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs: 52, 53 and 54, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
NOs: 56, 57 and 58, respectively, optionally comprising 1, 2 or 3 amino acid
25 substitutions, and
the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs: 484, 485 and 486, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
30 NOs: 488, 489 and 490, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, or
- f. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs: 68, 69 and 70, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
35 the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID

- NOs:72, 73 and 74, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID NOs: 468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
5 the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID NOs:472, 473 and 474, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or
- g. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID NOs:68, 69 and 70, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
10 the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID NOs:72, 73 and 74, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
- 15 the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID NOs:484, 485 and 486, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID NOs: 488, 489 and 490, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or
20
- h. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID NOs:1203, 1204 and 1205, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID NOs:1207, 1208 and 1209, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
25 the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
- 30 the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID NOs:472, 473, and 474, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or
- i. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID NOs:1211, 1212 and 1213, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and
35

- the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
NOs:1215, 1216 and 1217, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
- the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
5 NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
- the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
NOs:472, 473, and 474, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, or
- 10 j. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs:1219, 1220 and 1221, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
- the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
15 NOs:1223, 1224 and 1225, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
- the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
- 20 the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
NOs:472, 473, and 474, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, or
- k. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs:1227, 1228 and 1229, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
- 25 the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
NOs:1231, 1232 and 1233, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
- the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid
30 substitutions, and
- the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
NOs:472, 473, and 474, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, or
- l. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
35 NOs:1235, 1236 and 1337, respectively, optionally comprising 1, 2 or 3 amino acid

- substitutions, and
the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
NOs:1239, 1240 and 1241, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
- 5 the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
NOs:472, 473, and 474, respectively, optionally comprising 1, 2 or 3 amino acid
10 substitutions, or
- m. the anti-FIX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs:1243, 1244 and 1245, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
the anti-FIX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
15 NOs:1247, 1248 and 1249, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
the anti-FX(a) antibody heavy chain CDR1-3 sequences are identified by SEQ ID
NOs:468, 469 and 470, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions, and
- 20 the anti-FX(a) antibody light chain CDR1-3 sequences are identified by SEQ ID
NOs:472, 473, and 474, respectively, optionally comprising 1, 2 or 3 amino acid
substitutions.
- 13.** The antibody or antigen-binding fragment thereof according to any of the previous claims,
25 wherein
the first antigen-binding site is comprised by an anti-FIX(a) antibody or antigen-binding
fragment thereof comprising a heavy chain and a light chain, and
the second antigen-binding site is comprised by an anti-FX(a) antibody or antigen-binding
fragment thereof comprising a heavy chain and a light chain,
30 wherein the anti-FIX(a) antibody or antigen-binding fragment thereof comprises
- a heavy chain variable domain identified by SEQ ID NO:35 and a light chain
variable domain identified by SEQ ID NO:39, or
 - a heavy chain variable domain identified by SEQ ID NO:43 and a light chain
variable domain identified by SEQ ID NO:47, or

- c. a heavy chain variable domain identified by SEQ ID NO:51 and a light chain variable domain identified by SEQ ID NO:55, or
- d. a heavy chain variable domain identified by SEQ ID NO:67 and a light chain variable domain identified by SEQ ID NO:71,
- 5 e. a heavy chain variable domain identified by SEQ ID NO:1202 and a light chain variable domain identified by SEQ ID NO:1206,
- f. a heavy chain variable domain identified by SEQ ID NO:1210 and a light chain variable domain identified by SEQ ID NO:1214,
- 10 g. a heavy chain variable domain identified by SEQ ID NO:1218 and a light chain variable domain identified by SEQ ID NO:1222,
- h. a heavy chain variable domain identified by SEQ ID NO:1226 and a light chain variable domain identified by SEQ ID NO:1230,
- i. a heavy chain variable domain identified by SEQ ID NO:1234 and a light chain variable domain identified by SEQ ID NO:1238, or
- 15 j. a heavy chain variable domain identified by SEQ ID NO:1242 and a light chain variable domain identified by SEQ ID NO:1246,

and wherein the anti-FX(a) antibody or antigen-binding fragment thereof comprises

- 20 k. a heavy chain variable domain identified by SEQ ID NO:467 and a light chain variable domain identified by SEQ ID NO:471, or
- l. a heavy chain variable domain identified by SEQ ID NO:483 and a light chain variable domain identified by SEQ ID NO:487.

25 **14.** The antibody or antigen-binding fragment thereof according to claim 13, wherein both the heavy chain variable domains and the light chain variable domains are at least 96, 97, 98, 99, 99.1 or 99.2 % identical to the recited SEQ ID NOs.

30 **15.** The antibody or antigen-binding fragment thereof according to any of the previous claims wherein the antibody or antigen-binding fragment thereof is a bispecific antibody.

16. The antibody or antigen-binding fragment thereof according to any of the previous claims for use in the treatment of haemophilia A with or without inhibitors.

17. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any of claims 1-15 and one or more pharmaceutically acceptable carrier(s).

- 5 **18.** An antibody or antigen-binding fragment thereof which is capable of binding to FIX (SEQ ID NO:1) and/or the activated form thereof (FIXa) and capable of stimulating the enzymatic activity of FIXa towards FX comprising a heavy chain and a light chain wherein
- 10 a. the heavy chain CDR1-3 sequences are identified by SEQ ID NOs:36, 37 and 38, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and the light chain CDR1-3 sequences are identified by SEQ ID NOs:40, 41 and 42, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or
- 15 b. the heavy chain CDR1-3 sequences are identified by SEQ ID NOs:44, 45 and 46, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and the light chain CDR1-3 sequences are identified by SEQ ID NOs:48, 49 and 50, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or
- 20 c. the heavy chain CDR1-3 sequences are identified by SEQ ID NOs:52, 53 and 54, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and the light chain CDR1-3 sequences are identified by SEQ ID NOs: 56, 57 and 58, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or
- 25 d. the heavy chain CDR1-3 sequences are identified by SEQ ID NOs:68, 69 and 70, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and the light chain CDR1-3 sequences are identified by SEQ ID NOs:72, 73 and 74, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or
- 30 e. the heavy chain CDR1-3 sequences are identified by SEQ ID NOs:1203, 1204 and 1205, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and the light chain CDR1-3 sequences are identified by SEQ ID NOs:1207, 1208 and 1209, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or
- f. the heavy chain CDR1-3 sequences are identified by SEQ ID NOs:1211, 1212 and 1213, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and the light chain CDR1-3 sequences are identified by SEQ ID NOs:1215, 1216 and 1217, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or
- g. the heavy chain CDR1-3 sequences are identified by SEQ ID NOs:1219, 1220 and 1221, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and

the light chain CDR1-3 sequences are identified by SEQ ID NOs:1223, 1224 and 1225, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or

h. the heavy chain CDR1-3 sequences are identified by SEQ ID NOs:1227, 1228 and 1229, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and

5 the light chain CDR1-3 sequences are identified by SEQ ID NOs:1231, 1232 and 1233, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or

i. the heavy chain CDR1-3 sequences are identified by SEQ ID NOs:1235, 1236 and 1337, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and

10 the light chain CDR1-3 sequences are identified by SEQ ID NOs:1239, 1240 and 1241, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, or

j. the heavy chain CDR1-3 sequences are identified by SEQ ID NOs:1243, 1244 and 1245, respectively, optionally comprising 1, 2 or 3 amino acid substitutions, and

the light chain CDR1-3 sequences are identified by SEQ ID NOs:1247, 1248 and 1249, respectively, optionally comprising 1, 2 or 3 amino acid substitutions;

15

wherein said antibody or antigen-binding fragment thereof is an intermediate for use in the manufacture of a multispecific antibody which is capable of binding to FIX (SEQ ID NO:1) and/or the activated form thereof (FIXa), and capable of binding to FX (SEQ ID NO:2) and/or the activated form thereof (FXa).

20